<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" xml:lang="en"><front id="062e0b71-4f23-47e6-9a61-2626a6fb60bd"><journal-meta id="09a26347-31dd-4b69-8ec1-5d2a2b224fd2"><journal-id journal-id-type="hwp" id="1f8e2c40-fd5e-4123-bb1f-8709ef012c03">bjophthalmol</journal-id><journal-id journal-id-type="publisher-id" id="c4a50eac-94c1-4bbf-b28e-0301e6821025">bjophthalmol</journal-id><journal-title-group id="05b24cd5-0f18-4d99-bd45-e3f272167631"><journal-title id="1f92741b-24b3-4682-8e63-e4b9c1ee6e26">British Journal of Ophthalmology</journal-title><abbrev-journal-title id="83f684c7-6db3-4128-9d05-5928834ce85e">Br J Ophthalmol</abbrev-journal-title></journal-title-group><issn pub-type="ppub" id="7d745e7f-327e-40de-b4ca-010c511d7bc0">0007-1161</issn><issn pub-type="epub" id="5e0c4221-54f6-46a0-951c-163b2e8e9a8b">1468-2079</issn><publisher id="bbbfc582-0a3d-4b1a-bf18-404fb95bc2a0"><publisher-name id="ec3a6d41-444d-4516-a26c-5239ee414058">British Journal of Ophthalmology</publisher-name><publisher-loc id="020e9476-4af0-415c-87fb-edb51ab5b200">BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta id="66d403d8-a5cf-441f-a346-d1b2d8577933"><article-id pub-id-type="publisher-id" id="6826be62-0c9d-4eab-952f-d33924d57dfa">10.1136/bjophthalmol-2018-313462</article-id><article-id pub-id-type="doi" id="cf64bf39-66aa-493a-b460-fddd6fb5c9ed">bjophthalmol-2018-313462</article-id><article-id pub-id-type="paw-acronomy" id="88c91729-fb32-4067-b214-75c8c6325133">BJO</article-id><article-categories id="ad3522e8-70c0-45d1-a32c-f8e4c7b10510"><subj-group subj-group-type="display-channel" id="b072b641-98f1-44d9-b857-d0cffcd9b6a3"><subject id="20d594e4-45eb-4bc2-a554-f4034c67438a">Review</subject></subj-group></article-categories><title-group id="1b697fb2-a552-4b49-b8e5-7ebd4d24bc72">  <article-title id="c43f1f49-f804-4d54-a6d9-0a48dbdba1f9"><named-content rid="1554794312038" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" content-type="jrnlQueryRef" specific-use="start" id="9bef782c-360d-4ede-b00a-d06de096c5c4" data-replied="true"/>Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema</article-title></title-group><contrib-group section="front" node-xpath="article-meta" next-xpath="author-notes" data-group="author" id="78d26bfa-6cce-4fad-8526-d433e28d788e"><contrib contrib-type="author" id="author-31382590" data-id="author-31382590"><name id="101f4d76-17cf-4ecb-a23d-955b237c0cfd"><surname id="0ae02e79-b46f-49cd-adc0-0d341e79fe06">Wong</surname><given-names id="ddf3e211-7abb-4667-81cd-a097596337e8">Chee Wai</given-names><prefix id="16ca101b-3450-4ee2-8536-cf3712b91cf0">Dr</prefix></name><xref ref-type="aff" rid="aff1, aff2" id="3e89ca56-4be1-47ea-ba06-165d7f01af41">1,2</xref><email id="c9acb2b3-a551-48a5-8a19-aa0697f63359">wongcheewai81@gmail.com</email><email id="381b1f8b-18a8-46fb-a3c6-c12aafaa0381">wongcheewai81@gmail.com</email><contrib-id contrib-id-type="orcid" data-retain="true" id="da7cce34-3b7a-4b19-920d-d11b0062d473">http://orcid.org/0000-0002-0935-2016</contrib-id></contrib><contrib corresp="yes" contrib-type="author" id="author-22751514" data-id="author-22751514"><name id="c86f5a1c-0cf9-49d7-bd6a-9ef8c773b56d"><surname id="611df307-8739-4e8d-bb54-e49175afb710">Wong</surname><given-names id="a5b04ce9-2eb7-4b7d-a13b-463911737a3b">Tina T</given-names><prefix id="dd04d5ae-1979-4151-bb64-f4c0d378aed8">Professor</prefix></name><xref id="49e3497e-2525-4c66-82fc-1ffa80ccbcc6" rid="aff2, aff3" ref-type="aff">2,3</xref><xref ref-type="corresp" rid="cor1" id="298c8aff-d6f2-4e3a-89ec-3c159ac21493"/><email id="5305cd69-0df9-4565-9d32-deffa7ec60e9">tina.wong.t.l@snec.com.sg</email></contrib><aff section="front" node-xpath="contrib-group" prev-xpath="contrib[last()]" id="aff1" data-id="aff1" data-edited-node="true"><label id="1c7e2bf0-4ae7-403e-bcd4-700d402d9fd8">1</label><named-content content-type="dept" id="f0e1a545-a913-44cc-a192-32604f4ed8cf">Surgical Retina</named-content>, <named-content content-type="institution" id="16a3c88b-cf65-422b-8990-54caa7b70aa7">Singapore National Eye Centre</named-content>, <named-content content-type="city" id="06fb4487-08cd-4144-8a87-a889193a12ba">Singapore</named-content>, <named-content content-type="country" id="2c750734-f12e-4ffd-b713-f69d63e90822">Singapore</named-content></aff><aff section="front" node-xpath="contrib-group" prev-xpath="contrib[last()]" id="aff2" data-id="aff2"><named-content rid="e7156e07-5c1b-4fcf-a8eb-57473220283d" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="fc587649-fd85-43cc-a823-cb13a339f081" content-type="jrnlQueryRef" specific-use="start" data-replied="true"/><label id="ffc580e6-dc5d-4446-89a3-82c4dd093e08">2</label><named-content content-type="institution" id="14997822-225d-4cb2-880d-10ac1babdab4">Duke-NUS Graduate Medical School</named-content>, <named-content content-type="city" id="5aaa5f41-c47c-4077-8970-2744bab36cb7">Singapore</named-content>, <named-content content-type="country" id="cf2b04b7-da78-49db-bcec-c8bfd611d1b9">Singapore</named-content></aff><aff section="front" node-xpath="contrib-group" prev-xpath="contrib[last()]" id="aff3" data-id="aff3" data-edited-node="true"><label id="d4c6b8e2-5b3c-4e6e-8816-a5304b71c404">3</label><named-content content-type="dept" id="def47fc9-e4ac-4456-ab68-7bcd05351709">Glaucoma</named-content>, <named-content content-type="institution" id="d57cb3fb-0c3d-448d-b082-18b2f8dc6107">Singapore National Eye Centre</named-content>, <named-content content-type="city" id="eb8c5436-46c2-4f6c-9dbf-bf856e8a9e81">Singapore</named-content>, <named-content content-type="country" id="ec38e8ca-4849-4514-9edc-b5a76a8431e7">Singapore</named-content></aff></contrib-group><contrib-group content-type="section" id="c8beb76e-cf8e-4e48-bbfc-497fa8d76d81"><contrib contrib-type="editor" id="author-27351120"><name id="4ed735b8-c349-4e76-ad01-2c1be8363b5f"><surname id="b3c26373-ac9b-4d94-9c16-f771c4b60773">Chodosh</surname><given-names id="2c8e8989-7a93-4fe2-b411-b0b8e27be2d5">James</given-names><prefix id="defde3df-eebf-47b6-9f9b-cd3184223fda">Dr</prefix></name><xref ref-type="aff" rid="ae-aff1" id="c54d050e-140b-4fd1-b573-12c2040da9fc"/></contrib><contrib contrib-type="editor" id="author-27351120"><name id="a21323ba-1143-40f3-9c96-6b25b3cb3f46"><surname id="3a0ade03-8991-4c67-b6ac-cff8b9e1df41">Chodosh</surname><given-names id="b10fd159-db21-4769-8fc2-39d4b500461d">James</given-names><prefix id="2219eb1b-855d-495d-80a2-a36c83b72c03">Dr</prefix></name><xref ref-type="aff" rid="ae-aff2" id="632e3d7b-f96f-41fe-b365-aee4ac1d8956"/></contrib><aff id="ae-aff1" data-id="ae-aff1"><department id="ed430164-c7fa-4cfb-8c12-d9ceeeaa23ba">Ophthalmology</department>, <institution id="2b95831d-7493-4cde-8367-71564ba8c3da">Massachusetts Eye and Ear Infirmary Howe Laboratory Harvard Medical School 243 Charles Street Boston, MA 02114</institution>, <city id="f5f04c78-93c1-47c2-b123-fe2054fd001b">Boston</city>, <state id="75e7a9f5-54e3-40f4-810c-fd6f79c7682f">Massachusetts</state>, <country id="0bebec3d-cd72-4773-8b50-4a3fc4a0ac77">USA</country></aff><aff id="ae-aff2" data-id="ae-aff2"><department id="de4ea787-37ec-422e-907f-5dc5c418c5c6">Ophthalmology</department>, <institution id="99527d43-ca88-42ef-9689-353b6cd807ac">Massachusetts Eye and Ear Infirmary Howe Laboratory Harvard Medical School 243 Charles Street Boston, MA 02114</institution>, <city id="be0b73bf-b291-4779-aee6-5ff635299ce0">Boston</city>, <state id="e1295100-3612-4bef-967b-8388d540f3c3">Massachusetts</state>, <country id="d514681b-1163-4439-af11-085f23fc5da5">USA</country></aff></contrib-group><author-notes id="c783b548-0417-4542-9783-a7ac66e04ca2"><corresp section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" id="cor1" data-id="cor1"><name data-class="jrnlAuthor" id="3058b6e2-d893-4842-be0e-7de638051711"><prefix id="a8eb9ed4-1874-487b-9be5-7d787e570425">Professor</prefix> <given-names id="cc686423-f8b3-48d7-8914-bd732e204427">Tina T</given-names> <surname id="19bfd95b-58b9-412f-ac36-44de1eadf0de">Wong</surname></name>, <fn fn-type="corresp-address" id="c8d5523d-4266-4fdc-a1e8-aacb08dd77b5"><p id="a9ed0d90-bbf3-4b29-930c-d1b75dae1f7f"><named-content content-type="dept" id="b9d03516-8481-4a08-9180-936540b868ed">Glaucoma</named-content>, <named-content content-type="institution" id="39749292-bbcf-49d0-a996-1be5216267e1">Singapore National Eye Centre</named-content>, <named-content content-type="city" id="fe62ee1b-dd34-45d5-9acf-0e0693287532">Singapore 168751</named-content>, <named-content content-type="country" id="6343a1c4-6568-4dfd-be51-3124baa83576">Singapore</named-content></p></fn>; <email id="ef299a0a-78fa-4f81-8294-36c28a71891f">tina.wong.t.l@snec.com.sg</email></corresp><fn fn-type="con" data-label="Contributors" id="fn1" data-id="fn1"><label id="13b2d069-8106-483e-94c7-9a07ebf24f2d">Contributors</label><p id="04981676-2310-47ab-b433-727d2cedcced">CWW and TTW contributed to the study design, literature review, drafting and critical review of the manuscript.</p></fn><fn fn-type="conflict" data-label="Competing interests" id="fn2" data-id="fn2"><label id="807a63fb-b8ff-420d-85bd-a269f9cca916">Competing interests</label><p id="92bced10-7a38-49f8-9afc-9f6bc9e882bb">None declared.</p></fn><fn fn-type="consent" section="front" node-xpath="author-notes" prev-xpath="contrib-group[last()]" data-label="Patient consent for publication" id="fn3" data-id="fn3" data-edited-node="true"><label id="eac7a7b1-9230-4894-8d88-23d730fb4257">Patient consent for publication</label><p id="37f617a0-7d1a-4a9c-91ac-e80b1d374a71">Not required.</p></fn><fn fn-type="provenance-and-peer-review" data-label="Provenance and peer review" id="fn4" data-id="fn4"><label id="45cdd6d2-ccf7-4a41-8b7d-6cdb19a10d2b">Provenance and peer review</label><p id="f3b6164d-47b2-4a99-ae90-1bf5403d519a">Not commissioned; externally peer reviewed.</p></fn></author-notes><pub-date section="front" node-xpath="article-meta" node-prev-xpath="//author-notes" node-next-xpath="//history" pub-type="ppub" id="be9d9397-9c68-4fcc-b86c-40ca6ff97df4"><day id="39279367-93cd-4222-90a7-276006a60cbb">30</day><month id="e36ed568-e2fd-459f-9275-6c77ca372ec2">04</month><year id="c269d8f1-bd9d-40c7-8144-f266b0ea35d5">2019</year></pub-date><pub-date section="front" node-xpath="article-meta" node-prev-xpath="//author-notes" node-next-xpath="//history" pub-type="epub" id="828abdfd-148e-4fb6-a621-1391251c5762"><day id="5c860e0f-5b54-4b65-abba-deac7d5b77db">30</day><month id="b5e56ece-21f1-4735-bd73-bd394975a820">04</month><year id="335e819e-ffa0-43c0-a4e6-5b8eb4d7ae67">2019</year></pub-date><volume id="c85f9ce8-adb5-4875-b1b0-fc824ae0ef6e"/><issue id="30c25928-6248-46a9-bb79-2f9aeff67568"/><fpage>1</fpage><lpage>5</lpage><history id="9333d17f-c16c-46e8-8eb2-f525d3ec92e7" data-edited-node="true"><date date-type="received" id="8a892f11-2b55-4a98-ad73-8860bc1a07a1"><day id="b97751fc-56a8-4991-a857-25a4bd08061f">28</day><month id="d7078179-3118-4cfe-a8db-10162452ea0e">10</month><year id="9d795280-8afa-4a04-96b3-5f0d7432b0d8">2018</year></date><date date-type="rev-recd" id="53e1096a-55d6-4a54-ae1a-f134b0f021e9"><day id="4fc752b4-83fa-44d7-97b4-007092ef424b">04</day><month id="bb3bbbe4-1f49-4d37-9402-ff1ee8770492">04</month><year id="ec319c1a-05e3-4734-a8a1-af0b60aa2af3">2019</year></date><date date-type="accepted" id="01a9544b-5a14-43b9-a7b3-fe4602106aec"><day id="59ad6b5b-26a1-4b0d-a3b2-9b500ec76299">07</day><month id="0a3981c9-7a89-4433-99cc-a2eae7ac2e7f">04</month><year id="95ae647b-a07f-4ab0-a664-c097a2c047b5">2019</year></date></history><permissions data-type="nonOA" id="4ce3134c-927f-44d3-9541-aecf5f92b0f7"><copyright-statement data-statement="new" id="cfb66416-dfba-4abe-bc7e-5a15487c698b">Â© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year id="8b21d577-faa4-47b3-84a7-9743e1f74190">2019</copyright-year><license id="841d8900-e9d4-49aa-9920-6bb6ee3fe18c"><license-p id="45627fab-9a97-4b6c-9b0e-9cbe41b2cc01"/></license></permissions><files id="e1a7deac-b494-414b-a61a-251a8ebdd91c"><file file-type="Main Document" file_category="" file_name="bjophthalmol-2018-313462-File001.docx" submission_medium="online" id="73059d66-d419-408b-8d45-f43dfbb9d6b0"><file_createddate id="5fe1918e-f3ec-49f9-82c0-c0f6919deff7">2019-04-04 11:26:23.23</file_createddate><file-format id="a0d5c658-4979-47b0-9da3-8b1eeb6a890b">docx</file-format><file-extension id="c3fc3baa-2e3e-417d-ad8e-7bde0f5b1e55">docx</file-extension><file-name id="55f59b1f-a1b3-40d5-9d0b-f15115b5ee1e">Posterior segment drug delivery for the treatment of exudative age_revision3_clean copy.docx</file-name><file-caption id="2583f1eb-52c2-4c23-abd3-1c92e0b25d69"/><file_tag id="69622c9e-07a7-4493-87fe-f27c13f37afb"/><attribute attr_name="File Designation" id="1cba8470-c81a-4871-a00d-ec640fad3b63">Main Document</attribute></file></files><abstract id="265c80b3-4c47-4503-a77a-d7157663e33e"><title data-level="1" id="2f982429-7c1c-495c-99a5-0a888d671c04">A<named-content data-cid="1554803928" id="da4a48c5-7018-49d9-ad2c-0fc83155c805" content-type="changeCase sty cts-2" specific-use="1554804060754" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="lowercase Added by Asha (PREEDITOR) - 04/9/2019 3:31pm" data-track-detail="" data-track-hint="lowercase Added" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554804060754">bstract<span data-class="hidden" hidden-track="track" id="19a56b92-eccf-4bd7-bb8f-68776bd09c9f">BSTRACT</span></named-content></title><p id="ff88d30d-ef44-4e73-8fe2-58ec8b216754">Inhibitors of vascular endothelial growth factors are used to treat a myriad of retinal conditions, including exudative <named-content id="d4433330-8ccf-4621-a72c-4080d003098c" data-cid="d4433330-8ccf-4621-a72c-4080d003098c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="120" data-match="age-related macular degeneration" data-pattern="" data-tag-index="" data-abbr="AMD" data-time="" data-username="" data-userid="">age-related macular degeneration</named-content> (<named-content id="08d3b3bb-e1c5-4710-b43f-cdf5bfa5d9ac" data-cid="08d3b3bb-e1c5-4710-b43f-cdf5bfa5d9ac" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="154" data-match=" (AMD)" data-pattern="" data-tag-index="1_1" data-time="" data-username="" data-userid="">AMD</named-content>), <named-content id="50200190-612b-4367-977f-425510792855" data-cid="50200190-612b-4367-977f-425510792855" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="160" data-match="diabetic macular oedema" data-pattern="" data-tag-index="" data-abbr="DME" data-time="" data-username="" data-userid="">diabetic macular oedema</named-content> (<named-content id="2edc6085-7a54-404a-b3d4-fb9a08ebb194" data-cid="2edc6085-7a54-404a-b3d4-fb9a08ebb194" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="185" data-match=" (DME)" data-pattern="" data-tag-index="1_2" data-time="" data-username="" data-userid="">DME</named-content>) and diabetic retinopathy. Although effective, long<named-content data-cid="1555259570" id="5d43203f-5cee-4ae0-b149-ed95642c42db" content-type="del cts-3" specific-use="1555259973242" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259973242"> </named-content><named-content data-cid="1555259571" id="760b9cf9-f70e-4261-b64e-71e2f8aa43d1" content-type="ins cts-3" specific-use="1555259974082" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259974082">-</named-content>term efficacy is limited by the need for frequent and invasive intravitreal injections. The quest for sustained action therapeutics that can be delivered to target tissue in the least invasive manner is an arduous endeavour that has ended in premature failure for several technologies in Phase <named-content data-cid="1555259463" id="f6933446-ebf5-4bb3-9584-bf3c6d3154ae" content-type="ins cts-3" specific-use="1555259735144" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259735144">II</named-content><named-content data-cid="1555259465" id="007c46dc-d463-4add-94ad-0419d07101d4" content-type="del cts-3" specific-use="1555259736132" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259736132">2</named-content> or <named-content data-cid="1555259466" id="5bb436b4-06e5-4ac1-a579-44194ad97247" content-type="ins cts-3" specific-use="1555259737889" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259737889">III</named-content><named-content data-cid="1555259469" id="223d7637-2aab-436b-9ebe-0597ef2dd057" content-type="del cts-3" specific-use="1555259739059" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259739059">3</named-content> trials. Nevertheless, there have been promising preclinical studies, and more are on the horizon: port delivery systems for the treatment of exudative AMD have entered Phase <named-content data-cid="1555259470" id="22f656c3-42bd-40cf-9cc2-e6aa2070600a" content-type="ins cts-3" specific-use="1555259742216" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259742216">III</named-content><named-content data-cid="1555259473" id="bcd041db-f97e-410c-b80c-50785781822c" content-type="del cts-3" specific-use="1555259743363" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259743363">3</named-content> trials and a wide array of preclinical studies have demonstrated the potential for nanoparticles, such as liposomes, dendrimers and cell penetrating peptides to deliver therapeutics into the posterior segment via minimally invasive routes. In this review, we discuss the challenges posed by ocular barriers for drug penetration and present the recent advancements of the most pertinent drug delivery platforms with a focus on the treatment of exudative AMD and DME.</p> </abstract><kwd-group id="9451584d-6240-4e18-ac3f-13d28c10b8dc"><kwd id="33c6b6d7-2d39-4314-8e3b-7cf185a530c9">drugs</kwd><kwd id="a22d98a1-1598-40cd-af7c-f2d4816043b5">macula</kwd><kwd id="597a6736-37a9-48ea-a85c-c9fd35095a1c">neovascularisation</kwd><kwd id="7df0bc62-3ca6-4e0e-bc0f-28f72c8888b2">retina</kwd><kwd id="7b971e39-0e7c-4c79-9455-0735dd82f4d7">treatment medical</kwd></kwd-group><custom-meta-group id="409e82f4-3b2a-4be0-b1fe-6769ae3c0f5f"><custom-meta id="fa9d5774-aaa4-4f42-9cf5-0abf17f2bdda"><meta-name id="5b4546f6-be85-46f4-9acc-48856a5fb63c">Copy editing requirement</meta-name><meta-value id="fc1f67f9-c155-4672-bd71-1303d89f8ee4">2</meta-value></custom-meta><custom-meta id="d20b684c-4ef7-40fe-b319-ba90cd2d9767"><meta-name id="0cb70592-eb4f-46ea-80b4-80a3db0b2150">Author requirement</meta-name><meta-value id="85bcb757-edbf-477c-a504-e2c6aed4a3df">2</meta-value></custom-meta><custom-meta id="0d6abd53-7319-444f-bc17-dce6f79c1068"><meta-name id="15ac7328-8955-47ce-9cc6-ea8ff8975179">payment method</meta-name><meta-value holdtype="NoHold" id="e1958599-c53f-4758-95da-442c861d355a">No APC</meta-value></custom-meta><custom-meta id="d3e0b95e-44a1-47a4-ad45-47728919e881"><meta-name id="b0a922cf-fc81-4c69-82da-aa77174e604a">license type</meta-name><meta-value id="bb9086c4-fb02-4a6b-921d-a630d719920f">nonOA</meta-value></custom-meta><custom-meta id="534811cc-7737-42cf-a89f-878d58fa6e19"><meta-name id="7829ad28-2fc0-4e91-afb0-d2fbb897979d">Spelling language</meta-name><meta-value id="30d6c743-6590-403b-9f1d-f3320f9227fc">en-GB</meta-value></custom-meta><custom-meta specific-use="query" id="1554794312038" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true"><meta-value id="a0aee584-9ad4-4c23-89f9-d129b1587862"><named-content xlink:title="Exeter Pre-editing" specific-use="Apr 09 2019 (12:49)" content-type="Author" alt="preeditor" id="cabec7ed-5d5b-4cb2-8ce1-35c322a5ce63">Corrections at this stage should be limited to those that are essential. Extensive corrections will delay the time to publication and may also have to be approved by the Editor. Changes can not be made after the article has published online. Please acknowledge that you have read this message.</named-content><named-content xlink:title="Tina T Wong (AUTHOR)" specific-use="Apr 15 2019 (20:48)" content-type="reply" alt="author" id="857c39a6-9d3f-4e61-bcac-8bdd97df60b4">Acknowledged</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="1554794312039" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true"><meta-value id="470acaad-edd2-4084-a975-906bfd5f092f"><named-content xlink:title="Exeter Pre-editing" specific-use="Apr 09 2019 (12:49)" content-type="Author" alt="preeditor" id="9a827e4f-75e2-4517-b81a-c07053e86726">Please confirm that the section headings are correct.</named-content><named-content xlink:title="Tina T Wong (AUTHOR)" specific-use="Apr 15 2019 (20:51)" content-type="reply" alt="author" id="4466de02-22ba-4d1e-983e-ed27b60cfa6c">Yes they are correct</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="72010c22-b3a8-476c-8a36-a910aa6e9422" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-query-action="uncited-table" data-float-id="T1" data-remove-edit="true" data-replied="true"><meta-value id="f4f06d36-f89a-45c6-81de-97206141cf9c"><named-content xlink:title="Kriya (PREEDITOR)" specific-use="Apr 9 2019 12:50 PM" content-type="Author" alt="preeditor" id="44d249e3-447e-4f60-84b9-ddd2557e534c"><span data-class="floatID hidden" data-selector="./@data-id" data-type="htmlComponent" id="de7ad174-7d30-4d80-95fd-7845b1c7804d">BLK_T1</span> Please provide an in-text citation for <span data-selector=".//*[@class='label'][1]" data-type="htmlComponent" id="91a154e5-b717-4cdf-9980-47208b28ace0"><named-content data-cid="1555772958242" id="d92e31a6-88ea-42d0-8ad7-e5d8664000cd" content-type="ins cts-1" specific-use="1554794356000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794356000">Table 1</named-content></span> .</named-content><named-content xlink:title="Asha (PREEDITOR)" specific-use="Apr 9 2019 (15:31)" content-type="reply" alt="preeditor" id="e0c14faa-50d3-43c1-b971-e68564e2e988"><italic id="4de7e95e-6008-43ee-9b48-34fdb185d8bb">This table has been cited</italic></named-content></meta-value></custom-meta><custom-meta specific-use="query" id="e7156e07-5c1b-4fcf-a8eb-57473220283d" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true"><meta-value id="9512962b-068c-474a-afc7-12398c4e7616"><named-content xlink:title="Varadaraj (COPYEDITOR)" specific-use="Apr 14 2019 10:26 PM" content-type="Author" alt="copyeditor" id="eb6bbae1-6cef-452a-a0cc-273d27e6aff5">Please provide the Department name for affiliation 2, if available.</named-content><named-content xlink:title="Tina T Wong (AUTHOR)" specific-use="Apr 15 2019 (20:49)" content-type="reply" alt="author" id="813cc7f0-33bd-4e4e-b12d-8c9679d126c2">No specific department name </named-content></meta-value></custom-meta><custom-meta specific-use="query" id="b8cd53b3-4be9-4607-9d52-d3ce612c6809" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true"><meta-value id="dcf7d8f5-60c8-443a-97e4-04242f67e4f8"><named-content xlink:title="Varadaraj (COPYEDITOR)" specific-use="Apr 14 2019 10:35 PM" content-type="Typesetter" alt="copyeditor" id="0073e08d-cf05-4fda-bff5-ea6109cd9b3c">Please check 'less less than' symbol appearing as box in the final output.</named-content><named-content xlink:title="Asha (TYPESETTER)" specific-use="Apr 15 2019 (10:43)" content-type="reply" alt="typesetter" id="5f619c4a-63c5-42e2-ac85-dd6ff91094af">Checked.</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="9fc41276-4cf8-4211-b646-81fd2f53d1d0" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true" data-style="left: 676px; top: 325.594px;"><meta-value id="a16f2bae-1307-42fb-89e8-c0968e83bf6e"><named-content xlink:title="Production (BMJ)" specific-use="Apr 24 2019 2:49 PM" content-type="Typesetter" alt="publisher" id="e34c15ef-dbb2-46f4-b6be-29a7c9df28d9">Remove table 1 citation here</named-content><named-content xlink:title="Thilip (TYPESETTER)" specific-use="Apr 25 2019 (12:48)" content-type="reply" alt="typesetter" id="941b7a5b-afd0-40eb-8572-b4cdbffbade1">Removed</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="0b8c0f36-3f25-40e2-848b-881c8bbaf413" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true" data-style="left: 24px; top: 326px;"><meta-value id="1d98fe00-4e9d-4ab9-8bc1-9a98383e3d13"><named-content xlink:title="Production (BMJ)" specific-use="Apr 24 2019 2:50 PM" content-type="Typesetter" alt="publisher" id="94682a15-dd97-4588-97ae-20d741651547">Table 1 link should be added here</named-content><named-content xlink:title="Thilip (TYPESETTER)" specific-use="Apr 25 2019 (12:47)" content-type="reply" alt="typesetter" id="2b3e661d-5b73-4a28-b727-c9da309d7bbf">Linked</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="32393948-5550-47ee-a01b-78da80dbc012" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true" data-style="left: 647.547px; top: 326px;"><meta-value id="3f046567-1d77-419a-9a04-1a52160f7191"><named-content xlink:title="Production (BMJ)" specific-use="Apr 24 2019 2:51 PM" content-type="Typesetter" alt="publisher" id="e7550966-ad8c-4d6f-8f6d-b6eb14f3367d">remove this citation to table</named-content><named-content xlink:title="Thilip (TYPESETTER)" specific-use="Apr 25 2019 (12:48)" content-type="reply" alt="typesetter" id="24884a62-64c8-48eb-86a7-fc1049d0d247">Removed</named-content></meta-value></custom-meta><custom-meta specific-use="query" id="148136cc-ec36-4994-abba-fc1b9de3b20d" section="article-meta" node-xpath="custom-meta-group" xlink:type="action" data-type="action" data-replied="true"><meta-value id="4beef2ec-feda-4da8-a179-7fd2ef628bea"><named-content xlink:title="Asha (PREEDITOR)" specific-use="Apr 9 2019 3:33 PM" content-type="Author" alt="preeditor" id="80139916-5267-495f-93cb-60b6e0ad5185">As per style table citations are not allowed in heading levels, hence we have removed and replaced in end of the below paragraph. Please check and confirm.</named-content><named-content xlink:title="Tina T Wong (AUTHOR)" specific-use="Apr 15 2019 (20:50)" content-type="reply" alt="author" id="cc34ee71-9439-47f9-9665-019665176d60">The citation "table 1" should not be at the end of the below paragraph. Please add a sentence below the heading "Drug delivery for the posterior segment" as follows:<div id="f7aa64af-968e-496f-9bad-c6d3420c3b25"><break id="a450327f-d6d5-4491-9568-327b9a75ffbd"/></div><div id="d3766c2d-f7ee-4cfb-9347-cb6cd7593ffd">Table 1 summarizes the various posterior segment drug delivery technologies.</div></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="df1d8358-4cfd-41d8-b2e0-e852cdbf6111" xlink:title="9333d17f-c16c-46e8-8eb2-f525d3ec92e7" xlink:actuate="0b0ea00d-3c02-4ab4-9a81-09db426c9c05" xlink:role="typesetter" xlink:href="be9d9397-9c68-4fcc-b86c-40ca6ff97df4"><meta-value><named-content specific-use="historyContent" data-title="" id="381a614a-aa16-4abe-b0f3-7d816bd56f08"><named-content specific-use="change-person" data-title="" id="1c560c62-fcec-4e3f-9a49-6f6140fc8a43">Usha</named-content> <named-content specific-use="" data-title="" id="0c9da330-5f31-46ee-81cb-ea10f4fff7da">inserted</named-content> <named-content specific-use="newVal" data-title="" id="76f5bb74-a0d0-47bd-90d5-8da22f94836e">30042019</named-content> <named-content specific-use="" data-title="" id="96623558-b3a5-4200-a8ee-64399e35c537"> in ppub field on</named-content> <named-content specific-use="change-time" data-title="" id="65f5ca32-6b2c-47b8-a215-f5eed2bad4fc">30 Apr 2019 9:07 AM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="91ea0c8d-4b4e-4edc-bcec-0ea361c22a98" xlink:title="9333d17f-c16c-46e8-8eb2-f525d3ec92e7" xlink:actuate="0b0ea00d-3c02-4ab4-9a81-09db426c9c05" xlink:role="typesetter" xlink:href="828abdfd-148e-4fb6-a621-1391251c5762"><meta-value><named-content specific-use="historyContent" data-title="" id="830273e2-7cdc-48aa-87a0-70ee797590a1"><named-content specific-use="change-person" data-title="" id="ee28008e-33e7-421a-bbc5-0e594c9dd936">Usha</named-content> <named-content specific-use="" data-title="" id="dddf0466-25b6-4872-9970-4e538917b1c7">inserted</named-content> <named-content specific-use="newVal" data-title="" id="d3c03bbd-5c4b-4d31-8374-e07785bbf5c8">30042019</named-content> <named-content specific-use="" data-title="" id="3adc5d27-c9e5-4483-94cd-d7610901aaa8"> in epub field on</named-content> <named-content specific-use="change-time" data-title="" id="d0f196de-4e02-4aee-a3e1-282dea65d36a">30 Apr 2019 9:07 AM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="d48cfb1b-8d41-4233-bbb3-d2bdc4296bb1" xlink:title="fn3" xlink:actuate="74d455fb-5d27-44fd-a9e5-5e6807bcf916" xlink:role="preeditor" xlink:href="fn3"><meta-value id="d57d21d4-9883-4625-ab60-54f371b6b6d4"><named-content specific-use="historyContent" data-title="" id="7dd48b3a-c049-4def-b596-07f0ba2a05b2"><named-content specific-use="change-person" data-title="" id="1e547ae5-cc4b-43a9-ab9d-6c567742d044">Asha</named-content> <named-content specific-use="" data-title="" id="cac7b553-0c5d-4e3c-89d3-7b32b067650e">changed</named-content> <named-content specific-use="oldVal" data-title="" id="5e197331-5abb-4a71-b1e8-a76e52311b6e">Not Required</named-content> <named-content specific-use="" data-title="" id="50a4bacc-ffd0-488c-8a8d-a5787637f8fd">to</named-content> <named-content specific-use="newVal" data-title="" id="a812ae49-9905-4603-8f2e-f10719cf7319">Not required.</named-content> <named-content specific-use="" data-title="" id="f69ca994-6c8b-44c9-8885-43e3c2217927"> in Content field on</named-content> <named-content specific-use="change-time" data-title="" id="384c202b-5a43-4479-ba0c-b2da59f8772d">9 Apr 2019 3:43 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="e585252e-e0b5-456d-a9bb-1c4970cf952b" xlink:title="aff3" xlink:actuate="74d455fb-5d27-44fd-a9e5-5e6807bcf916" xlink:role="preeditor" xlink:href="b1092fbe-14c8-42d1-a2d7-4e95e36d1e8b"><meta-value id="9d54dff9-312c-42a6-b022-1214b779e868"><named-content specific-use="historyContent" data-title="" id="e98b5737-84d9-4fe9-8ac3-14d18d6dca69"><named-content specific-use="change-person" data-title="" id="8a61d7ac-137c-40c6-bea1-965a2f1bb695">Asha</named-content> <named-content specific-use="" data-title="" id="b5e20389-3ed6-49c8-a789-aa152631475a">deleted</named-content> <named-content specific-use="oldVal" data-title="" id="fa9f842d-d95c-49fd-9148-13c87ac2efd4">Singapore</named-content> <named-content specific-use="" data-title="" id="16f9b0d7-04ff-4d05-b355-dcaf18bb84e7"> in State field on</named-content> <named-content specific-use="change-time" data-title="" id="d4e739e7-b7d6-44b6-97df-f1b45f85da9b">9 Apr 2019 3:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="a7de0de3-e997-4b94-b61d-0130fe4cc06d" xlink:title="aff1" xlink:actuate="74d455fb-5d27-44fd-a9e5-5e6807bcf916" xlink:role="preeditor" xlink:href="cbc923ed-e00e-42ec-9076-c4355ab9d506"><meta-value id="691f157d-af60-45a1-842d-fedf1d9b4e2e"><named-content specific-use="historyContent" data-title="" id="467e18b4-844f-4aaf-a272-ae61a6c62ea4"><named-content specific-use="change-person" data-title="" id="7a0c80b6-6a64-45ab-bc31-aff2d5cc0ac4">Asha</named-content> <named-content specific-use="" data-title="" id="8ea026b8-b16d-4e21-b598-bc7af1b5a1de">deleted</named-content> <named-content specific-use="oldVal" data-title="" id="4da88fec-baf6-4122-bbe4-70a9e2522ad9">Singapore</named-content> <named-content specific-use="" data-title="" id="c6210cb5-6c07-4b88-91e9-e995fe838dcc"> in State field on</named-content> <named-content specific-use="change-time" data-title="" id="55446369-c929-48cb-a71c-046f000ed98f">9 Apr 2019 3:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" section="article-meta" node-xpath="custom-meta-group" id="75b04adf-3044-4875-84f6-595cbcb0f0d1" xlink:title="c8d5523d-4266-4fdc-a1e8-aacb08dd77b5" xlink:actuate="74d455fb-5d27-44fd-a9e5-5e6807bcf916" xlink:role="preeditor" xlink:href="fe62ee1b-dd34-45d5-9acf-0e0693287532"><meta-value id="0edbf495-cb85-4ce3-a4e4-3aa165e58790"><named-content specific-use="historyContent" data-title="" id="53b87a35-109c-406a-92c8-abf24a2a2ac7"><named-content specific-use="change-person" data-title="" id="27b37ca2-5c05-48fc-b17e-6922ad9cc4a6">Asha</named-content> <named-content specific-use="" data-title="" id="04e72fc0-9f57-4f6a-bd23-0377e0a75eec">changed</named-content> <named-content specific-use="oldVal" data-title="" id="993ed2ab-28f9-4b88-8264-4e99405cea0b">Singapore</named-content> <named-content specific-use="" data-title="" id="a0ec819e-951b-45d9-8d5a-cd5e56a6049b">to</named-content> <named-content specific-use="newVal" data-title="Singapore 168751" id="61bee82a-7df7-4cce-bcaa-7b698b72005a">Singapore 168751</named-content> <named-content specific-use="" data-title="" id="7e7d7d24-c398-4033-8589-042b5fbe1ec8"> in City field on</named-content> <named-content specific-use="change-time" data-title="" id="9509a7eb-b913-4bd1-b394-020da1eab530">9 Apr 2019 3:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta specific-use="history" id="808a4992-6cf1-4b02-8954-4260742f2b75" xlink:title="c8d5523d-4266-4fdc-a1e8-aacb08dd77b5" xlink:actuate="74d455fb-5d27-44fd-a9e5-5e6807bcf916" xlink:role="preeditor" xlink:href="b106ff7d-c2ad-4793-a815-cb33c36b426e"><meta-value id="401d8f50-fbf3-423b-8803-4c9e21385b76"><named-content specific-use="historyContent" data-title="" id="f6eb6628-fc53-407c-86fb-5a37332fe68c"><named-content specific-use="change-person" data-title="" id="b770015d-9a3e-4fa2-b793-60d8fbbc3251">Asha</named-content> <named-content specific-use="" data-title="" id="6510a8a9-413f-4a24-98b0-58a511de1cb8">deleted</named-content> <named-content specific-use="oldVal" data-title="" id="1c86733d-b8d5-471d-9789-5677e90ac4fa">Singapore</named-content> <named-content specific-use="" data-title="" id="b5f79e11-c102-413a-8cc2-dc345fae9df1"> in State field on</named-content> <named-content specific-use="change-time" data-title="" id="69652128-c8c6-4373-90a5-75ff04acabdc">9 Apr 2019 3:30 PM</named-content></named-content></meta-value></custom-meta><custom-meta id="c614009b-5ac4-44fe-8285-af90e6de7266"><meta-name id="cdd05c8c-541a-459e-a4b1-57ab13c56f95">Copyediting_user_level</meta-name><meta-value id="03faf962-fef3-4767-bc93-ebd10340228e">expert</meta-value></custom-meta></custom-meta-group><counts id="1b166f9c-1f4f-40e5-858c-a6a965c46c71"><fig-count count="0"/><table-count count="1"/><equation-count count="0"/><ref-count count="53"/><page-count count="4.9"/><word-count count="5306"/></counts><funding-group id="ebeed62e-440a-4e82-8d6e-000c9f0bf1b8"><funding-statement section="article-meta" node-xpath="funding-group" next-xpath="custom-meta-group" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'addDataTempSelector', 'param' : {'component' : 'jrnlFN'}}" data-ele-type="funding-statement" fn-type="funding" data-label="Funding" id="0d2d3e94-af0a-49c4-b36d-c8643f22dccb">The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</funding-statement></funding-group></article-meta></front><body id="f90d0cc7-2618-4071-8ff9-895c4a676613"><p data-class="jrnlDeleted" data-head-type="bold" data-authors="true" id="529bc4bb-b6a9-4253-84c2-69d9c9404fef">Chee Wai Wong, MMed(Ophth)<sup id="b882385b-2aed-4b9d-8550-9c345f62eb1a">1,2,4</sup> ,Tina T. Wong, PhD<sup id="435baa86-1302-4e34-a3f7-9a52c880922c">1,2,3,4</sup></p><span data-class="jrnlDeleted" id="32785543-d16f-4109-ba17-360a8e604816">Authors:</span><p data-class="jrnlDeleted" data-affs="true" id="17661a35-c0dc-4694-83a9-406f705ed4e3">1. Singapore National Eye Centre (SNEC), 11 Third Hospital Avenue, Singapore 168751</p><p data-class="jrnlDeleted" data-affs="true" id="c85eac7e-a276-43af-90a8-f2aa83d29d9a">2. Singapore Eye Research Institute, 11 Third Hospital Avenue, Singapore 168751</p><p data-class="jrnlDeleted" data-affs="true" id="541630b1-4476-4bd5-b2f2-6b799267d847">3. School of Materials Science and Engineering (MSE), Nanyang Technological University, 11 Faculty Avenue, Singapore 639977</p><p data-class="jrnlDeleted" data-affs="true" id="45087e98-dc0c-40d9-b1dd-c2b9170ca82a">4. Duke-NUS Graduate Medical School, 8 College Rd, Singapore 169857</p><p data-class="jrnlDeleted" colorcode="windowtext" id="46b8db83-25a8-4e0c-a90e-63851b6fc067">Corresponding author: Email: tina.wong.t.l@snec.com.sg; Email: G.Storm@uu.nl</p><p data-class="jrnlDeleted" id="35f3a26e-4fc7-425c-ad27-b7ddb713a3e5">Address: Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751 Telephone: (65) 63227477</p><p data-class="jrnlDeleted" data-style="font-family: 'Calibri',sans-serif; font-size: 12.0pt; margin-left: 0cm; margin-right: 0cm; margin: 0cm; margin-bottom: .0001pt; line-height: 200%;" fontsize="12.0" id="d22a7c96-241d-4c7d-a973-a601293df43c">Fax: (65) 62252568</p><p data-class="jrnlDeleted" id="924a3aef-39a8-4a94-8943-1aa510b631bd"><span data-class="Del cts-1" id="89f426c5-eb28-4e8e-a648-7674927bdefa">Word count: 2973</span></p><p data-class="jrnlDeleted" id="cd20bb80-70b6-43d7-9c16-144ea2594182">Keywords: drug delivery, posterior segment, exudative age-related macular degeneration, DME, liposomes, dendrimers, polymeric micelles, cell penetrating peptides.</p><p data-class="jrnlDeleted" id="3e6cccc4-a447-44e5-b965-59a2c895a8b4">Authorship contributorship statement: CWW and TTW contributed to the study design, literature review, drafting and critical review of the manuscript.</p><p data-class="jrnlDeleted" id="caeeff9f-966a-42cc-8ec7-b5da433db7d8">Competing interests and funding: There are no competing interests or funding.</p><title data-level="1" data-class="jrnlHead1" id="8798cd6d-c800-49ea-a914-34f273bfc875"><named-content rid="1554794312039" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" content-type="jrnlQueryRef" specific-use="start" id="64917736-681a-4c4c-ba92-12e2cb3c0b40" data-replied="true"/><named-content data-cid="1554794312032" id="9c117918-d5cf-45e4-a1de-279bca963d03" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase">INTRODUCTION</named-content><named-content data-cid="1554794312032" id="f2abe3a0-31fe-452d-a038-da14e0378def" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase">Introduction</named-content></title><p data-class="jrnlSecPara" id="71e785e6-d5de-4c74-af49-c15582156d69">Anti<named-content data-cid="1555332917" id="96278071-f778-47ac-bc47-8d7bd83b7272" content-type="ins cts-4" specific-use="1555333148344" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Inserted by Tina T Wong (AUTHOR) - Apr 15 2019 8:59pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555333148344">-</named-content><named-content data-cid="1555259574" id="de1f2adf-87d8-4b29-a87a-e8def63f3201" content-type="del cts-3" specific-use="1555260002690" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:10pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260002690">-</named-content>vascular endothelial growth factors (anti-VEGF) are the most common posterior segment therapeutics. They are used to treat a myriad of retinal conditions including exudative age<named-content data-cid="1555259606" id="ed6d2bc5-c551-479a-a879-cd36c2553562" content-type="del cts-3" specific-use="1555260383670" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260383670"> </named-content><named-content data-cid="1555259607" id="e525e7d5-0f7d-4978-874f-8a4bc352a074" content-type="ins cts-3" specific-use="1555260384189" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260384189">-</named-content>related macular degeneration (<named-content id="aea276ca-514b-4b9c-943a-23a71b898351" data-cid="aea276ca-514b-4b9c-943a-23a71b898351" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="213" data-match=" (AMD)" data-pattern="" data-tag-index="2_3" data-time="" data-username="" data-userid="">AMD</named-content>), myopic choroidal neovasculari<named-content data-cid="1555259709" id="02843e9c-b7b9-498c-a1fa-ef892c7653cc" content-type="del cts-3" specific-use="1555262119114" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262119114">z</named-content><named-content data-cid="1555259708" id="2d6044ed-ca32-41fb-bdc3-fc8a883f8b41" content-type="ins cts-3" specific-use="1555262118239" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262118239">s</named-content>ation<named-content data-cid="1555259710" id="8a8ff719-1949-4a50-a5f9-c1e7a3d9ff71" content-type="ins cts-3" specific-use="1555262120911" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262120911"> (CNV)</named-content>, <named-content id="916d879c-dfe3-46aa-91d1-4532feb556da" data-cid="916d879c-dfe3-46aa-91d1-4532feb556da" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="256" data-match="diabetic macular oedema" data-pattern="" data-tag-index="" data-abbr="DME" data-time="" data-username="" data-userid="">diabetic macular oedema</named-content> (<named-content id="7ba6ca3d-f9c2-4d1a-9f86-675c823686ea" data-cid="7ba6ca3d-f9c2-4d1a-9f86-675c823686ea" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="281" data-match=" (DME)" data-pattern="" data-tag-index="2_4" data-time="" data-username="" data-userid="">DME</named-content>), diabetic retinopathy<named-content data-cid="1555332918" id="bbefba2b-482c-4618-b79e-c92ee7a53b3e" content-type="del cts-4" specific-use="1555333199804" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Deleted by Tina T Wong (AUTHOR) - Apr 15 2019 8:59pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555333199804">,</named-content><named-content data-cid="1555332919" id="3b0af190-d6a4-411f-aa63-5d44dfb01551" content-type="ins cts-4" specific-use="1555333202866" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Inserted by Tina T Wong (AUTHOR) - Apr 15 2019 9:00pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555333202866"> and</named-content> retinal vein occlusion<named-content data-cid="1555259610" id="6bcd7c72-40fd-4c80-8b8d-d263ef09e71a" content-type="del cts-3" specific-use="1555260410933" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260410933"> </named-content><named-content data-cid="1555259611" id="3eb2e576-82db-4cf1-94cd-64b2c921e966" content-type="ins cts-3" specific-use="1555260411454" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260411454">-</named-content>related cystoid macular oedema <named-content data-cid="1555332923" id="283992aa-e8fb-45a0-b924-6a205f2db791" content-type="del cts-4" specific-use="1555333211285" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Deleted by Tina T Wong (AUTHOR) - Apr 15 2019 9:00pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555333211285">and as adjunct therapy for proliferative vitreoretinopathy</named-content>. Though effective, there are several drawbacks to these therapies. First, anti-VEGF molecules are large and highly hydrophilic, making penetration through ocular barriers problematic. Thus, invasive intravitreal injections are required to deliver sufficient drug concentrations to the retina. Intravitreal injections are associated with risks of infection, retinal detachment, glaucoma and lens damage. Second, they have short ocular half-lives relative to the duration of disease activity, thus necessitating frequent and repeated intravitreal injections. Consequently, the need for frequent injections increases the cumulative risks of injection<named-content data-cid="1555259608" id="7c58476d-f021-4086-8458-2781b2f7610e" content-type="del cts-3" specific-use="1555260393926" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260393926"> </named-content><named-content data-cid="1555259609" id="2a057c32-cc85-42d7-ad58-365d0b960686" content-type="ins cts-3" specific-use="1555260394589" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260394589">-</named-content>related complications and has led to a tremendous treatment burden as well as escalating costs. Long-term <named-content data-cid="1554794312018" id="0520334f-82ac-4736-a513-4cb4b0564949" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">follow up</named-content><named-content data-cid="1554794312018" id="fe7f3e09-f322-45aa-82c9-f771db10d3f4" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'followâ£up' to 'follow-up'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1176" data-match="follow up" data-replace="follow-up" data-pattern="follow-up" data-tag-index="2_5" data-function="addTrackChanges" data-track-change="follow up" data-userid="preediting" data-username="Exeter" data-time="1554794312000">follow-up</named-content> of <named-content id="763fb1c6-73d5-4a55-b98b-367fbe6e7343" data-cid="763fb1c6-73d5-4a55-b98b-367fbe6e7343" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1189" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="2_6" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> who have exited large AMD treatment trials illustrate the challenges of sustaining frequent and costly intravitreal injections, with most <named-content id="665c2a92-1104-468e-b93b-f508e735a536" data-cid="665c2a92-1104-468e-b93b-f508e735a536" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1336" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="2_7" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> losing vision gained from the first <named-content id="a6566b4a-4fcf-445d-ac8d-534fc6acab8a" data-cid="a6566b4a-4fcf-445d-ac8d-534fc6acab8a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="1381" data-match="2 years" data-replace="2" data-pattern="$1" data-tag-index="2_2" data-time="" data-username="" data-userid="">2</named-content><named-content id="100fcd7c-59db-4b9a-9dc6-2c9920d76624" data-cid="100fcd7c-59db-4b9a-9dc6-2c9920d76624" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="1382" data-match="2 years" data-replace=" years" data-pattern=" $2" data-tag-index="2_2" data-time="" data-username="" data-userid=""> years</named-content> of anti-VEGF therapy.<xref id="3e58c28f-8068-40ef-91ef-aa1dfe120816" ref-type="bibr" rid="R1 R2" data-citation-string=" R1 R2 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1411" data-match="1 2" data-pattern="" data-tag-index="2_1" data-track-change="1 2"><sup id="9656c729-2f6b-4035-b922-67eb00dde0f1">1 2</sup></xref> Clearly, there is a need for therapeutics to be delivered in the most effective and targeted manner to overcome the limitations of current anti<named-content data-cid="1555259575" id="e0d3cda8-ed6f-4271-a651-f5c560f4419a" content-type="del cts-3" specific-use="1555260018002" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:10pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260018002">-</named-content>angiogenic therapy for wet AMD.</p><p data-class="jrnlSecPara" id="de4b14f9-44e4-4651-b491-e1bd21e76c84">Driven by the shortcomings of invasive and inefficient posterior segment drug delivery, there is a huge impetus for the research and development of <named-content id="d9f33f8a-da61-46c1-8fbf-5e7e1e648aaa" data-cid="d9f33f8a-da61-46c1-8fbf-5e7e1e648aaa" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="HYPPRE" data-track-detail="" data-tag-desc="HYPPRE" data-tag-type="HYPPRE" data-offset="148" data-match="non " data-pattern="" data-tag-index="3_1" data-time="" data-username="" data-userid="">non<named-content data-cid="1555259655" id="22e82377-3b2f-47f0-a7c3-eb1f95828ee2" content-type="ins cts-3" specific-use="1555260599055" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:19pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260599055">-<named-content data-cid="1555259656" id="77c7888e-932e-41d8-a2bb-e7dadca1d0ae" content-type="ins cts-3" specific-use="1555260599516" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:19pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260599516">invasive</named-content></named-content> </named-content>or minimally invasive, sustained action therapeutics for these diseases. To circumvent ocular barriers to posterior segment drug delivery and reduce the need for repeated injections, several drug delivery mechanisms have been developed. Among these, nanoparticles such as liposomes, dendrimers, polymeric micelles, conjugation of therapeutic payload with cell penetrating peptides <named-content data-cid="1555259723" id="45152d90-a31b-44bb-8531-20762fb13bbb" content-type="ins cts-3" specific-use="1555262261076" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:47pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262261076">(CPPs) </named-content>and port delivery systems have shown the most promise. In this review, we describe the challenges posed by ocular barriers to drug penetration and present the recent advancements in the most pertinent drug delivery platforms with a focus on the treatment of exudative AMD and DME.</p><title data-level="1" data-class="jrnlHead1" id="d1fd1671-2459-4e2b-8021-c652b8e72a72"><named-content data-cid="1554794312033" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase" id="faf7cea2-bbbd-48aa-87c3-930d9f0e7819">BARRIERS TO OCULAR DRUG DELIVERY</named-content><named-content data-cid="1554794312033" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase" id="2a9a64ec-1378-4296-9fb6-4c8955282555">Barriers to ocular drug delivery</named-content></title><p data-class="jrnlSecPara" id="6473d628-4c70-446d-a75f-74666713521b">Ocular drug delivery in a non-invasive manner remains a unique challenge due to complex barriers that limit drug bioavailability by the topical and systemic routes. The main penetration barriers to the posterior segment are the tear film, conjunctiva, cornea, sclera, the blood aqueous barrier and the <named-content id="7c956147-c135-47d5-ac05-8ccde93bfdb1" data-cid="7c956147-c135-47d5-ac05-8ccde93bfdb1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="302" data-match="blood retinal barrier" data-pattern="" data-tag-index="" data-abbr="BRB" data-time="" data-username="" data-userid="">blood retinal barrier<named-content data-cid="1555259681" id="18a83f30-f88b-4fa2-af71-c8979dfc9906" content-type="ins cts-3" specific-use="1555261770643" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:39pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261770643"> (BRB)</named-content></named-content>.</p><title data-level="2" data-class="jrnlHead2" id="05ccb001-946a-450d-aaa1-ca66cf239cd5">Tear film and conjunctival sac</title><p data-class="jrnlSecPara" id="9041c2f7-05a3-4a76-80f8-05442518f5ac">Bioavailability of topically administered eyedrops is poor due to limited capacity of the conjunctival sac (<named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="108" data-match="25Î¼l" data-replace="25" data-pattern="$1" data-tag-index="5_4" id="53e0b83f-27c6-4d99-b504-5b5be0da120e">25</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'Î¼l' to 'âÂµl'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="110" data-match="25Î¼l" data-replace="â&amp;#x00B5;l" data-pattern="â$2" data-tag-index="5_4" data-track-change="Î¼l" id="a65cd6e9-abc6-464b-999d-0b1d45751c16"> Âµl</named-content>), short precorneal drug residence time and drainage of drug via the nasolacrimal duct. It has been estimated that the ocular absorption of topically applied drugs is less than <named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="290" data-match="5%" data-replace="5" data-pattern="$1" data-tag-index="5_5" id="30f4aa67-c600-4535-bde0-3436c0cfaea5">5</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="291" data-match="5%" data-replace="%" data-pattern="%" data-tag-index="5_5" id="21236f6d-9075-45c0-95d4-77d8ea869d02">%</named-content>.<xref ref-type="bibr" rid="R3" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="294" data-match="3" data-pattern="" data-tag-index="5_1" data-citation-string=" R3 " data-track-change="3" id="b121d174-d888-4e7a-a7a5-b7ebd2cda073"><sup id="8649180a-a9b4-488c-ac34-aea28a80a5b6">3</sup></xref> Following topical application, a significant increase in tearing dilutes the administered dose, decreasing drug concentration and diminished drug absorption.<xref ref-type="bibr" rid="R4" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="455" data-match="4" data-pattern="" data-tag-index="5_2" data-citation-string=" R4 " data-track-change="4" id="ec644721-eb27-49c4-9a44-61cc5eb21da8"><sup id="29904e64-e573-414d-80eb-f58a4b8d6158">4</sup></xref></p><title data-level="2" data-class="jrnlHead2" id="79b37b5a-2ee1-4cbc-acbe-58a0f760ac91">Cornea</title><p data-class="jrnlSecPara" id="c94dcc87-2abb-45e6-ae75-d4e116e95a3d">The cornea epithelium is the main barrier to drug penetration. Intercellular tight junctions, known as zonula occludens, within the lipophilic epithelium prevent<named-content data-cid="1555259576" id="0c18d636-cdb2-44a4-ba63-326e5f742927" content-type="del cts-3" specific-use="1555260044442" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:10pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260044442">s</named-content> diffusion of large molecules with only small, lipophilic molecules able to traverse the epithelium transcellularly. The stroma is highly hydrophilic in nature and only allows the diffusion of hydrophilic molecules up to <named-content id="7594cc10-d4c2-4024-b9d7-f677a599398f" data-cid="7594cc10-d4c2-4024-b9d7-f677a599398f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="383" data-match="500 kDa" data-replace="500" data-pattern="$1" data-tag-index="6_3" data-time="" data-username="" data-userid="">500</named-content><named-content id="63acd78b-beee-4f5e-bc4a-fc7482d743d5" data-cid="63acd78b-beee-4f5e-bc4a-fc7482d743d5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£kDa' to 'âkDa'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="386" data-match="500 kDa" data-replace="âkDa" data-pattern="â$2" data-tag-index="6_3" data-track-change=" kDa" data-time="" data-username="" data-userid=""> kDa</named-content> of size, while restricting the entry of most lipophilic drugs.<xref id="c1d4a342-d903-44fe-86c5-35bcd4fca328" ref-type="bibr" rid="R5" data-citation-string=" R5 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="454" data-match="5" data-pattern="" data-tag-index="6_1" data-track-change="5"><sup id="ede9f5ef-7501-44d2-b9d2-915dc87e9518">5</sup></xref> Last<named-content data-cid="1555259577" id="4f509ad4-fccf-43bf-8858-ed54223c9698" content-type="del cts-3" specific-use="1555260054297" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:10pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260054297">ly</named-content>, the corneal endothelium restricts diffusion to small molecules up to about <named-content id="3d05bc6d-b731-4aed-a6ab-43c6e836935b" data-cid="3d05bc6d-b731-4aed-a6ab-43c6e836935b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="540" data-match="20 nm" data-replace="20" data-pattern="$1" data-tag-index="6_4" data-time="" data-username="" data-userid="">20</named-content><named-content id="a8ec9ede-d57f-4a29-9b83-cad18807da34" data-cid="a8ec9ede-d57f-4a29-9b83-cad18807da34" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£nm' to 'ânm'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="542" data-match="20 nm" data-replace="ânm" data-pattern="â$2" data-tag-index="6_4" data-track-change=" nm" data-time="" data-username="" data-userid=""> nm</named-content>.<xref id="5bb180b0-a70a-4fbf-8fcb-75c4463b67c1" ref-type="bibr" rid="R6" data-citation-string=" R6 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="547" data-match="6" data-pattern="" data-tag-index="6_2" data-track-change="6"><sup id="53a6d46e-fc09-4772-afb8-ab2e602414e9">6</sup></xref></p><title data-level="2" data-class="jrnlHead2" id="62ee8a39-1ffc-464c-a546-df46560b47f8">Conjunctiva and sclera</title><p data-class="jrnlSecPara" id="08d0c9c4-4270-47af-b671-8afce58b9a27">The vascularity of both the conjunctival stroma and the corneoscleral limbus increases the clearance and systemic absorption of drug molecules.<xref id="f4f38e81-829b-4a51-b3da-480556944617" ref-type="bibr" rid="R7" data-citation-string=" R7 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="144" data-match="7" data-pattern="" data-tag-index="7_1" data-track-change="7"><sup id="8c0de903-d5aa-4e52-80f5-9f5c55b20abd">7</sup></xref> Subconjunctival or subtenonâs injections bypass the conjunctival barrier and places the drug molecules in direct contact with the sclera. The sclera, with its large surface area (<named-content id="b1b80294-e2be-4445-b66e-707954aee712" data-cid="b1b80294-e2be-4445-b66e-707954aee712" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="328" data-match="95%" data-replace="95" data-pattern="$1" data-tag-index="7_5" data-time="" data-username="" data-userid="">95</named-content><named-content id="9623d938-67c2-4ff1-bb13-ad9bc3c6fe40" data-cid="9623d938-67c2-4ff1-bb13-ad9bc3c6fe40" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="330" data-match="95%" data-replace="%" data-pattern="%" data-tag-index="7_5" data-time="" data-username="" data-userid="">%</named-content> of total globe surface) and high permeability<named-content data-cid="1555259579" id="4300fe9f-446a-45d3-9c44-2876021045a6" content-type="ins cts-3" specific-use="1555260078086" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:11pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260078086">,</named-content> makes the trans-scleral route an ideal minimally invasive route for drug delivery to the posterior segment<named-content data-cid="1554804002" id="92c32779-bdec-4198-9129-4d5677a8bed7" content-type="del cts-2" specific-use="1554807862099" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:34pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807862099">.</named-content>.<xref id="5f438128-4d71-4048-99d6-a27e94060918" ref-type="bibr" rid="R8 R9" data-citation-string=" R8 R9 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="487" data-match="8 9" data-pattern="" data-tag-index="7_2" data-track-change="8 9"><sup id="61d976c6-c7f1-41af-87ba-2a264120e5ed">8 9</sup></xref> Scleral permeability is facilitated by scleral water channels/pores (ranging from <named-content id="3c238f84-3caa-48f4-b326-e17745694490" data-cid="3c238f84-3caa-48f4-b326-e17745694490" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="574" data-match="30 to 300 nm" data-replace="30" data-pattern="$2" data-tag-index="7_4" data-time="" data-username="" data-userid="">30</named-content><named-content id="314540ac-f95a-462a-bd2a-2c88839a6c93" data-cid="314540ac-f95a-462a-bd2a-2c88839a6c93" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGC" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="576" data-match="30 to 300 nm" data-replace=" to " data-pattern=" $3 " data-tag-index="7_4" data-time="" data-username="" data-userid=""> to </named-content><named-content id="37bbad6a-c918-4f26-8df2-5cf6fd532aff" data-cid="37bbad6a-c918-4f26-8df2-5cf6fd532aff" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="VAL" data-offset="580" data-match="30 to 300 nm" data-replace="300" data-pattern="$1" data-tag-index="7_4" data-time="" data-username="" data-userid="">300</named-content><named-content id="e3b53247-af6a-43df-a01c-2e6645d7b31a" data-cid="e3b53247-af6a-43df-a01c-2e6645d7b31a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£nm' to 'ânm'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="UNT" data-offset="583" data-match="30 to 300 nm" data-replace="ânm" data-pattern="â$2" data-tag-index="7_4" data-track-change=" nm" data-time="" data-username="" data-userid=""> nm</named-content> in size) through which passive diffusion of drug molecules can occur.<xref id="2745f854-0db6-4d0f-bb8d-4c01847c5c7d" ref-type="bibr" rid="R10" data-citation-string=" R10 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="657" data-match="10" data-pattern="" data-tag-index="7_3" data-track-change="10"><sup id="5405bca1-3197-472f-a773-296f9e336a01">10</sup></xref></p><title data-level="2" data-class="jrnlHead2" id="347a979e-26bc-41cc-bafa-2d0e9a08c210">Vitreous and <named-content id="70efe168-9910-433d-8661-3a43de88d626" data-cid="70efe168-9910-433d-8661-3a43de88d626" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="13" data-match="Inner limiting membrane" data-pattern="" data-tag-index="" data-abbr="ILM" data-time="" data-username="" data-userid=""><named-content data-cid="1555259581" id="fd3d4f5d-0342-49a6-902d-cbf1e46c5650" content-type="del cts-3" specific-use="1555260085097" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:11pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260085097">I</named-content><named-content data-cid="1555259580" id="93e81e0a-fd7f-4e1f-941e-fc7358390224" content-type="ins cts-3" specific-use="1555260084215" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:11pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260084215">i</named-content>nner limiting membrane</named-content></title><p data-class="jrnlSecPara" id="ddceda86-80e3-46f2-8c71-4d6196fef529">Drug molecules move through the vitreous via <named-content data-cid="1554794312003" id="34001652-d0e2-4f69-806d-be03f3120f55" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">2</named-content><named-content data-cid="1554794312003" id="3ad7c726-d353-4b0b-afbf-4850d5fe698c" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from '2' to 'two'" data-track-detail="" data-tag-desc="SNUM" data-tag-type="SNUM" data-offset="45" data-match="2" data-pattern="" data-tag-index="8_6" data-function="numberToText,addTrackChanges" data-track-change="2" data-userid="preediting" data-username="Exeter" data-time="1554794312000">two</named-content> main processes: diffusion and convection. The vitreous poses no diffusional resistance to movement of small (<named-content id="47d408ba-bab7-4bf5-b5cd-5ea35280cde6" data-cid="47d408ba-bab7-4bf5-b5cd-5ea35280cde6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="OPR" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="OPR" data-offset="156" data-match="&amp;lt;500nm" data-replace="&lt;" data-pattern="$2" data-tag-index="8_4" data-time="" data-username="" data-userid="">&lt;</named-content><named-content id="3b6329ad-c12a-450d-9c26-c057c59e1a2c" data-cid="3b6329ad-c12a-450d-9c26-c057c59e1a2c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="VAL" data-offset="157" data-match="&amp;lt;500nm" data-replace="500" data-pattern="$3" data-tag-index="8_4" data-time="" data-username="" data-userid="">500</named-content><named-content id="cee26530-f6ab-47aa-abaf-3b0bb1c26d32" data-cid="cee26530-f6ab-47aa-abaf-3b0bb1c26d32" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'nm' to 'ânm'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="UNT" data-offset="160" data-match="&amp;lt;500nm" data-replace="ânm" data-pattern="â$6" data-tag-index="8_4" data-track-change="nm" data-time="" data-username="" data-userid=""> nm</named-content>) and anionic particles but restricts the movement of larger cationic particles.<xref id="7e6bc72e-0d9d-4bd2-b308-e9f3c987387c" ref-type="bibr" rid="R11" data-citation-string=" R11 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="243" data-match="11" data-pattern="" data-tag-index="8_1" data-track-change="11"><sup id="90e25d8c-e17e-494e-bcde-799687e3602b">11</sup></xref> Liquefaction of the vitreous with ageing, and in the case of previous vitrectomy, complete loss of the collagenous vitreous gel structure, enhances convective flow within the vitreous cavity and leads to a shorter drug residence time.<xref id="f22baa55-859a-4b0c-90b2-1e0e9e28af75" ref-type="bibr" rid="R12" data-citation-string=" R12 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="482" data-match="12" data-pattern="" data-tag-index="8_2" data-track-change="12"><sup id="29f81fcc-ef3b-4332-bef6-8bc9e7ec2cb2">12</sup></xref> The <named-content id="98fd426d-c6b7-4eb0-a831-6f4cc5e9b66e" data-cid="98fd426d-c6b7-4eb0-a831-6f4cc5e9b66e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="490" data-match="inner limiting membrane" data-pattern="" data-tag-index="" data-abbr="ILM" data-time="" data-username="" data-userid="">inner limiting membrane</named-content> <named-content data-cid="1555259680" id="a8726419-8371-49cb-b00d-5df28fd7af9a" content-type="del cts-3" specific-use="1555261737378" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:38pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261737378">(</named-content><named-content id="4e74f907-9945-42b6-a08b-34c202186c45" data-cid="4e74f907-9945-42b6-a08b-34c202186c45" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="515" data-match=" (ILM)" data-pattern="" data-tag-index="8_5" data-time="" data-username="" data-userid=""><named-content data-cid="1555259680" id="815457ca-637c-4a26-be45-7c41641857fb" content-type="del cts-3" specific-use="1555261737378" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:38pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261737378">ILM</named-content></named-content><named-content data-cid="1555259680" id="4bc30561-4943-4327-ad01-aa4a982a2296" content-type="del cts-3" specific-use="1555261737378" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:38pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261737378">)</named-content>may pose a significant barrier for drug molecules from the desired site of action in the retina.<xref id="f93ae2a4-37e6-4fef-9e5a-b73c5b5dc8bc" ref-type="bibr" rid="R13" data-citation-string=" R13 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="617" data-match="13" data-pattern="" data-tag-index="8_3" data-track-change="13"><sup id="b8e6d202-6e11-4b14-a486-19007989fba0">13</sup></xref></p><title data-level="2" data-class="jrnlHead2" id="00e07cc9-09a3-4f01-9ccf-32bb746fd8ae"><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="0" data-match="Blood retinal barrier" data-pattern="" data-tag-index="" data-abbr="BRB" id="3d82f8e1-c765-407f-b489-b8e37bb765f0">Blood retinal barrier</named-content></title><p data-class="jrnlSecPara" id="95b2fd10-b172-48ea-8468-1da56f52c7e8">The <named-content id="5f6f4351-3f98-4240-b64d-d2a6da2c1c53" data-cid="5f6f4351-3f98-4240-b64d-d2a6da2c1c53" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="4" data-match="blood retinal barrier" data-pattern="" data-tag-index="" data-abbr="BRB" data-time="" data-username="" data-userid=""><named-content data-cid="1555259693" id="ff48cff2-64ef-420f-b32f-f7901561b87b" content-type="del cts-3" specific-use="1555261787059" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:39pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261787059">blood retinal barrier</named-content></named-content><named-content data-cid="1555259693" id="e2e7d851-0ed7-4c3d-a8b2-70453bf2bff2" content-type="del cts-3" specific-use="1555261787059" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:39pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261787059"> (</named-content><named-content id="5839839f-24be-45c1-bb69-abc1ed2139b5" data-cid="5839839f-24be-45c1-bb69-abc1ed2139b5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="27" data-match=" (BRB)" data-pattern="" data-tag-index="9_2" data-time="" data-username="" data-userid="">BRB</named-content><named-content data-cid="1555259694" id="154ba0c1-d5a7-4457-ba1c-155d2e51e8c7" content-type="del cts-3" specific-use="1555261788431" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:39pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261788431">)</named-content> can be divided into the inner and outer BRB. The inner BRB is closest to the vitreous and is composed of tight junctions between retinal endothelial blood vessels. The outer BRB is closest to the choroid and is formed by tight junctions between <named-content id="f60183ed-9cde-47b8-b68f-f989e35cd7b6" data-cid="f60183ed-9cde-47b8-b68f-f989e35cd7b6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="277" data-match="retinal pigment epithelium" data-pattern="" data-tag-index="" data-abbr="RPE" data-time="" data-username="" data-userid="">retinal pigment epithelium</named-content> (<named-content id="5309c48d-13df-4b67-8775-5a290f3c28a6" data-cid="5309c48d-13df-4b67-8775-5a290f3c28a6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="305" data-match=" (RPE)" data-pattern="" data-tag-index="9_3" data-time="" data-username="" data-userid="">RPE</named-content>) cells.<xref id="51c556b1-eafa-492d-a824-7bf891a7fd64" ref-type="bibr" rid="R14" data-citation-string=" R14 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="317" data-match="14" data-pattern="" data-tag-index="9_1" data-track-change="14"><sup id="6f183f3f-4665-4182-b34a-5d116cd43f87">14</sup></xref> These barriers restrict passive penetration of drug molecules into the retina via both the systemic and trans<named-content data-cid="1555259739" id="7aedf7c2-453f-4a29-a735-11dd2dcb8754" content-type="ins cts-3" specific-use="1555263098826" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 11:01pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555263098826">-</named-content>scleral routes.</p><title data-level="1" data-class="jrnlHead1" id="c479d7ea-bbba-454e-89c3-aa4267475e4d"><named-content data-cid="1554794312034" id="f9d515ca-caf1-48e5-a96c-424fe717b3c1" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase">DRUG DELIVERY FOR THE POSTERIOR SEGMENT (TABLE 1)</named-content><named-content data-cid="1554794312034" id="871bf232-552c-4017-9bea-9b5fc4472c08" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase">Drug delivery for the posterior <named-content rid="148136cc-ec36-4994-abba-fc1b9de3b20d" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-query-from="preeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" data-style="" id="2c583dd0-1ca3-43af-85d7-d03322bc8d67" content-type="jrnlQueryRef" specific-use="start" data-answered="true" data-replied="true"/>segment<named-content rid="148136cc-ec36-4994-abba-fc1b9de3b20d" data-class="jrnlQueryRef" data-type="end" id="120b5657-04d5-4db8-86d9-3faca0509b8b" content-type="jrnlQueryRef" specific-use="end" data-answered="true" data-replied="true"/><named-content data-cid="1554803948" id="5a2a1555-6f97-4f52-93c9-bca6298fb7ea" content-type="del cts-2" specific-use="1554804107952" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 3:31pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554804107952"> (table 1)</named-content></named-content></title><p data-class="jrnlSecPara" id="89024090-941c-4647-a3d2-dfdd170cea02" data-word-spacing="0.23w"><named-content data-cid="1555332915" id="e2775e2a-73e6-422d-82b6-413db8293929" content-type="styrm cts-4" specific-use="1555333070039" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Bold Removed by Tina T Wong (AUTHOR) - Apr 15 2019 8:57pm" data-track-detail="" data-format-command="bold" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555333070039" data-track-hint="Bold Removed">ï»¿</named-content><named-content data-cid="1555332834" id="e719fe0f-d03d-48d5-a682-3d1ca54d4548" content-type="ins cts-4" specific-use="1555332975016" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Inserted by Tina T Wong (AUTHOR) - Apr 15 2019 8:56pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555332975016"><named-content data-cid="1555332915" id="fc49d253-ba60-4d8d-abff-ec94a19ecd3c" content-type="styrm cts-4" specific-use="1555333070039" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Bold Removed by Tina T Wong (AUTHOR) - Apr 15 2019 8:57pm" data-track-detail="" data-format-command="Bold" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555333070039" data-track-hint="Bold Removed"><named-content rid="0b8c0f36-3f25-40e2-848b-881c8bbaf413" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="typesetter" data-query-from="publisher" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="588bc28b-5b46-44f3-b107-5d51e782dae0" content-type="jrnlQueryRef" specific-use="start" data-replied="true"/><named-content data-cid="1556176612" id="6feddc0a-204d-47af-9fca-def528451d1a" content-type="del cts-6" specific-use="1556176657155" xlink:title="Thilip (TYPESETTER)" alt="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-title="Deleted by Thilip (TYPESETTER) - Apr 25 2019 12:47pm" data-track-detail="" data-userid="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-username="Thilip (TYPESETTER)" data-time="1556176657155">Table 1</named-content><xref id="bad391ac-9166-4be8-a5c9-6a86f21383d6" ref-type="table" rid="T1" data-citation-string=" T1 " data-track="ins" data-cid="1556176652799" data-username="Thilip (TYPESETTER)" data-userid="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-time="1556176652799" data-cite-type="insert" data-anchor="true"><named-content data-cid="1556176613" id="08e6e420-1d5d-4e12-8e70-ad81780cf169" content-type="changeCase sty cts-6" specific-use="1556176662678" xlink:title="Thilip (TYPESETTER)" alt="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-title="UPPERCASE Added by Thilip (TYPESETTER) - 04/25/2019 12:47pm" data-track-detail="" data-track-hint="UPPERCASE Added" data-userid="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-username="Thilip (TYPESETTER)" data-time="1556176662678">T<span data-class="hidden" hidden-track="track" id="09fa1983-5b8c-4e51-973b-0fe61ee26751">t</span></named-content>able 1</xref><named-content rid="0b8c0f36-3f25-40e2-848b-881c8bbaf413" data-class="jrnlQueryRef" data-type="end" id="01dfa3e4-bc83-4751-9836-4cb55868b53c" content-type="jrnlQueryRef" specific-use="end" data-replied="true"/> summari<named-content data-cid="1556113618" id="3f017664-2f53-40d5-b7a0-454d596e5e39" content-type="del cts-5" specific-use="1556113654933" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Deleted by Production (BMJ) - Apr 24 2019 2:47pm" data-track-detail="" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-username="Production (BMJ)" data-time="1556113654933">z</named-content><named-content data-cid="1556113619" id="7b4db233-c784-4cf3-9a5b-9c7625c4d5e9" content-type="ins cts-5" specific-use="1556113655193" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Inserted by Production (BMJ) - Apr 24 2019 2:47pm" data-track-detail="" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-username="Production (BMJ)" data-time="1556113655193">s</named-content>es the various posterior segment drug delivery technologies<named-content data-cid="1556113620" id="cd4e7a87-84e6-4978-bce3-f065334c0819" content-type="del cts-5" specific-use="1556113708984" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Deleted by Production (BMJ) - Apr 24 2019 2:48pm" data-track-detail="" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-username="Production (BMJ)" data-time="1556113708984">.</named-content><named-content id="6353f788-ccfd-407c-bd3a-a860cd671c51" data-cid="1556113703938" content-type="ins cts-1" specific-use="1556113703938" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Inserted by Production (BMJ) - Apr 24 2019 2:48pm" data-track-detail="" data-username="Production (BMJ)" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-time="1556113703938"><xref id="e672068a-4845-4ab4-bb20-6ec7c2d2c69a" ref-type="table" rid="T1" data-citation-string=" T1 " data-cite-type="delete" data-track="del" data-cid="1556176666538" data-username="Thilip (TYPESETTER)" data-userid="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-time="1556176666538">table 1</xref><named-content rid="32393948-5550-47ee-a01b-78da80dbc012" data-class="jrnlQueryRef" data-type="end" id="fdaa0134-2d53-4514-bf97-2122c6da2260" content-type="jrnlQueryRef" specific-use="end" data-replied="true"/><named-content rid="32393948-5550-47ee-a01b-78da80dbc012" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="typesetter" data-query-from="publisher" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="f12ec0ad-daa4-421e-b898-b65265b5b9d4" content-type="jrnlQueryRef" specific-use="start" data-replied="true"/>.</named-content></named-content></named-content></p><table-wrap id="BLK_T1" data-id="BLK_T1" data-stream-name="a_T1" position="float"><label id="0c64eca0-30bc-4e4f-8f42-22fa2d04b801"><named-content data-cid="1555772958242" id="d92e31a6-88ea-42d0-8ad7-e5d8664000cd" content-type="ins cts-1" specific-use="1554794356000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794356000">Table 1</named-content></label><caption id="6174178f-a105-4010-a22c-d60852ed9277"><title id="T1" data-id="T1"><named-content rid="72010c22-b3a8-476c-8a36-a910aa6e9422" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="author" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-action="uncited-table" id="ee7b7cc8-cfd5-4514-a008-76692f008bd5" content-type="jrnlQueryRef" specific-use="start" data-replied="true"/>A summary of posterior segment drug delivery technologies</title></caption><table data-col-count="6" data-col-widths-px="83.212666666667,115.21266666667,78.212666666667,76.212666666667,91.212666666667,67.212666666667" data-table-type="doubleColumn" id="e01b6a16-1348-4efc-95b3-7c1c05490963"><thead id="b22bb078-c538-4bdd-b086-7e6ddd244fe1"><tr data-col-count="6" id="b30e1a45-60a9-4ecc-9158-3d5d88a6c8ce"><td data-original-border="border:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="bottom" id="bbc7ebb3-df46-4b3f-8c1a-d5ad0c3f21fe"><p id="59db5bfc-fa27-4f6b-bbde-bac58009e753" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Study/Drug name</p></td><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-left:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="bottom" id="9f46e6a5-54d7-4556-ae37-7e2adb22f3ae"><p id="f89047c2-8532-48ac-88b7-aa716b35800d" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Drug molecule</p></td><td data-original-border="border:solid windowtext 1.0pt; border-left:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="bottom" id="0ed528bb-021b-4407-8b77-757da82711fe"><p id="cf728259-c64c-45f0-b79a-d8467638a026" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Delivery mechanism</p></td><td data-original-border="border:solid windowtext 1.0pt; border-left:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="bottom" id="b1203800-14ea-4f84-8163-6958283ea1b3"><p id="48895cd2-4fdc-4f1f-b7b2-f21f2413b23e" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Indication</p></td><td data-original-border="border:solid windowtext 1.0pt; border-left:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="bottom" id="a74bf133-452c-49ea-b4a7-f1a08e06a3e4"><p id="4ee336a9-40c7-4776-a999-aa48c3985640" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Proposed route of administration</p></td><td data-original-border="border:solid windowtext 1.0pt; border-left:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="bottom" id="a1ae73b6-4a31-4d04-9ede-0f2fabac955c"><p id="a9d117ab-bf3e-48e7-b138-96ebe86ae7b9" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Status</p></td></tr></thead><tbody id="2bedfa87-bfeb-4d72-82b2-e5c4ffbfc4a4"><tr data-col-count="6" data-fill="true" id="e5808e78-cc94-4f18-803d-21e10f5657ac"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="9eb909aa-1022-40d3-a129-8dddd654e6c5"><p id="c564268f-d249-4d70-8b43-4c17a5b3c43d" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Gooch <named-content data-cid="1555259667" id="667a4cda-ff41-40ee-878e-b6754d005282" content-type="del cts-3" specific-use="1555260686560" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260686560">N</named-content><named-content id="0a9d8178-224d-4279-aea7-3e47477e03b6" data-cid="0a9d8178-224d-4279-aea7-3e47477e03b6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'etâ£al' to '&lt;i&gt;etâ£al&lt;/i&gt;'" data-track-detail="" data-tag-desc="ETL" data-tag-type="ETL" data-offset="8" data-match="et al" data-replace="&lt;i&gt;et al&lt;/i&gt;" data-pattern="&lt;i&gt;et al&lt;/i&gt;" data-tag-index="38_3" data-track-change="et al" data-time="" data-username="" data-userid=""><italic id="f1be2377-b639-422b-a3dc-dd24223da975">et al</italic></named-content>, 2013<named-content id="26dd3a08-b6ec-42d5-924c-df4c6549e479" data-cid="26dd3a08-b6ec-42d5-924c-df4c6549e479" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="19" data-match="[15]" data-replace="(" data-pattern="(" data-tag-index="s349_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803959" id="d53d39f3-e80f-4293-982f-79f66b1bdf1d" content-type="del cts-2" specific-use="1554807471172" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807471172">(</named-content></named-content><named-content id="12e40eb8-a0fd-4922-ac29-11128fdff0c9" data-cid="12e40eb8-a0fd-4922-ac29-11128fdff0c9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="22" data-match="[15]" data-replace=")" data-pattern=")" data-tag-index="s349_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803958" id="2ee20b63-2d61-48fc-afb1-069dade26e4a" content-type="del cts-2" specific-use="1554807470724" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807470724">)</named-content></named-content><xref id="86b92237-ece6-4fe7-a634-ae50bd0b4067" ref-type="bibr" rid="R15" data-citation-string=" R15 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="20" data-match="15" data-pattern="" data-tag-index="38_1" data-track-change="15"><sup id="f15c2ee5-0f82-4254-9662-0c383e95075d">15</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="c3bf6129-f613-4420-9755-a9b90c9c9142"><p id="ccacf281-0ad3-411e-b142-0299c0a03f1d" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Bevacizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="2b192428-28f2-4c81-b8d6-795f2350b1ad"><p id="a4dfc0eb-c79c-4f1c-bf40-529b607d7b96" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intracapsular drug ring</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="61b931f4-4dd2-41b0-8057-f92fcefda98d"><p id="3c3ba4c1-b8d5-4f0f-96e0-10f6fecad56c" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="64ab2fac-a161-4622-b8a8-d286b3c41196"><p id="758f5709-ea62-4ee1-93cd-70d583f5a8d4" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">During cataract surgery</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="55fa7a67-f0b4-49c5-9242-d76d7a689b6a"><p id="8323cc0e-cd78-42fa-8032-45d2ca16d6dd" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" id="a267d26a-f834-457e-a093-085e6bdf56ba"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="c10661dc-f6a2-4d99-ac6f-6f2f64801be5"><p id="a3739d5a-9f05-43c6-af20-6fde340ecd56" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">NT-503</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="a89a4a17-003a-433e-b606-344e419c16bc"><p id="7ff86030-ee2a-4b93-9cc5-fc162329a533" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Soluble anti-<named-content data-cid="1555259562" id="2cc47fe3-e89a-4379-9a6b-7a328e10bddb" content-type="ins cts-3" specific-use="1555259956639" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259956639">VEGF</named-content><named-content data-cid="1555259566" id="8425d12c-99f8-4b1f-bbb9-8ec976503ddd" content-type="del cts-3" specific-use="1555259958821" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259958821">vegf</named-content> receptor protein</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="4af05063-3dda-405f-a2a5-25e2e07609fa"><p id="e59c3b48-94b0-4e78-888c-75b4280bef30" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intravitreal implant (encapsulated cell technology)</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="6f09d191-1871-4f0e-839e-9253a665a03c"><p id="9b05e079-8bae-4d6e-a977-d3b04ba4bdc9" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="e976e855-f1ff-4c05-a4a5-9174642d3e9b"><p id="a2f0b637-a2c7-49fb-99fe-0dfcc5b55af2" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intravitreal</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="00916b39-45fb-4401-a23a-0eb14e4a3d0d"><p id="ecb7de52-b773-4c32-bcc8-56280ef7d6de" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Failed Phase <named-content data-cid="1555259474" id="79f703fe-7955-4d71-82a8-2c50d4b1f141" content-type="ins cts-3" specific-use="1555259747145" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259747145">II</named-content><named-content data-cid="1555259476" id="8315d99a-268a-4393-86ef-d4ca23fb3772" content-type="del cts-3" specific-use="1555259747885" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259747885">2</named-content></p></td></tr><tr data-col-count="6" data-fill="true" id="977c65d1-36ec-40d2-abaf-4c7506254469"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="fc806ece-95a6-49fd-ba99-48df0dcad05c"><p id="c2cfa03f-ec17-4e33-8142-a3df4866761f" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">GB-102</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="0cc183b7-7762-4677-9cff-15fd3019e877"><p id="551e4a40-f718-44c3-a8b1-bd345c608ac8" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Sunitinib Malate</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="bbaf1cf0-74a4-4570-8aed-0c1d57142250"><p id="4a94c6e7-3da7-436d-95c3-741a035ddf34" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intravitreal depot</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="351d6e20-94f4-4369-a77b-3f1d637f6b3f"><p id="b88f8af1-fadf-42f0-a9f0-581c3dc97e1d" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="86cd1a53-824b-45e1-a3a2-db25f69208bf"><p id="5512106c-3a2b-4a3d-bab8-02400772610c" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intravitreal</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="5ac5eb06-bacb-4890-878f-8dd218feff94"><p id="87cd7055-031e-4562-8aa7-aedc9f1d3208" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Phase <named-content data-cid="1555259477" id="028b0d21-f898-44e1-88d9-382ce74a1c1e" content-type="del cts-3" specific-use="1555259751772" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259751772">1</named-content><named-content data-cid="1555259478" id="ceb0ef43-f296-4f54-acd2-540315cbf303" content-type="ins cts-3" specific-use="1555259752571" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259752571">I</named-content>/<named-content data-cid="1555259479" id="f79341aa-61c6-4023-a7d4-8f6d23b51725" content-type="ins cts-3" specific-use="1555259755122" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259755122">II</named-content><named-content data-cid="1555259481" id="de73b3ad-7723-4634-b40d-666c52406e00" content-type="del cts-3" specific-use="1555259755902" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259755902">2</named-content></p></td></tr><tr data-col-count="6" id="9553cd49-8cdc-4488-a6e6-6cd2919641f5"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="17129e45-c6aa-4034-879a-5b0b3c038dfe"><p id="74a3e9e7-8932-420e-8da1-23f0f05895dc" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Pazopanib<named-content id="99812635-ae69-4330-9599-f78da9247145" data-cid="99812635-ae69-4330-9599-f78da9247145" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="9" data-match="[19]" data-replace="(" data-pattern="(" data-tag-index="s367_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803961" id="92ac7282-77f1-4492-8ea0-fae0cd752993" content-type="del cts-2" specific-use="1554807473257" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807473257">(</named-content></named-content><named-content id="ddc200de-4eea-470f-8064-b4c61f9d264c" data-cid="ddc200de-4eea-470f-8064-b4c61f9d264c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="12" data-match="[19]" data-replace=")" data-pattern=")" data-tag-index="s367_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803960" id="1a1e5b16-6e38-48fe-a245-fc102383cd7b" content-type="del cts-2" specific-use="1554807472878" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807472878">)</named-content></named-content><xref id="5d5e0c4a-04f2-498b-b309-1c0fc84bb115" ref-type="bibr" rid="R19" data-citation-string=" R19 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="10" data-match="19" data-pattern="" data-tag-index="56_1" data-track-change="19"><sup id="b57a676a-8981-4dff-b7c8-bda4e0a125b4">19</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="6cfe225d-9e62-480a-a35b-08dd22fa9fea"><p id="eab90569-cd3d-4508-b565-eee8e8a413af" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Tyrosine kinase inhibitor</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="8dfa54ab-b39d-45ae-9013-17db78cd57f3"><p id="94a05a2c-6696-4add-949e-6d3475e7b11c" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;"><named-content data-cid="1555259669" id="077fce6b-d907-40c6-9377-2987bf3be89b" content-type="del cts-3" specific-use="1555260728144" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:22pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260728144">e</named-content><named-content data-cid="1555259668" id="1640b37a-8a9a-4197-ac5f-eeba44e6bd80" content-type="ins cts-3" specific-use="1555260727418" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:22pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260727418">E</named-content>yedrops</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="83a1f3bd-e5f6-4631-8fe9-a7e815bd385d"><p id="f6353e4e-a165-4e39-a510-867d48e362a0" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="ec898556-8cc2-4cdd-805c-c1035206db0b"><p id="e0b915d9-048d-4528-a1ae-64d458036f9b" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="225cb071-d553-4c79-aad1-3acd217924bc"><p id="f7b2fadc-bf22-466a-ac87-7616fc46f3e6" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Failed Phase <named-content data-cid="1555259482" id="5a555276-a77c-4d7e-ada0-de24ba31c15b" content-type="ins cts-3" specific-use="1555259768088" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259768088">II</named-content><named-content data-cid="1555259484" id="58415991-e369-4c4d-8854-dc7ba81f13a4" content-type="del cts-3" specific-use="1555259769550" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259769550">2</named-content>a</p></td></tr><tr data-col-count="6" data-fill="true" id="db0ea689-f9c9-4a2c-b4b3-a296aae4800f"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="0524c862-8c5b-4888-a5c7-58f16a0f7677"><p id="ee945e6b-6544-4f4f-8679-729d9a1f4c19" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Squalamine<named-content id="cd76cb4a-b8fd-48c9-94fb-5469f4fbffbc" data-cid="cd76cb4a-b8fd-48c9-94fb-5469f4fbffbc" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="10" data-match="[21]" data-replace="(" data-pattern="(" data-tag-index="s373_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803963" id="00abfbfe-47b4-4a7b-b31d-815108d5629b" content-type="del cts-2" specific-use="1554807475135" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807475135">(</named-content></named-content><named-content id="591d3a90-7127-4bfe-a98d-cd75e45ebd40" data-cid="591d3a90-7127-4bfe-a98d-cd75e45ebd40" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="13" data-match="[21]" data-replace=")" data-pattern=")" data-tag-index="s373_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803962" id="da1ce9f1-7eb2-44b7-94cb-518ba53bbf96" content-type="del cts-2" specific-use="1554807474804" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807474804">)</named-content></named-content><xref id="b810bf62-3be2-45b2-ada0-52fb4dd26944" ref-type="bibr" rid="R21" data-citation-string=" R21 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="11" data-match="21" data-pattern="" data-tag-index="62_1" data-track-change="21"><sup id="311d73fc-33b7-43e9-8598-11e56f216ec2">21</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="17acb304-f378-4f40-a2df-48edbb219009"><p id="62ec9090-1746-4497-96f0-1bef7d2fb5a5" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">VEGF/PDGF/bFGF inhibitor</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="6a994f54-464d-4bb6-ad29-a62a2c3d6279"><p id="caf94b8e-c3a8-40ad-b1e5-60f685bf08d2" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Eyedrops</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="d92036a5-2bfa-469c-a3b4-b703ab1fb62a"><p id="8bee1200-0bb8-4fef-9a9f-03d41c9032d2" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="e21a4b27-f4f2-4dd4-99f8-5e6abd1c3255"><p id="ee514dd3-ced2-478e-a886-1a0726df3648" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="9d22d21b-55c4-40f9-b6a1-c7dac28f2b74"><p id="5b219d7c-43e8-4a5e-a50b-6f5f31c83d2c" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Failed Phase <named-content data-cid="1555259485" id="09a40bb0-c62a-4e80-b8a3-eb4f26577bf8" content-type="ins cts-3" specific-use="1555259776384" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259776384">III</named-content><named-content data-cid="1555259488" id="697b809b-828b-4f45-8c0f-5ce44d63e916" content-type="del cts-3" specific-use="1555259777502" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259777502">3</named-content></p></td></tr><tr data-col-count="6" id="5f43e292-2901-4630-9d4b-305d747ed859"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="1c8b611a-1702-4adb-9d61-6ef2a9198f5f"><p id="2695d6f4-7a69-4408-9c05-0a5129215f8d" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Pan-90806<named-content id="902697a3-1149-4d4b-895c-ebe3614fcc05" data-cid="902697a3-1149-4d4b-895c-ebe3614fcc05" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="9" data-match="[22]" data-replace="(" data-pattern="(" data-tag-index="s379_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803965" id="5ab0c75f-9d44-40c4-bf66-5c1de7fbde39" content-type="del cts-2" specific-use="1554807476805" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807476805">(</named-content></named-content><named-content id="63e55b83-4502-4775-b1ee-9765e81e6a78" data-cid="63e55b83-4502-4775-b1ee-9765e81e6a78" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="12" data-match="[22]" data-replace=")" data-pattern=")" data-tag-index="s379_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803964" id="c351ae36-6708-46c1-9be6-ed5b15d14bd0" content-type="del cts-2" specific-use="1554807476569" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:27pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807476569">)</named-content></named-content><xref id="0a39aafc-4d8d-4566-a974-af49eda4dbb0" ref-type="bibr" rid="R22" data-citation-string=" R22 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="10" data-match="22" data-pattern="" data-tag-index="68_1" data-track-change="22"><sup id="e77cb37e-dfa8-42e9-a7b0-c7c7ed5f6d2d">22</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="c09158e9-c393-49cc-9160-f8d2bbdb4837"><p id="140519bb-c9e6-4a3d-912e-fe01b176eaf8" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">VEGF/FGF/tyrosine kinase inhibitor</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="c667ae4e-6514-4d8f-844d-c8e43c29c5c5"><p id="d02e63c5-6368-4ddb-a7e5-8431cb8e0606" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Eyedrops</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="5b52c491-e8d3-478d-8766-0b20706bb889"><p id="6cd676aa-1fb3-4afa-8192-10a09b3bb593" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="9dc263bf-34f8-4bf4-b405-001103373ecf"><p id="d4a7351e-9e4e-4234-b0b7-70dd57be297a" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="a817177f-791e-4998-8f0e-8295ffe7ac1a"><p id="5727ead9-98a8-44f6-bb7d-bb2cc7971263" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Phase <named-content data-cid="1555259489" id="16f4c3bf-6c94-44fc-919e-4779e97850c7" content-type="ins cts-3" specific-use="1555259779945" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259779945">I</named-content><named-content data-cid="1555259490" id="a955acaa-3c06-4198-af63-6ec7345c3d8f" content-type="del cts-3" specific-use="1555259780902" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259780902">1</named-content>/<named-content data-cid="1555259491" id="ba415df3-da91-4927-86de-d5d6282e3d6e" content-type="ins cts-3" specific-use="1555259781962" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259781962">II</named-content><named-content data-cid="1555259493" id="c65f13e1-6be2-4d90-80cd-5a73d51fdf13" content-type="del cts-3" specific-use="1555259783046" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259783046">2</named-content></p></td></tr><tr data-col-count="6" data-fill="true" id="c34cf2a1-d190-495a-9737-e4751db43417"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="08294bf2-1016-48e1-b224-cdab79bce043"><p id="f8875bf8-0db7-43b1-a615-94ca096a96a0" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">LHA-510<named-content id="d7e34cdf-f645-43d5-a927-02bb2be73416" data-cid="d7e34cdf-f645-43d5-a927-02bb2be73416" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="7" data-match="[23]" data-replace="(" data-pattern="(" data-tag-index="s385_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803967" id="95456657-189c-4d20-8617-7e8a0aee5a5e" content-type="del cts-2" specific-use="1554807480536" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:28pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807480536">(</named-content></named-content><named-content id="6541df41-f336-4870-b96d-66390ad5b84a" data-cid="6541df41-f336-4870-b96d-66390ad5b84a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="10" data-match="[23]" data-replace=")" data-pattern=")" data-tag-index="s385_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803966" id="e1c1d0b0-163e-4cae-934a-e7db4857582e" content-type="del cts-2" specific-use="1554807480294" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:28pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807480294">)</named-content></named-content><xref id="6ba145de-cc6f-47c9-9db7-e6fcbceb4a76" ref-type="bibr" rid="R23" data-citation-string=" R23 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="8" data-match="23" data-pattern="" data-tag-index="74_1" data-track-change="23"><sup id="4fdd0415-383c-4115-84d2-946cbee7885c">23</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="eee703ac-2e84-4b02-9dbf-9a1e7822ac41"><p id="c228673d-526f-4618-8a11-953ea4415988" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Acrizanib</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="8031bc47-678e-47d3-acca-223694c487b0"><p id="0d4b1f97-d2f1-449c-885b-fa45a0c58965" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Eyedrops</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="d01787a9-0e6d-4543-a8a8-8cf18d93fbae"><p id="5c49a1b4-fa1e-439e-a5b8-15fa10864a04" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="72e1f341-9577-4090-bbf9-da96c39ea785"><p id="0d6236c2-3eaf-4c91-a0f2-55047da0065a" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="9300d7ca-6a23-4ee6-8b38-f8fec90f1900"><p id="25b16dbc-3c33-424a-b64a-514369e243ed" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Failed Phase <named-content data-cid="1555259494" id="320228e2-0ea6-42cf-ab5d-b268821835e4" content-type="ins cts-3" specific-use="1555259788050" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259788050">II</named-content><named-content data-cid="1555259496" id="d597de21-612b-4963-bc7d-7876260a18ac" content-type="del cts-3" specific-use="1555259788862" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259788862">2</named-content></p></td></tr><tr data-col-count="6" id="73c751ce-c77e-4721-af6f-0c73a32a87d4"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="dfd1ba77-8ae2-4bcd-a318-10aed0772a90"><p id="89b0ed4b-df23-428a-88af-f2af9fed4ff4" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Davis <named-content data-cid="1555259658" id="1244232f-5c78-4ab2-9960-5954538be2a0" content-type="del cts-3" specific-use="1555260654093" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:20pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260654093">BM </named-content><italic id="8c1d8fab-497f-44ad-b982-1995b1037377">et al</italic>, 2014<named-content id="e1f2b72e-1dc6-4a8e-87ec-3b0765c04ee3" data-cid="e1f2b72e-1dc6-4a8e-87ec-3b0765c04ee3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="20" data-match="[31]" data-replace="(" data-pattern="(" data-tag-index="s391_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803969" id="7fe26a69-4467-4561-8bee-e314d0eed541" content-type="del cts-2" specific-use="1554807533144" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:28pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807533144">(</named-content></named-content><named-content id="71703680-5f10-495a-af1e-09191907fbcb" data-cid="71703680-5f10-495a-af1e-09191907fbcb" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="23" data-match="[31]" data-replace=")" data-pattern=")" data-tag-index="s391_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803968" id="101433e2-2eb7-4771-8156-e2572eb035a2" content-type="del cts-2" specific-use="1554807532920" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:28pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807532920">)</named-content></named-content><xref id="0d867d8c-26a9-4fb6-b19c-e056b85a235a" ref-type="bibr" rid="R31" data-citation-string=" R31 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="21" data-match="31" data-pattern="" data-tag-index="80_1" data-track-change="31"><sup id="f8c9a0df-384f-4be7-a63c-f8287dd5c027">31</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="d1e430d1-4051-4b59-85a9-0ea7c710413b"><p id="800dedca-99d0-4bea-8015-90aed46102e9" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Bevacizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="570f35f5-4d9e-4573-a978-6e82549251f8"><p id="34484ac9-f6bc-46e4-ac1b-a1c7a3968cb6" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Liposome</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="05a1eac7-8367-42db-b823-126b83b6ca00"><p id="ca3aa34d-8085-49ad-95a0-fc341a8ddb1f" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="5d935ba7-fa55-42ef-89dd-aedd42ccbb60"><p id="82e0e5f2-80e5-4fca-92ed-e24f6a4756f2" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="45262663-99d1-45ee-94a3-911fb72d5a41"><p id="5ec6f77d-4180-4903-b578-d9fba5360d1c" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" data-fill="true" id="0a781010-698d-4a8c-89f8-24c930ae829e"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="7eed0d10-f836-4766-98de-12268da8330a"><p id="8f764b68-caa1-4cf7-b49b-3ed9e2fa2ea2" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Abrishami <named-content data-cid="1555259659" id="44cc6e13-8aec-456f-a3be-e0f823590c90" content-type="del cts-3" specific-use="1555260657921" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:20pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260657921">M</named-content><named-content id="62a55458-bc0d-4df7-9e42-fbc59149ccfa" data-cid="62a55458-bc0d-4df7-9e42-fbc59149ccfa" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'etâ£al' to '&lt;i&gt;etâ£al&lt;/i&gt;'" data-track-detail="" data-tag-desc="ETL" data-tag-type="ETL" data-offset="12" data-match="et al" data-replace="&lt;i&gt;et al&lt;/i&gt;" data-pattern="&lt;i&gt;et al&lt;/i&gt;" data-tag-index="86_3" data-track-change="et al" data-time="" data-username="" data-userid=""><italic id="a28f0c76-268c-42b4-93d2-dbbda0148743">et al</italic></named-content>, 2009<named-content id="88e40b40-ac7b-45bf-a5a6-8f1557caefd3" data-cid="88e40b40-ac7b-45bf-a5a6-8f1557caefd3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="23" data-match="[32]" data-replace="(" data-pattern="(" data-tag-index="s397_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803971" id="aa6b8c2a-17cf-4156-abea-58f5c78afa65" content-type="del cts-2" specific-use="1554807539970" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:28pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807539970">(</named-content></named-content><named-content id="b2292194-711d-4094-82b5-f36e485df58f" data-cid="b2292194-711d-4094-82b5-f36e485df58f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="26" data-match="[32]" data-replace=")" data-pattern=")" data-tag-index="s397_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803970" id="d8c4fce3-9ade-4efe-9a87-e77ab00ba55c" content-type="del cts-2" specific-use="1554807539652" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:28pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807539652">)</named-content></named-content><xref id="467886b2-f561-4a98-9a5b-cae1a3635e86" ref-type="bibr" rid="R32" data-citation-string=" R32 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="24" data-match="32" data-pattern="" data-tag-index="86_1" data-track-change="32"><sup id="cb63b086-0b2a-4abd-82a2-fa886b431e73">32</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="59aadb25-5dd4-407e-8ed5-375eca1ec9c8"><p id="d30f2608-838e-46cf-9dd8-77877089de29" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Bevacizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="b8f430fa-cee2-4905-815b-cf8312be12c5"><p id="95c975a7-def4-4981-ab3d-0550efeb80ba" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Liposome</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="bbfe911f-1f81-4aee-a1bb-b4ce37dff21e"><p id="2a4da747-da89-46f2-9a6f-1b9b6ae10bf7" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="2fee3d00-db94-4c35-8005-c1e3acd57c01"><p id="6d18c9ab-2e68-4efb-b8af-1ff05e94a3d4" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intravitreal</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="67d18ac0-18dc-4b75-af3f-e5f39eb024c2"><p id="508b4602-9470-46c3-a27f-e87286c4fcf9" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" id="928d9ef0-92be-42b3-84e6-6eff856489eb"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="21e4b950-804e-436a-8557-ebc758dddff8"><p id="cb789e1d-fb6b-4a41-b167-a34cdabc6ca3" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Joseph <named-content data-cid="1555259660" id="b1e7c54d-e727-4a8e-8ee3-30555c18f5e6" content-type="del cts-3" specific-use="1555260661019" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260661019">R</named-content><named-content data-cid="1555259661" id="85490ec8-f115-4636-b4f4-66f40c4db171" content-type="del cts-3" specific-use="1555260661277" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260661277">R</named-content><italic id="f044f28d-b46c-4e56-956f-f2a626a7a3f5">et al</italic>, 2017<named-content id="32e41b30-6cd2-4abe-81e9-a40f9f244484" data-cid="32e41b30-6cd2-4abe-81e9-a40f9f244484" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="21" data-match="[30]" data-replace="(" data-pattern="(" data-tag-index="s403_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803973" id="57dc3b09-80e0-4b79-988f-c814c135c92f" content-type="del cts-2" specific-use="1554807545011" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807545011">(</named-content></named-content><named-content id="b512d519-e2d6-472f-a3a3-8d9b673f40f4" data-cid="b512d519-e2d6-472f-a3a3-8d9b673f40f4" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="24" data-match="[30]" data-replace=")" data-pattern=")" data-tag-index="s403_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803972" id="f166e90f-3b03-4588-aa06-669df51bf390" content-type="del cts-2" specific-use="1554807544803" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807544803">)</named-content></named-content><xref id="ea871145-6c1f-411c-9ef8-2b0c478dcd81" ref-type="bibr" rid="R30" data-citation-string=" R30 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="22" data-match="30" data-pattern="" data-tag-index="92_1" data-track-change="30"><sup id="38e169f4-a6e8-4669-b93b-f9fb48637839">30</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="ce3df008-15d2-46f8-bed0-75f241ee0883"><p id="6b30d7f2-1b21-4870-84b8-f3737bc9130c" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Ranibizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="84a71023-d6b0-42c6-8f2e-51868f3a8a63"><p id="b670d452-4a1b-4404-a1e0-3ca552bde912" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Liposome</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="6086cfa4-9851-418f-b9c9-a3378f551ec2"><p id="d89ad3d1-ee30-4bc2-93b2-50639f3a3aeb" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="c74a1814-4cdb-464b-b1ba-2ed75e1fb3c9"><p id="e294db73-3eb2-43ee-9266-14f19469a8fd" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Subconjunctival</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="d6e4e88a-10f2-42ee-ad6d-ffa7707f8a1e"><p id="c51cd989-37c3-4b17-a657-5c38c6440c15" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" data-fill="true" id="9e0252b6-952c-43c4-b5d8-9dff4c01c2db"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="414bc1b2-5ae1-49a9-803b-14b68b98d104"><p id="56e9d054-553f-41fa-be12-be69bf67c814" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Marano <named-content data-cid="1555259662" id="3e97ec3f-4478-46a6-a3d2-9390380f2ccf" content-type="del cts-3" specific-use="1555260664648" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260664648">R</named-content><named-content data-cid="1555259663" id="3deaad7e-f749-43b3-b43a-da7ca142d2f1" content-type="del cts-3" specific-use="1555260665070" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260665070">J</named-content><italic id="09baee31-1619-47ea-9737-276264eb678a">et al</italic>, 2005<named-content id="d231a3f2-04a0-4a8c-b904-bf9f85ffe2b6" data-cid="d231a3f2-04a0-4a8c-b904-bf9f85ffe2b6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="21" data-match="[34]" data-replace="(" data-pattern="(" data-tag-index="s409_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803975" id="8ef45fcc-f802-46c7-a79a-a8d632d87dd1" content-type="del cts-2" specific-use="1554807548540" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807548540">(</named-content></named-content><named-content id="8692aec8-ea40-44ff-8ee0-9fdf134a680c" data-cid="8692aec8-ea40-44ff-8ee0-9fdf134a680c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="24" data-match="[34]" data-replace=")" data-pattern=")" data-tag-index="s409_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803974" id="180ee568-efb9-4d1c-8065-3461ef0dd3b7" content-type="del cts-2" specific-use="1554807548312" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807548312">)</named-content></named-content><xref id="c398e099-395e-4dc6-8103-cc6b26683153" ref-type="bibr" rid="R34" data-citation-string=" R34 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="22" data-match="34" data-pattern="" data-tag-index="98_1" data-track-change="34"><sup id="f9f3178c-4e06-4dfc-8303-97fae8135e42">34</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="02f092ab-487a-4cf5-886a-6bf02c771fbb"><p id="e619d873-d054-463c-97cb-7efbbcb49ead" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">ODN-1</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="b67239c0-6ec5-47ec-a7a8-61853103fc2d"><p id="60f479ef-89f9-40b0-bc00-52e6ed1bf608" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Dendrimer</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="9993966f-673d-450a-aafc-42eb5f7f0822"><p id="b58b5a1e-2bb0-43f6-9f06-59cfd17d13c0" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="8385f2ea-4fe1-4830-888f-5fe68ad4db27"><p id="7c750e3d-ed13-436b-8163-36f45d495eb9" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intravitreal</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="3567c2fd-fc40-48ba-838d-6e9326b47714"><p id="30a535ca-65f2-4fbc-9768-6d3c514b9fa8" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" id="a3d5ea51-e9c6-4989-ab4a-0156e6b41bae"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="10ee21b4-a274-4a49-a3d1-971fb9cae9f9"><p id="9d3a2df9-209d-43e4-a943-e87dcae5d93e" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">PDS<named-content id="2641cb2b-23d8-4534-a730-86f8b1fa650f" data-cid="2641cb2b-23d8-4534-a730-86f8b1fa650f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="3" data-match="[36]" data-replace="(" data-pattern="(" data-tag-index="s415_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803977" id="7baab1ac-5863-42b9-9e23-b5da670d6a7d" content-type="del cts-2" specific-use="1554807551651" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807551651">(</named-content></named-content><named-content id="e18164ef-4d1d-4592-8421-49ae1fbed8d0" data-cid="e18164ef-4d1d-4592-8421-49ae1fbed8d0" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="6" data-match="[36]" data-replace=")" data-pattern=")" data-tag-index="s415_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803976" id="bb22c86e-0823-44c6-bd2a-6fc1c3c6e202" content-type="del cts-2" specific-use="1554807551432" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807551432">)</named-content></named-content><xref id="57e5d2e4-5d26-4be0-8f9c-e17fc425dee0" ref-type="bibr" rid="R36" data-citation-string=" R36 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="4" data-match="36" data-pattern="" data-tag-index="104_1" data-track-change="36"><sup id="43a10d9e-89d7-41fb-8c77-046f8793b10e">36</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="04c7c060-fea6-47ea-8237-6632af0ffb06"><p id="35d7415a-8ff5-4046-8831-1e6e74e5df64" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Ranibizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="6e8bbf01-f17c-421c-9a64-e8173aaaa09f"><p id="3c41d927-f6e2-4074-bfb1-68bbd1a9c7d6" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Refillable port delivery system</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="52780867-1c97-4e1d-bee7-50932ddd224b"><p id="68862b18-a1d7-4b88-8915-72b1d9cbc27a" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="9055270c-f217-4db8-bee7-3543802a3780"><p id="213ac645-6734-4479-bf61-796cddbd1151" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Trans-scleral implantation</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="79a854d7-5103-4e39-b342-8ee9dffc8fd0"><p id="c64ce699-c153-4094-b21a-d53f48dbe469" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Phase <named-content data-cid="1555259497" id="ea48f4c8-4ce4-40ec-94be-9b4e623c3796" content-type="ins cts-3" specific-use="1555259804450" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259804450">III</named-content><named-content data-cid="1555259500" id="0cbdb95d-3ef4-4c27-863d-eab97a56fe41" content-type="del cts-3" specific-use="1555259805727" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259805727">3</named-content> trials</p></td></tr><tr data-col-count="6" data-fill="true" id="22669269-281d-4f4d-9fe9-acfe3d82d121"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="ecacd98a-9823-46f4-ae02-88b51397c36d"><p id="395961ac-fe73-4a30-9b26-5610057ebb13" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">PMP<named-content id="31590b92-15a1-4fb4-aae8-1ca69c7c4788" data-cid="31590b92-15a1-4fb4-aae8-1ca69c7c4788" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="3" data-match="[37]" data-replace="(" data-pattern="(" data-tag-index="s421_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803979" id="ecf27e59-bbbf-4eba-a03c-d0c3d1c53d37" content-type="del cts-2" specific-use="1554807555463" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807555463">(</named-content></named-content><named-content id="af07ec78-c232-425d-ba4c-ffb31576b5c1" data-cid="af07ec78-c232-425d-ba4c-ffb31576b5c1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="6" data-match="[37]" data-replace=")" data-pattern=")" data-tag-index="s421_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803978" id="d0e846ae-28d5-487f-be0b-38f31f7fbb21" content-type="del cts-2" specific-use="1554807555250" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807555250">)</named-content></named-content><xref id="3e97a3ef-f73e-40ae-ad99-4dc266ea3979" ref-type="bibr" rid="R37" data-citation-string=" R37 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="4" data-match="37" data-pattern="" data-tag-index="110_1" data-track-change="37"><sup id="a167fc8d-65e6-4ee1-b60d-88a8e6963b52">37</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="fc1e98ac-2758-4965-88c8-0932ee4fc726"><p id="1f5be129-f282-4f07-a478-ba9eb2f11070" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Ranibizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="187df6fb-69ae-4722-8c72-2fe4a40821a0"><p id="3532e743-4d08-4fe3-9762-63c832879df8" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Refillable micropump</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="8ff34c26-3c4b-4f0e-90dc-10bc29f2be90"><p id="7fa11588-5f40-44fa-8f04-a5bcb4b77ecc" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">DME</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="eeecb719-436e-41a4-9be1-cd50dc63f82a"><p id="6476a2c7-a306-44ee-893e-8fd08d58c73f" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Trans-scleral implantation</p></td><td data-class="" data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="750e0b03-6da7-451f-b176-4c110ff9ad8a"><p id="c95a29a4-3475-442e-b787-92bea1b22328" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Phase <named-content data-cid="1555259501" id="da4771ef-244d-4a9f-8629-a4b5cfa89a7e" content-type="ins cts-3" specific-use="1555259809234" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259809234">I</named-content><named-content data-cid="1555259502" id="8bd73fd0-d72b-4d1c-8dbe-66df4fb29e14" content-type="del cts-3" specific-use="1555259809806" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259809806">1</named-content></p></td></tr><tr data-col-count="6" id="eeb75645-47cf-49c3-ac2d-823da2254905"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="4616b2a7-f39b-4dca-8f4c-836a744b254d"><p id="76496297-e04e-4918-95e5-b7e113cf617f" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Brimapitide (XG-102)<named-content id="e7379655-99af-45f5-8719-2339bca3fe0e" data-cid="e7379655-99af-45f5-8719-2339bca3fe0e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="20" data-match="[41]" data-replace="(" data-pattern="(" data-tag-index="s427_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803981" id="5de81154-962a-426e-affe-c1ac1da164e0" content-type="del cts-2" specific-use="1554807562934" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807562934">(</named-content></named-content><named-content id="6688da4c-9724-42f6-a1f7-0030689809f2" data-cid="6688da4c-9724-42f6-a1f7-0030689809f2" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="23" data-match="[41]" data-replace=")" data-pattern=")" data-tag-index="s427_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803980" id="e5ffda80-0dc2-48b5-9bc5-942f076fdbeb" content-type="del cts-2" specific-use="1554807562692" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807562692">)</named-content></named-content><xref id="8d949193-1012-4b85-9ee8-7b8006384313" ref-type="bibr" rid="R41" data-citation-string=" R41 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="21" data-match="41" data-pattern="" data-tag-index="116_1" data-track-change="41"><sup id="f9b11fc2-c0d7-46a2-8b65-6a881e66dde0">41</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="970b26b3-da4e-4aa0-b81e-7ab47261f7f6"><p id="7f8bebfd-89dd-4a81-9cf5-26b76d300e48" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">JNK inhibitor</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="ccb0da47-3441-4778-b35d-6b3f7d8354f6"><p id="a8a3c497-a4b2-4ee0-b61d-bef1adc84131" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Cell penetrating peptides</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="3c9254b6-3758-4a01-9a78-a55a5bccb6e0"><p id="e1594ab0-d6c0-4146-b233-77db7f91c525" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Intraocular inflammation</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="ae272008-8dda-400f-8adf-85a0a70767ba"><p id="e0197c68-21f7-4abe-88c2-651f954ff29b" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Subconjunctival</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="7abaa194-821f-45be-820e-16217e491cd3"><p id="134c9e42-8b29-49be-8284-bffeb78ecbb0" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" data-fill="true" id="fcfc586a-95f8-4ed8-8cd3-8453d44890ce"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="0523aaa2-e75b-497f-a1a4-afd194647928"><p id="8e706982-87ac-4e4d-8cfd-4428844e9b54" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">De Cogan <italic id="4db25ed7-53ab-43fd-a37d-c357dadf40d2">et al</italic>, 2017<named-content id="bd903290-dcf4-45e5-a046-d240abab3762" data-cid="bd903290-dcf4-45e5-a046-d240abab3762" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="20" data-match="[42]" data-replace="(" data-pattern="(" data-tag-index="s433_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803983" id="b408495a-edb0-4008-93ec-ea11d1805af6" content-type="del cts-2" specific-use="1554807566148" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807566148">(</named-content></named-content><named-content id="fe20cd27-4951-4298-a13d-f89223f2888f" data-cid="fe20cd27-4951-4298-a13d-f89223f2888f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="23" data-match="[42]" data-replace=")" data-pattern=")" data-tag-index="s433_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803982" id="968bc7a0-497b-45dc-9887-f81e986ed757" content-type="del cts-2" specific-use="1554807565897" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807565897">)</named-content></named-content><xref id="605eb41f-bd3a-48a2-80ad-8fa87f965bd0" ref-type="bibr" rid="R42" data-citation-string=" R42 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="21" data-match="42" data-pattern="" data-tag-index="122_1" data-track-change="42"><sup id="9badf435-a41e-460c-9e96-d39e3fcf78a5">42</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="6c49c4b3-5acf-4d47-9b3e-25fdeb1b5e55"><p id="852d1085-a52d-43a6-97e6-8436004722e5" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Bevacizumab/Ranibizumab</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="188ce95d-0660-43fa-af5d-b2f3ad7e4cdb"><p id="96eb5486-35ee-4880-ad5a-b5d8812a7237" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Cell penetrating peptides</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="bb8dcd6e-269b-4a64-bc77-85ecea3e78ac"><p id="640b5d11-0390-402e-80a3-f5a02275f117" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="8ab43bda-5b57-4683-b3f0-83f1b0759d23"><p id="6d3bcf65-1491-4579-b8e5-2ffa701bbc9b" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="ed421c41-7f8f-4439-9f4b-7394b79934df"><p id="1a18a645-b1e5-4e0a-98a9-c670814353f3" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" id="5dfb80e6-61bc-48b7-b8b4-94b0f421aba0"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="bbf7cbdd-7acc-4149-87c6-31b4a30f89d2"><p id="56c4f265-cfa1-4a02-9d83-4e2b77b6eebd" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Zhang <named-content data-cid="1555259664" id="9f111832-bc53-4eea-9354-d58281ce9485" content-type="del cts-3" specific-use="1555260672640" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260672640">X</named-content><named-content id="350955ed-f470-4846-b58e-53d48d893ca7" data-cid="350955ed-f470-4846-b58e-53d48d893ca7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'etâ£al' to '&lt;i&gt;etâ£al&lt;/i&gt;'" data-track-detail="" data-tag-desc="ETL" data-tag-type="ETL" data-offset="8" data-match="et al" data-replace="&lt;i&gt;et al&lt;/i&gt;" data-pattern="&lt;i&gt;et al&lt;/i&gt;" data-tag-index="128_3" data-track-change="et al" data-time="" data-username="" data-userid=""><italic id="ab433a11-89ea-4d66-837c-cd35d36c0d02">et al</italic></named-content>, 2015<named-content id="edee8ef1-bfff-4d97-af97-69f591197508" data-cid="edee8ef1-bfff-4d97-af97-69f591197508" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="19" data-match="[43]" data-replace="(" data-pattern="(" data-tag-index="s439_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803985" id="fc465f43-202e-4602-b0e2-0da1cd8b7bea" content-type="del cts-2" specific-use="1554807569483" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807569483">(</named-content></named-content><named-content id="b6235481-c65b-45dc-8bf9-4c7d46e2ecf1" data-cid="b6235481-c65b-45dc-8bf9-4c7d46e2ecf1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="22" data-match="[43]" data-replace=")" data-pattern=")" data-tag-index="s439_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803984" id="bfcfbf01-ac8d-4688-8ba6-fa65a8c6c34a" content-type="del cts-2" specific-use="1554807569313" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807569313">)</named-content></named-content><xref id="ec4f8b70-771e-4b57-83e4-1008d82877b5" ref-type="bibr" rid="R43" data-citation-string=" R43 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="20" data-match="43" data-pattern="" data-tag-index="128_1" data-track-change="43"><sup id="6e0343f8-e609-4019-990d-79b76e0ff842">43</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="192209d9-d169-47f6-aadd-7e39bd92dbeb"><p id="31169df1-4bd4-407e-a2f9-46080a8961ab" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Endostatin</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="705469db-9dd4-47d2-8812-c341d49e0357"><p id="07d2c213-adfb-4441-bb73-34dad053b0c9" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Cell penetrating peptides</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="f4dfab21-c2cc-4f2e-ae41-cc52a65f0d2a"><p id="9244b3f9-f6a6-4b7b-83a0-e068758c999a" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="5ded0f6b-301a-477d-850c-7b6b6c88aab9"><p id="bb30c673-9360-4657-b993-9339587f8a8d" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="7791da96-2acd-4936-837b-17f9e981682f"><p id="9fdb16dd-3df6-447a-88c9-a900cd1c8043" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" data-fill="true" id="a39c1dc9-93c8-4a2d-832c-b400ba465c81"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="c22576c3-c8d0-43cc-a6d0-ef6525d2bd76"><p id="625669f6-a678-40b0-9607-d3d7339e89db" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Chen <named-content data-cid="1555259665" id="36428352-f694-4c66-ad8e-195cb9da7b05" content-type="del cts-3" specific-use="1555260675396" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260675396">C</named-content><named-content id="4a4266a0-1c0a-4926-9e7e-ce62bda887f3" data-cid="4a4266a0-1c0a-4926-9e7e-ce62bda887f3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'etâ£al' to '&lt;i&gt;etâ£al&lt;/i&gt;'" data-track-detail="" data-tag-desc="ETL" data-tag-type="ETL" data-offset="7" data-match="et al" data-replace="&lt;i&gt;et al&lt;/i&gt;" data-pattern="&lt;i&gt;et al&lt;/i&gt;" data-tag-index="134_3" data-track-change="et al" data-time="" data-username="" data-userid=""><italic id="c6b5195e-1afe-4153-ae63-96e756802f1a">et al</italic></named-content>, 2017<named-content id="35692389-82e0-45f4-a5a7-98d870cd3d4e" data-cid="35692389-82e0-45f4-a5a7-98d870cd3d4e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="18" data-match="[44]" data-replace="(" data-pattern="(" data-tag-index="s445_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803987" id="453bc449-1c74-4b28-a3d1-387cbb4923f2" content-type="del cts-2" specific-use="1554807582613" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807582613">(</named-content></named-content><named-content id="ad99e81b-0a0d-43e4-97e2-ad590929b853" data-cid="ad99e81b-0a0d-43e4-97e2-ad590929b853" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="21" data-match="[44]" data-replace=")" data-pattern=")" data-tag-index="s445_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803986" id="cc0d8690-23cc-48ef-8a11-36542128bf86" content-type="del cts-2" specific-use="1554807578866" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807578866">)</named-content></named-content><xref id="3b9dfe50-62af-41eb-b455-0858eb8a7c19" ref-type="bibr" rid="R44" data-citation-string=" R44 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="19" data-match="44" data-pattern="" data-tag-index="134_1" data-track-change="44"><sup id="971eb705-209a-4981-b105-ca984cab9c33">44</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="777c524d-91f1-4e70-b60b-57b275198572"><p id="64f66d8b-967d-436c-bb59-e80b7422eb9b" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">KV11</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="65fbd477-2732-4edf-9f33-1b47351159f7"><p id="7b7d9254-cbe0-47d6-a891-e8481fb208e6" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Cell penetrating peptides</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="4c749a9b-7a84-4487-8669-5c1f5c25d600"><p id="947ae6ea-1718-4f65-80d7-da8960757506" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="66c52284-ddd0-4c66-9054-d94d25f2467e"><p id="f2ed01a0-7080-463f-af33-fb68c68e7158" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical/retrobulbar injection</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="8a132e0f-29d3-44ad-909b-494a8fb83107"><p id="3307289b-f536-4317-a94b-423c76a02442" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr><tr data-col-count="6" id="55562186-7e7d-4c49-a299-eac0110bdda2"><td data-class="" data-original-border="border:solid windowtext 1.0pt; border-top:none;" data-original-padding="padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-0" data-col-index="1" data-possbibref="true" valign="top" id="e2cc2105-db2d-4cec-90a1-c319807a80c3"><p id="685553a2-46b8-4054-b035-b8cd2aea0a16" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Suda <named-content data-cid="1555259666" id="547f19e2-e202-48cd-9aa9-cdc983f9296c" content-type="del cts-3" specific-use="1555260678481" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:21pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260678481">K</named-content><named-content id="cfceaf00-e34e-4cf1-9dda-07c5611306f9" data-cid="cfceaf00-e34e-4cf1-9dda-07c5611306f9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'etâ£al' to '&lt;i&gt;etâ£al&lt;/i&gt;'" data-track-detail="" data-tag-desc="ETL" data-tag-type="ETL" data-offset="7" data-match="et al" data-replace="&lt;i&gt;et al&lt;/i&gt;" data-pattern="&lt;i&gt;et al&lt;/i&gt;" data-tag-index="140_3" data-track-change="et al" data-time="" data-username="" data-userid=""><italic id="060a1b42-667f-49b8-98b5-f48b130f8a90">et al</italic></named-content>, 2017<named-content id="b6ccc2d8-3185-43ae-b40c-dd10814a638f" data-cid="b6ccc2d8-3185-43ae-b40c-dd10814a638f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '[' to '('" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="LSQBRKT" data-offset="18" data-match="[45]" data-replace="(" data-pattern="(" data-tag-index="s451_1" data-track-change="[" data-time="" data-username="" data-userid=""><named-content data-cid="1554803989" id="f02b7459-2297-4a8a-a608-3d0cd85b2f5d" content-type="del cts-2" specific-use="1554807586027" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807586027">(</named-content></named-content><named-content id="8be5ccb3-bb30-4e59-a0b0-eea3fde541fe" data-cid="8be5ccb3-bb30-4e59-a0b0-eea3fde541fe" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed ']' to ')'" data-track-detail="" data-tag-desc="LSQBRKT,VAL,RSQBRKT" data-tag-type="RSQBRKT" data-offset="21" data-match="[45]" data-replace=")" data-pattern=")" data-tag-index="s451_1" data-track-change="]" data-time="" data-username="" data-userid=""><named-content data-cid="1554803988" id="b2bcb797-63e6-4b15-8cd3-8aaa2a40d93d" content-type="del cts-2" specific-use="1554807585818" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Deleted by Asha (PREEDITOR) - Apr 9 2019 4:29pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807585818">)</named-content></named-content><xref id="4953401e-ce4b-414c-a34f-922c83b058dd" ref-type="bibr" rid="R45" data-citation-string=" R45 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="19" data-match="45" data-pattern="" data-tag-index="140_1" data-track-change="45"><sup id="c6b219d3-3f19-4697-8b74-a26f4f37ef3f">45</sup></xref></p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-1" data-col-index="2" valign="top" id="754e32b1-2304-4c0d-834a-32b2cba6da9d"><p id="fbc6a8d6-2439-42b3-932c-54a6f3a4c716" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Tyrosine kinase inhibitor</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-2" data-col-index="3" valign="top" id="6c809c50-41f3-42ed-ac0e-e2b97d60cc44"><p id="5174d5d8-bee2-4642-8399-75ccd1e6e86b" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Cell penetrating peptides</p></td><td data-original-border="border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-3" data-col-index="4" valign="top" id="309d84df-27d9-445a-b639-f841e7b6b4ac"><p id="7296bbf0-63b3-4dec-aadf-3f620db02a24" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Exudative AMD</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-4" data-col-index="5" valign="top" id="ea310baa-993b-4e1e-ab5a-a90c123b45b2"><p id="4ab827bc-6e25-4bce-9668-8718e1dcb149" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Topical</p></td><td data-original-border="border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;" data-original-padding=" padding:0cm 5.4pt 0cm 5.4pt;" data-col-pos="col-5" data-col-index="6" valign="top" id="95c8de80-b276-4468-8e9e-355cee8c716c"><p id="adc3cca5-5372-4e7a-a614-afa2b47a48b8" data-original-margin=" margin-left: 0cm; margin-right: 0cm; margin: 0cm;">Preclinical</p></td></tr></tbody></table><table-wrap-foot id="087b00bb-842d-48e5-871c-ccdb1c6de702"><fn data-class="jrnlTblFoot" data-id="T1_FN1" fn-type="abbrev" id="T1_FN1" data-def-list="true" contenteditable="true"><p id="70aaee5a-dcb0-4156-9d0c-d2253f764586"><def-list id="b34436fb-04e1-4619-ba91-b32fa40fa1f7"><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="347a2a3b-c60b-4c12-b0ca-d79b6a856b56"><term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="0" data-match="AMD, age related macular degeneration;" data-pattern="" data-tag-index="" id="2a2559a9-7a03-475e-863d-34842160c39f">AMD</term><named-content id="5546c9d7-22a8-4990-abec-9b46f2d73ed5" data-cid="5546c9d7-22a8-4990-abec-9b46f2d73ed5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="3" data-match="AMD, age related macular degeneration;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="5" data-match="AMD, age related macular degeneration;" data-pattern="" data-tag-index="" id="8c695e47-0a3a-4f6c-b8e5-84859eb60afa"><p id="54acd5d3-d217-413f-b00e-7a623cb6f755">age-related macular degeneration</p></def><named-content id="d80f10f3-2ba9-4244-95c0-7a07ce7a3481" data-cid="d80f10f3-2ba9-4244-95c0-7a07ce7a3481" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFEND" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFEND" data-offset="37" data-match="AMD, age related macular degeneration;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">;</named-content></def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="49f2bf4a-b4a4-4545-9302-e4afa4b26acd"> <term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="39" data-match="DME, DME;" data-pattern="" data-tag-index="" id="e3f339a0-a558-40e8-a8f8-018f84943156">DME</term><named-content id="89bd1fa0-eb0f-4ed6-b6ac-e8125a9edf76" data-cid="89bd1fa0-eb0f-4ed6-b6ac-e8125a9edf76" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="42" data-match="DME, DME;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="44" data-match="DME, DME;" data-pattern="" data-tag-index="" id="af3c617f-fd69-4b31-815a-cd24d8d2f8bb"><p id="e8f1e0d9-9244-429d-9d8b-d4b6dcca6408">diabetic macular oedema</p></def><named-content id="930c1822-f271-4c28-89a1-1e286d66c946" data-cid="930c1822-f271-4c28-89a1-1e286d66c946" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFEND" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFEND" data-offset="47" data-match="DME, DME;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">;</named-content></def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="fdbaff21-3c13-41d2-9fd7-7fd4f79287a4"> <term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="167" data-match="FGF, fibroblast growth factor;" data-pattern="" data-tag-index="" id="dde5ebab-9d83-494d-b550-41689fe009e6">FGF</term><named-content id="a3e1e62d-7f6b-4107-8e55-a7bc7d1fe3fb" data-cid="a3e1e62d-7f6b-4107-8e55-a7bc7d1fe3fb" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="170" data-match="FGF, fibroblast growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="172" data-match="FGF, fibroblast growth factor;" data-pattern="" data-tag-index="" id="04ddf373-d1a2-4057-ad82-2a3f211d1a07"><p id="ea5f42d8-3e87-4d3a-b8bb-cb07118659ca">fibroblast growth factor</p></def><named-content id="e33174b9-b48e-4f48-8ebf-2fc9e8979853" data-cid="e33174b9-b48e-4f48-8ebf-2fc9e8979853" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFEND" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFEND" data-offset="196" data-match="FGF, fibroblast growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">;</named-content></def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" alphabetical-order="true" id="742af717-8b8e-42aa-8bbd-9e119aaf10ee" fn-type="abbrev" data-id="T1_FN2"><term data-class="jrnlAbbrevTerm" id="39bbd112-907f-47cf-976b-c6fed31d98c0">JNK</term>, <def data-class="jrnlFootDefinition" remove-last-node-suffix="true" set-last-node-suffix="." id="d6228bd1-9465-4ab2-a932-2ef4cb55fda2"><p id="34a2ccb9-7be8-4045-aaca-1d460dbe4b2e">jun-N-terminal protein kinase</p></def>; </def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="0ac2e212-fdff-42e7-bc17-867749f51a02"><term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="198" data-match="ODN-1, VEGF oligonucleotide" data-pattern="" data-tag-index="" id="a8563b56-d275-4908-9fb2-a363579f82a6">ODN-1</term><named-content id="29a01763-f429-4d84-b572-93a24da455a7" data-cid="29a01763-f429-4d84-b572-93a24da455a7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="203" data-match="ODN-1, VEGF oligonucleotide" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="205" data-match="ODN-1, VEGF oligonucleotide" data-pattern="" data-tag-index="" id="9711f26e-55ad-4dfb-b26e-a5fac6f19ae9"><p id="efc01f60-b151-4731-b99f-4108049e1d96">VEGF oligonucleotide</p></def>; </def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="1ea3c466-3be8-4bae-b0b8-ed7c779dd599"><term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="91" data-match="PDGF, platelet derived growth factor;" data-pattern="" data-tag-index="" id="b4e89e05-2ba2-437e-a3ab-a376fbdc6238">PDGF</term><named-content id="eba3645c-e080-4638-a77c-d9c7f47d2853" data-cid="eba3645c-e080-4638-a77c-d9c7f47d2853" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="95" data-match="PDGF, platelet derived growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="97" data-match="PDGF, platelet derived growth factor;" data-pattern="" data-tag-index="" id="15e2ca2f-473f-4547-8118-bdabb9d093f6"><p id="d4c53f66-95ad-48be-8157-ca79997db1ed">platelet-derived growth factor</p></def><named-content id="4c5528f7-3bdc-4112-b7c0-923c53f6ac91" data-cid="4c5528f7-3bdc-4112-b7c0-923c53f6ac91" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFEND" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFEND" data-offset="127" data-match="PDGF, platelet derived growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">;</named-content></def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="95e590af-5a32-425e-a1e1-a22318a04d72"> <term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="49" data-match="VEGF, vascular endothelial growth factor;" data-pattern="" data-tag-index="" id="85fc5409-fb72-4377-8566-5686308520b0">VEGF</term><named-content id="df77f2d1-ae82-492b-ad69-b0a7659c1a3a" data-cid="df77f2d1-ae82-492b-ad69-b0a7659c1a3a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="53" data-match="VEGF, vascular endothelial growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="55" data-match="VEGF, vascular endothelial growth factor;" data-pattern="" data-tag-index="" id="fd4e89d5-066c-44d8-bec7-877133e54e3b"><p id="6db2c2d0-53c0-4bb3-924e-9da2116d0cbe">vascular endothelial growth factor</p></def><named-content id="a64e2ef2-2c04-44c0-9e25-46e0a6d95397" data-cid="a64e2ef2-2c04-44c0-9e25-46e0a6d95397" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFEND" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFEND" data-offset="89" data-match="VEGF, vascular endothelial growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">;</named-content></def-item><def-item data-class="jrnlTblDefItem" data-channel="components" data-topic="PopUp" data-event="click" data-message="{'funcToCall': 'populateAbbrevFootNote', 'param' : {'component' : 'jrnlAbbrevFoot'}}" id="03cea2b3-54f7-41a0-bba7-6c04a788bada"> <term data-class="jrnlAbbrevTerm" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="129" data-match="bFGF, basic fibroblast growth factor;" data-pattern="" data-tag-index="" id="538495f8-2603-41a9-ba1b-66dfbd37a6a6">bFGF</term><named-content id="71dced77-6d46-4295-a8c8-baff65ff622f" data-cid="71dced77-6d46-4295-a8c8-baff65ff622f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="DEFSEP" data-track-detail="" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-tag-type="DEFSEP" data-offset="133" data-match="bFGF, basic fibroblast growth factor;" data-pattern="" data-tag-index="" data-time="" data-username="" data-userid="">, </named-content><def data-class="jrnlFootDefinition" data-tag-desc="DEFITEM,DEFSEP,DEFITEM,DEFEND" data-title="DEFITEM" data-tag-type="DEFITEM" data-offset="135" data-match="bFGF, basic fibroblast growth factor;" data-pattern="" data-tag-index="" id="b9987f58-2d60-4dab-973e-d49dc1968a91"><p id="55d5de16-d4fc-47fc-9083-7c68c452c62e"><named-content id="78feb5be-593b-4840-a006-9a11eeab283e" data-cid="78feb5be-593b-4840-a006-9a11eeab283e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="150" data-match="basic fibroblast growth factor" data-pattern="" data-tag-index="" data-abbr="bFGF" data-time="" data-username="" data-userid="">basic fibroblast growth factor</named-content></p></def>.</def-item></def-list></p></fn></table-wrap-foot></table-wrap><title data-level="1" data-class="jrnlDeleted" id="907aefc1-0d60-4899-99e0-ae27b61487cd" data-track="del" data-modified="Remove empty tag"/><title data-level="2" data-class="jrnlHead2" id="f3c4f03c-144d-4bcd-becc-a45bc73c2fe4">Intraocular implants</title><p data-class="jrnlSecPara" id="a3983b64-3c66-4dd4-8950-d1c6df414a8b">A bevacizumab-containing capsule drug ring, a non<named-content data-cid="1555259582" id="a5650026-ddfb-4a86-91c7-b5bf940993e7" content-type="ins cts-3" specific-use="1555260111496" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:11pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260111496">-</named-content>biodegradable drug reservoir placed within the capsular bag during cataract surgery, has been developed as a sustained release and potentially refillable drug delivery device. <named-content id="706f86af-e272-4067-80bd-5f73d02445c6" data-cid="706f86af-e272-4067-80bd-5f73d02445c6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'In vivo' to 'In vivo'" data-track-detail="" data-tag-desc="FNW" data-tag-type="FNW" data-offset="225" data-match="In vivo" data-pattern="" data-tag-index="10_4" data-function="removeItalics" data-time="" data-username="" data-userid="">In vivo</named-content> drug release in rabbits through <named-content id="4e3ca951-bf31-45df-b909-03238e421c9f" data-cid="4e3ca951-bf31-45df-b909-03238e421c9f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="265" data-match="40 days" data-replace="40" data-pattern="$1" data-tag-index="10_2" data-time="" data-username="" data-userid="">40</named-content><named-content id="9de6c2ec-48a2-455a-95a1-4c56975b7169" data-cid="9de6c2ec-48a2-455a-95a1-4c56975b7169" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="267" data-match="40 days" data-replace=" days" data-pattern=" $2" data-tag-index="10_2" data-time="" data-username="" data-userid=""> days</named-content> was reported and low retinal concentrations of bevacizumab were detected at <named-content id="7d776608-5075-45b5-9c38-d7f8c2f1de36" data-cid="7d776608-5075-45b5-9c38-d7f8c2f1de36" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="349" data-match="3 months" data-replace="3" data-pattern="$1" data-tag-index="10_3" data-time="" data-username="" data-userid="">3</named-content><named-content id="3bd8d988-3958-4fe5-980b-92c2e9be2396" data-cid="3bd8d988-3958-4fe5-980b-92c2e9be2396" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="350" data-match="3 months" data-replace=" months" data-pattern=" $2" data-tag-index="10_3" data-time="" data-username="" data-userid=""> months</named-content>.<xref id="d23d1d00-8bf7-4a40-a5f3-ceb54029158b" ref-type="bibr" rid="R15" data-citation-string=" R15 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="359" data-match="15" data-pattern="" data-tag-index="10_1" data-track-change="15"><sup id="5d38e336-8bc9-4884-a3bd-ff166da803da">15</sup></xref> The long<named-content data-cid="1555259572" id="d8928548-45cd-4a4e-bf04-e19b3336150d" content-type="del cts-3" specific-use="1555259979354" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259979354"> </named-content><named-content data-cid="1555259573" id="689a56f9-126c-46ee-904c-35be8585d9b3" content-type="ins cts-3" specific-use="1555259980211" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259980211">-</named-content>term safety of such an implant within the capsular bag is not known, and possible risks include erosion through the capsular bag, opacification of the capsule and dislocation of the intraocular <named-content rid="9fc41276-4cf8-4211-b646-81fd2f53d1d0" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="typesetter" data-query-from="publisher" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="6b0eb171-4af2-46ce-9dd1-86cf3e189eb6" content-type="jrnlQueryRef" specific-use="start" data-replied="true"/>lens<named-content rid="9fc41276-4cf8-4211-b646-81fd2f53d1d0" data-class="jrnlQueryRef" data-type="end" id="782bd9cb-7c45-40f0-a7a5-a192d4f1425c" content-type="jrnlQueryRef" specific-use="end" data-replied="true"/><named-content data-cid="1555259454" id="c8f40192-d353-4f2a-a93f-4e655fd49bcc" content-type="del cts-3" specific-use="1555259501561" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:01pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259501561">.</named-content><named-content data-cid="1554803929" id="8000f6b1-71e4-4dd4-9788-6d64b8d305f4" content-type="ins cts-2" specific-use="1554804084128" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 3:31pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554804084128"><named-content data-cid="1556113623" id="49c0d605-2989-472f-af5e-07c35fad42c1" content-type="del cts-5" specific-use="1556113750805" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Deleted by Production (BMJ) - Apr 24 2019 2:49pm" data-track-detail="" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-username="Production (BMJ)" data-time="1556113750805"> </named-content><named-content id="0ec84d30-040d-4ed6-b2e4-e2e3138c624b" data-cid="1554804100922" content-type="ins cts-1" specific-use="1554804100922" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 3:31pm" data-track-detail="" data-username="Asha (PREEDITOR)" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-time="1554804100922"><named-content data-cid="1555332831" id="43062505-b5a8-4237-9a8f-48a3972d38f7" content-type="del cts-4" specific-use="1555332954458" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Deleted by Tina T Wong (AUTHOR) - Apr 15 2019 8:55pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555332954458">(</named-content><xref id="c7d7cbfb-b882-4553-bead-b4b0a3d173cd" ref-type="table" rid="T1" data-citation-string=" T1 " data-cite-type="delete" data-track="del" data-cid="1556176689815" data-username="Thilip (TYPESETTER)" data-userid="typesetter 321b47f6-3e89-4373-9302-4177702ffb45" data-time="1556176689815">table 1</xref><named-content data-cid="1555332831" id="7de9c4d1-3f78-4e91-a832-fabfd9b7d897" content-type="del cts-4" specific-use="1555332954458" xlink:title="Tina T Wong (AUTHOR)" alt="author 644094267" data-title="Deleted by Tina T Wong (AUTHOR) - Apr 15 2019 8:55pm" data-track-detail="" data-userid="author 644094267" data-username="Tina T Wong (AUTHOR)" data-time="1555332954458">)</named-content><named-content data-cid="1555259455" id="44593ba0-6c72-41cd-8d4e-cf0ab1134865" content-type="ins cts-3" specific-use="1555259502678" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:01pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259502678"><named-content data-cid="1556113623" id="6b634659-ddc4-4a96-aa4b-5672a0d81f32" content-type="del cts-5" specific-use="1556113750805" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Deleted by Production (BMJ) - Apr 24 2019 2:49pm" data-track-detail="" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-username="Production (BMJ)" data-time="1556113750805">.</named-content><named-content data-cid="1556113624" id="f3312c2f-c31e-448d-98c1-8370be03c2b5" content-type="ins cts-5" specific-use="1556113750961" xlink:title="Production (BMJ)" alt="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-title="Inserted by Production (BMJ) - Apr 24 2019 2:49pm" data-track-detail="" data-userid="publisher 3d498c43-f949-4f18-93ae-a0b2a48c4068" data-username="Production (BMJ)" data-time="1556113750961">.</named-content></named-content></named-content></named-content></p><p data-class="jrnlSecPara" id="501d54e8-d268-4b74-8fc6-e8020fde234f">A non<named-content data-cid="1555259583" id="86035b2c-c5f2-4d87-9d83-d64c1fe5ea6d" content-type="ins cts-3" specific-use="1555260114710" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:11pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260114710">-</named-content>bioerodable implant that produces ciliary neurotrophic factor with encapsulated cell technology, designated NT-501, has been reported to deliver stable levels of protein over <named-content id="fa718143-a098-4550-b768-057fbff66a2c" data-cid="fa718143-a098-4550-b768-057fbff66a2c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="180" data-match="2 years" data-replace="2" data-pattern="$1" data-tag-index="11_3" data-time="" data-username="" data-userid="">2</named-content><named-content id="e551f3dd-b7b2-453b-905c-c643ae501c99" data-cid="e551f3dd-b7b2-453b-905c-c643ae501c99" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="181" data-match="2 years" data-replace=" years" data-pattern=" $2" data-tag-index="11_3" data-time="" data-username="" data-userid=""> years</named-content> in <named-content id="3db4dfc8-595c-4f59-95c5-93f212609b6e" data-cid="3db4dfc8-595c-4f59-95c5-93f212609b6e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="191" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="11_6" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with various retinal diseases, including geographic atrophy due to non-neovascular AMD.<xref id="ba24f039-d24f-4652-95f6-130b97f0650a" ref-type="bibr" rid="R16" data-citation-string=" R16 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="288" data-match="16" data-pattern="" data-tag-index="11_1" data-track-change="16"><sup id="f02596fd-a524-44c2-9ca4-6a2c715bb967">16</sup></xref> The protein production half-life achieved with this technology is <named-content id="db43a5da-d50f-4649-8189-5d1c415a97eb" data-cid="db43a5da-d50f-4649-8189-5d1c415a97eb" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="358" data-match="51 months" data-replace="51" data-pattern="$1" data-tag-index="11_4" data-time="" data-username="" data-userid="">51</named-content><named-content id="d1642a26-3a7a-4bca-a6c5-2667402d01b7" data-cid="d1642a26-3a7a-4bca-a6c5-2667402d01b7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="360" data-match="51 months" data-replace=" months" data-pattern=" $2" data-tag-index="11_4" data-time="" data-username="" data-userid=""> months</named-content>. <named-content data-cid="1555259456" id="b124cb35-8f8e-4ce1-858c-9534fe517872" content-type="styrm cts-3" specific-use="1555259643812" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Bold Removed by Varadaraj (COPYEDITOR) - Apr 14 2019 10:04pm" data-track-detail="" data-format-command="bold" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259643812" data-track-hint="Bold Removed"><italic data-cid="1555259461" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259678836" data-class="sty cts-3" data-track-hint="Italic Added" id="a15e91ab-0a76-4c53-ae14-6efda79fe7f1" data-title="Italic Added by Varadaraj (COPYEDITOR) - Apr 14 2019 10:04pm">NT-503</italic></named-content> is a soluble anti-<named-content data-cid="1555259584" id="7e566d84-87a4-4911-a502-6349fda65839" content-type="changeCase sty cts-3" specific-use="1555260135092" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="UPPERCASE Added by Varadaraj (COPYEDITOR) - 04/14/2019 10:12pm" data-track-detail="" data-track-hint="UPPERCASE Added" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260135092">VEGF<span data-class="hidden" hidden-track="track" id="3ed7733f-9128-43e6-b97f-559f7f39bd44">vegf</span></named-content> receptor protein delivered by encapsulated cell technology developed for the treatment of neovascular AMD, but a lack of efficacy <named-content data-cid="1554794312019" id="85ef4506-c5ed-4228-9734-1b0d14031424" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared to</named-content><named-content data-cid="1554794312019" id="1b0a8d71-e71a-42b0-8cbd-ac3a07ea90f9" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'comparedâ£to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="529" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="11_7" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared with</named-content> aflibercept had led to the termination of the <named-content data-cid="1555259503" id="74e3d4ce-e204-45da-9312-d5d4a6a8cced" content-type="ins cts-3" specific-use="1555259824512" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259824512">P</named-content><named-content data-cid="1555259504" id="7007c0a7-942f-4e1f-a5ed-f6549882771e" content-type="del cts-3" specific-use="1555259825200" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259825200">p</named-content>hase <named-content data-cid="1555259505" id="45eb8f98-cb37-4041-a0b6-067309b76298" content-type="ins cts-3" specific-use="1555259827025" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259827025">II</named-content><named-content data-cid="1555259507" id="6f1fa023-d37b-4c9d-b1f8-cf9c71200cfc" content-type="del cts-3" specific-use="1555259827823" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259827823">2</named-content> trial.<xref id="50da0072-3c8d-45f0-bdb0-bdbb6f91068f" ref-type="bibr" rid="R17" data-citation-string=" R17 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="602" data-match="17" data-pattern="" data-tag-index="11_2" data-track-change="17"><sup id="8662e03a-f303-4c8a-bfe1-942bc89bbda5">17</sup></xref></p><p data-class="jrnlSecPara" data-head-type="bold" id="fa4360cf-a831-482c-af20-d37027b320ad">GB-102<named-content data-cid="1554803991" id="59be0d20-031a-40b7-a7a8-8b2ea94f2323" content-type="ins cts-2" specific-use="1554807733547" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 4:32pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807733547"> </named-content>(Graybug Vision) is a depot formulation of <named-content data-cid="1555259740" id="973c5d3e-088e-407e-b9c9-007dd98239d6" content-type="del cts-3" specific-use="1555263178391" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 11:02pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555263178391">s</named-content><named-content data-cid="1555259741" id="581d7ccd-1c8b-49b6-a912-c75f6939ab28" content-type="ins cts-3" specific-use="1555263178788" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 11:02pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555263178788">S</named-content>unitinib <named-content data-cid="1555259742" id="f75653ee-9fbe-40c4-a2b8-a384527209ea" content-type="del cts-3" specific-use="1555263179751" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 11:02pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555263179751">m</named-content><named-content data-cid="1555259743" id="bbc96827-fc67-413c-8008-e7dcb69c3d47" content-type="ins cts-3" specific-use="1555263180485" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 11:03pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555263180485">M</named-content>alate, a tyrosine kinase inhibitor that blocks multiple targets including platelet-derived growth factor<named-content data-cid="1555259700" id="79b780ec-2fe4-4b00-a917-2049f53b9ad2" content-type="ins cts-3" specific-use="1555261994797" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:43pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261994797"> (PDGF)</named-content> and VEGF receptors. The drug is encapsulated within bioerodable polymeric nanoparticles and is designed as a 6 monthly intravitreal depot injection. Phase <named-content data-cid="1555259508" id="40d64b9f-64d6-4295-abd8-382dbe5f7c80" content-type="ins cts-3" specific-use="1555259831808" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259831808">I</named-content><named-content data-cid="1555259509" id="ec98ee23-b0de-41dd-8317-b262c29154f4" content-type="del cts-3" specific-use="1555259832432" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259832432">1</named-content>/<named-content data-cid="1555259510" id="7655b160-4732-47fd-8535-1ad91933614c" content-type="ins cts-3" specific-use="1555259833737" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259833737">II</named-content><named-content data-cid="1555259512" id="69e526ec-5481-4ffa-a70f-97c9d27c84a4" content-type="del cts-3" specific-use="1555259834565" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259834565">2</named-content> trials evaluating the safety and efficacy of intravitreal GB-102 for neovascular AMD are ongoing.<xref id="2bedceab-b5e4-45b5-ad4c-81e00a591390" ref-type="bibr" rid="R18" data-citation-string=" R18 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="416" data-match="18" data-pattern="" data-tag-index="12_1" data-track-change="18"><sup id="8c7f1566-5b80-47e7-b835-8e0f625b8b51">18</sup></xref></p><title data-level="2" data-class="jrnlHead2" id="ccd4973e-5527-4ba9-9d51-297e0df73b91">Topical eyedrops</title><p data-class="jrnlSecPara" id="9e3edcbe-9a79-49d0-966d-44fe14377e0d">Drug potency and effective dose are crucial for its suitability to be delivered topically. Retinal bioavailability is low after topical administration (&lt;&lt;<named-content data-cid="1555259672" id="79e370cd-f0b5-4b3d-82e2-921b8b41f2d6" content-type="del cts-3" specific-use="1555261446414" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:34pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261446414"> &lt;&lt;</named-content><named-content rid="b8cd53b3-4be9-4607-9d52-d3ce612c6809" data-class="jrnlQueryRef" data-type="start" data-query-ref="true" data-query-for="typesetter" data-query-from="copyeditor" data-channel="query" data-topic="action" data-event="click" data-message="{'funcToCall': 'highlightQuery'}" data-query-type="action" id="09aa7ea0-7150-45c4-b50f-3dbce1abed4f" content-type="jrnlQueryRef" specific-use="start" data-style="" data-replied="true"/>0.1<named-content rid="b8cd53b3-4be9-4607-9d52-d3ce612c6809" data-class="jrnlQueryRef" data-type="end" id="5be122c3-06e4-42f8-b188-3f136defd4b0" content-type="jrnlQueryRef" specific-use="end" data-replied="true"/>%),<xref id="84426781-78ec-49a6-8c45-9ebf600c5e8d" ref-type="bibr" rid="R8" data-citation-string=" R8 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="162" data-match="8" data-pattern="" data-tag-index="13_1" data-track-change="8"><sup id="d3ec7577-f46d-47c1-a8fd-f16866127ae3">8</sup></xref> but the concentrations needed for pharmacological activity are compound and size dependent. Topical administration may be suitable only for highly potent compounds that are active at low concentrations, preferably in the nanomolar or picomolar range in size. Accordingly, several topical anti<named-content data-cid="1555259585" id="62e06ca4-026e-44ff-b2e7-2a1c1e1e5b2a" content-type="del cts-3" specific-use="1555260182700" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260182700">-</named-content>angiogenic eyedrops have been developed but most have failed to demonstrate benefit over intravitreal anti-VEGF in clinical trials. These therapies are described briefly in this section.</p><p data-class="jrnlSecPara" data-head-type="bold" id="e74b6498-51ce-4116-be09-420c4c931582">Pazopanib<named-content data-cid="1554803993" id="4a5fa045-ca6a-4a6b-8d64-9ce249c3b4f4" content-type="ins cts-2" specific-use="1554807741658" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 4:32pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807741658"> </named-content>(GlaxoSmithKline, Brentford, UK) is a multi<named-content data-cid="1555259591" id="b9f5093a-e6cd-4ab3-b914-718db15764e4" content-type="del cts-3" specific-use="1555260206372" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260206372">-</named-content>targeted tyrosine kinase inhibitor that inhibits <named-content data-cid="1554794312025" id="a80e5c18-4c19-48ac-99a2-de4ef1ee7aef" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">tumor</named-content><named-content data-cid="1554794312025" id="1588ca32-98db-46b8-a619-89a7aab6349f" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'tumor' to 'tumour'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="93" data-match="tumor" data-replace="tumour" data-pattern="tumour" data-tag-index="14_8" data-function="addTrackChanges" data-track-change="tumor" data-userid="preediting" data-username="Exeter" data-time="1554794312000">tumour</named-content> growth factors such as stem cell growth factor (c-KIT), fibroblast growth factor receptor<named-content data-cid="1555259699" id="2cc44c6e-a2ab-492b-98e3-3b1f0245eb82" content-type="del cts-3" specific-use="1555261888702" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:41pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261888702"> (</named-content><named-content id="6825e67c-6f4f-4c78-9786-b304912e07e1" data-cid="6825e67c-6f4f-4c78-9786-b304912e07e1" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="190" data-match=" (FGFR)" data-pattern="" data-tag-index="14_6" data-time="" data-username="" data-userid=""><named-content data-cid="1555259699" id="f25a083d-92b3-49d0-9731-e75a7106bab4" content-type="del cts-3" specific-use="1555261888702" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:41pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261888702">FGFR</named-content></named-content><named-content data-cid="1555259699" id="6f301436-b2e4-4723-b4b8-2de4d82555a3" content-type="del cts-3" specific-use="1555261888702" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:41pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261888702">)</named-content>, PDGFR and VEGFR <named-content id="0c467959-8b92-4075-8428-1c2bb5146abd" data-cid="0c467959-8b92-4075-8428-1c2bb5146abd" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="213" data-match="1-3" data-replace="1" data-pattern="$2" data-tag-index="14_4" data-time="" data-username="" data-userid="">1</named-content><named-content id="342bfeab-b47f-4e8c-bf69-b39a23bd4d23" data-cid="342bfeab-b47f-4e8c-bf69-b39a23bd4d23" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to 'â'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="214" data-match="1-3" data-replace="â" data-pattern="â" data-tag-index="14_4" data-track-change="-" data-time="" data-username="" data-userid="">â</named-content><named-content id="b5fd1088-cc98-49f5-9a3f-c54fe08baacd" data-cid="b5fd1088-cc98-49f5-9a3f-c54fe08baacd" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGE" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGE" data-offset="215" data-match="1-3" data-replace="3" data-pattern="$4" data-tag-index="14_4" data-time="" data-username="" data-userid="">3</named-content>. In a large Phase <named-content data-cid="1555259513" id="3ecf8992-5ebe-4e79-84bb-bfc90ea59275" content-type="ins cts-3" specific-use="1555259838488" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259838488">III</named-content><named-content data-cid="1555259516" id="0b56ddb1-7da6-4d89-ac3a-91ea8d1ebefa" content-type="del cts-3" specific-use="1555259839776" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259839776">3</named-content> clinical trial, pazopanib eye drops administered daily in conjunction with monthly or as needed ranibizumab did not provide additional therapeutic benefit and did not reduce the number of as needed ranibizumab injections by the prespecified<named-content id="a18f95ae-6ec3-4a40-9cb2-f651f0d28879" data-cid="a18f95ae-6ec3-4a40-9cb2-f651f0d28879" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£â¥' to 'â½â¥'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="OPR" data-offset="477" data-match="prespecified â¥50%" data-replace=" â¥" data-pattern=" $2" data-tag-index="14_3" data-track-change=" â¥" data-time="" data-username="" data-userid=""> â¥</named-content><named-content id="c8523669-b7c7-441b-9841-f92e17f93b0a" data-cid="c8523669-b7c7-441b-9841-f92e17f93b0a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="481" data-match="50%" data-replace="50" data-pattern="$3" data-tag-index="14_3" data-time="" data-username="" data-userid="">50</named-content><named-content id="ec98930d-55c7-4324-a376-461d3917cf1a" data-cid="ec98930d-55c7-4324-a376-461d3917cf1a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="483" data-match="50%" data-replace="%" data-pattern="%" data-tag-index="14_5" data-time="" data-username="" data-userid="">%</named-content> criteria.<xref id="782367cc-351d-4833-8229-e5dc1b54fc10" ref-type="bibr" rid="R19" data-citation-string=" R19 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="495" data-match="19" data-pattern="" data-tag-index="14_1" data-track-change="19"><sup id="9e89c4fb-2cbe-48c0-83d8-434dee2331f3">19</sup></xref> Similarly, <named-content data-cid="1555259459" id="8eeffbbe-3e80-4783-971a-278286cbdb39" content-type="styrm cts-3" specific-use="1555259667387" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Bold Removed by Varadaraj (COPYEDITOR) - Apr 14 2019 10:04pm" data-track-detail="" data-format-command="bold" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259667387" data-track-hint="Bold Removed"><italic data-cid="1555259460" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259670810" data-class="sty cts-3" data-track-hint="Italic Added" id="30c1234b-4db5-4a34-a1a0-06e81581aeb5" data-title="Italic Added by Varadaraj (COPYEDITOR) - Apr 14 2019 10:04pm">Regorafenib</italic></named-content> (Bayer Pharma, Leverkusen, Germany), another multi<named-content data-cid="1555259592" id="46f1d029-bdb4-43b9-a190-82e6879a60fc" content-type="del cts-3" specific-use="1555260211796" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260211796">-</named-content>kinase inhibitor that exerts anti<named-content data-cid="1555259586" id="62e2e0fc-8ae3-4f9d-a472-475eb0af5e9f" content-type="del cts-3" specific-use="1555260185412" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260185412">-</named-content>angiogenic effects by targeting the VEGFR-TIE2 tyrosine kinase has been evaluated as an eye drop therapy for exudative AMD. In the DREAM study, a single arm open label Phase <named-content data-cid="1555259517" id="57eb795e-001c-4558-93e9-bff65e74027b" content-type="ins cts-3" specific-use="1555259843816" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259843816">II</named-content><named-content data-cid="1555259519" id="4c1c418c-6103-4a5e-ac0c-7f8b1c2aad81" content-type="del cts-3" specific-use="1555259844796" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259844796">2</named-content>a/b study, regorafenib was unable to achieve similar visual acuity gains to established anti-VEGF therapies and was terminated after completion of Phase <named-content data-cid="1555259520" id="9e65a85e-4833-41ee-b430-0a2c6e7025ea" content-type="ins cts-3" specific-use="1555259848480" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259848480">II</named-content><named-content data-cid="1555259522" id="4c906fa5-6c2c-4619-b8c5-8b4664d32d57" content-type="del cts-3" specific-use="1555259848887" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259848887">2</named-content>a.<xref id="24dd4472-7ad3-49fe-b755-61b7298e35c1" ref-type="bibr" rid="R20" data-citation-string=" R20 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="939" data-match="20" data-pattern="" data-tag-index="14_2" data-track-change="20"><sup id="15b6c62c-f75e-42b8-8be5-103741b49806">20</sup></xref></p><p data-class="jrnlSecPara" data-head-type="bold" id="74802b9f-1c11-4bc3-a319-8f5ea6cb7edd">Squalamine<named-content data-cid="1554803995" id="11eca2f5-1910-4805-a415-144bc0e17b59" content-type="ins cts-2" specific-use="1554807752508" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 4:32pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807752508"> </named-content>is a small molecule inhibitor of multiple growth factors, including VEGF, PDGF and <named-content id="3a7cc5b1-9a69-4f85-89cf-b35d81503f7b" data-cid="3a7cc5b1-9a69-4f85-89cf-b35d81503f7b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="83" data-match="basic fibroblast growth factor" data-pattern="" data-tag-index="" data-abbr="bFGF" data-time="" data-username="" data-userid="">basic fibroblast growth factor</named-content><named-content data-cid="1555259707" id="106c5780-cc3e-4d07-87de-db6019585514" content-type="del cts-3" specific-use="1555262084740" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:44pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262084740"> (</named-content><named-content id="516926ab-5f62-41f1-af8d-55b10ac1080f" data-cid="516926ab-5f62-41f1-af8d-55b10ac1080f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="115" data-match=" (bFGF)" data-pattern="" data-tag-index="15_2" data-time="" data-username="" data-userid=""><named-content data-cid="1555259707" id="53d54c16-b01c-414a-b36f-cbe3fbdf38df" content-type="del cts-3" specific-use="1555262084740" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:44pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262084740">bFGF</named-content></named-content><named-content data-cid="1555259707" id="b2f290f2-50f0-49f0-9513-35c05e904c1d" content-type="del cts-3" specific-use="1555262084740" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:44pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262084740">)</named-content>. In the MAKO trial, a Phase <named-content data-cid="1555259523" id="28321ace-9e3f-4ee2-b10c-d7d33373a803" content-type="ins cts-3" specific-use="1555259853008" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259853008">III</named-content><named-content data-cid="1555259526" id="d2727606-2d5c-4ac1-a270-9e062bb4ba30" content-type="del cts-3" specific-use="1555259854039" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259854039">3</named-content> trial that included 237 <named-content id="4491e881-f1b3-4c9c-8349-ae0e17769934" data-cid="4491e881-f1b3-4c9c-8349-ae0e17769934" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="175" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="15_4" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with neovascular AMD, squalamine failed to add any benefit when used in combination with ranibizumab, <named-content data-cid="1554794312020" id="50108c33-fe29-44c5-ad76-a4a119faf387" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared to</named-content><named-content data-cid="1554794312020" id="0784564a-791d-4ff0-90d4-83a059ffd6a2" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'comparedâ£to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="286" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="15_5" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared with</named-content> ranibizumab therapy.<xref id="ba42a9c9-861f-40c5-a41c-bfcf49496644" ref-type="bibr" rid="R21" data-citation-string=" R21 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="319" data-match="21" data-pattern="" data-tag-index="15_1" data-track-change="21"><sup id="94ddc1f2-5edd-4279-ba15-d115b2c7cb7f">21</sup></xref></p><p data-class="jrnlSecPara" data-head-type="bold" id="c7032455-d03e-42c6-ab03-331180d1f462">Pan-90806<named-content data-cid="1554803997" id="399db855-1b42-439f-9ed9-1628263a326c" content-type="ins cts-2" specific-use="1554807760667" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 4:32pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807760667"> </named-content>(PanOptica, Bernardsville, <named-content data-cid="1555259593" id="1b2913d5-5a10-4a12-a883-8944de373beb" content-type="ins cts-3" specific-use="1555260246991" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:14pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260246991"><span id="17e6517f-7f5b-49da-bb7d-2e7f3896808b">New Jersey</span></named-content><named-content data-cid="1555259594" id="9906315e-eb4f-4110-a97b-2bab5e2fef20" content-type="del cts-3" specific-use="1555260247697" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:14pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260247697">NJ</named-content>, USA) is a topically administered inhibitor of VEGF receptor 2, fibroblast growth factor <named-content id="7665ac97-eddf-4983-addc-358cb1ff824e" data-cid="7665ac97-eddf-4983-addc-358cb1ff824e" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="119" data-match="1â3" data-replace="1" data-pattern="$2" data-tag-index="16_3" data-time="" data-username="" data-userid="">1</named-content><named-content id="3a890425-b0e9-4797-aaf1-4e0c671e4c99" data-cid="3a890425-b0e9-4797-aaf1-4e0c671e4c99" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGC" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="120" data-match="1â3" data-replace="â" data-pattern="â" data-tag-index="16_3" data-time="" data-username="" data-userid=""><bold id="e03f31e9-e2ff-42de-8a1e-1dee0bb3ebe1">â</bold></named-content><named-content id="2f7c519e-9e84-447a-8e9f-90a211268455" data-cid="2f7c519e-9e84-447a-8e9f-90a211268455" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGE" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGE" data-offset="123" data-match="1â3" data-replace="3" data-pattern="$4" data-tag-index="16_3" data-time="" data-username="" data-userid="">3</named-content>, tyrosine kinase endothelial receptor 2<named-content data-cid="1555259596" id="d2761b29-0752-47bf-ad98-385a2bec0835" content-type="del cts-3" specific-use="1555260260292" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:14pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260260292">,</named-content> and other proangiogenic factors.<xref id="2ca4b0ab-bb40-4732-8a88-36c34c797ede" ref-type="bibr" rid="R22" data-citation-string=" R22 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="199" data-match="22" data-pattern="" data-tag-index="16_1" data-track-change="22"><sup id="329972f4-a6c1-4cc5-9b7f-d65c53209737">22</sup></xref> Initial results from the Phase<named-content data-cid="1555259527" id="583c3a7e-ded7-4fab-9f0c-32aec42ec7f1" content-type="ins cts-3" specific-use="1555259857187" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259857187"> </named-content><named-content data-cid="1555259528" id="d1131014-ad81-4d4c-9665-4c0055edb366" content-type="del cts-3" specific-use="1555259857889" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259857889">1</named-content><named-content data-cid="1555259529" id="63379ea3-948c-456b-918a-92e230a7a767" content-type="ins cts-3" specific-use="1555259858202" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259858202">I</named-content>/<named-content data-cid="1555259530" id="9c0ec8f3-2af5-485e-9a73-7aeefe9f1ced" content-type="ins cts-3" specific-use="1555259859648" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259859648">II</named-content><named-content data-cid="1555259532" id="0c823980-e6ed-43f9-b6b2-3534101c44ae" content-type="del cts-3" specific-use="1555259860180" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259860180">2</named-content> study are promising, with <named-content id="9a539ee3-d10d-4efe-b93c-5660e1ad2ed5" data-cid="9a539ee3-d10d-4efe-b93c-5660e1ad2ed5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '45' to '45%'" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="PRE" data-offset="263" data-match="45-50%" data-replace="45%" data-pattern="$2$6" data-tag-index="16_2" data-track-change="45" data-time="" data-username="" data-userid="">45%</named-content><named-content id="6e7e2156-204b-4f6e-b6f8-73c91d249305" data-cid="6e7e2156-204b-4f6e-b6f8-73c91d249305" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to 'â'" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="RNG" data-offset="265" data-match="45-50%" data-replace="â" data-pattern="â" data-tag-index="16_2" data-track-change="-" data-time="" data-username="" data-userid="">â</named-content><named-content id="4cb26060-71a5-49dd-95a9-5613e0c8c9d7" data-cid="4cb26060-71a5-49dd-95a9-5613e0c8c9d7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SUF" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="SUF" data-offset="266" data-match="45-50%" data-replace="50" data-pattern="$5" data-tag-index="16_2" data-time="" data-username="" data-userid="">50</named-content><named-content id="4dfd25db-b03d-4a80-8df9-8673ed9e5699" data-cid="4dfd25db-b03d-4a80-8df9-8673ed9e5699" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SREP" data-track-detail="" data-tag-desc="APP,PRE,PREP,RNG,SUF,SREP,UNT" data-tag-type="SREP" data-offset="268" data-match="45-50%" data-replace="%" data-pattern="$6" data-tag-index="16_2" data-time="" data-username="" data-userid="">%</named-content> of treated <named-content id="b343a365-3187-4fb9-aec8-4c221aa132b6" data-cid="b343a365-3187-4fb9-aec8-4c221aa132b6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="281" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="16_5" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with a positive response with regards to vision, lesion morphology and retinal thickness.</p><p data-class="jrnlSecPara" data-head-type="bold" id="7c6e5b71-fea2-4ad1-80fd-6a6cd8943136">LHA-510 (Acrizanib)<named-content data-cid="1554803999" id="e05fa594-cd59-46e6-9c62-2d6ec9c8c0d9" content-type="ins cts-2" specific-use="1554807763110" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 4:32pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807763110"> </named-content>is a small molecule VEGFR-2 inhibitor that has completed Phase <named-content data-cid="1555259533" id="cf2f6d28-c878-4e7f-9778-b50d14619d78" content-type="ins cts-3" specific-use="1555259863984" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259863984">II</named-content><named-content data-cid="1555259535" id="cb3d8109-6022-42a6-928e-32c7bfd4185a" content-type="del cts-3" specific-use="1555259864436" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259864436">2</named-content> trial evaluating the efficacy of 84 successive days of topically administered LHA510 <named-content data-cid="1554794312021" id="097de9cb-13f7-4410-8fbc-d091f2f06195" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared to</named-content><named-content data-cid="1554794312021" id="c4cf1e66-7593-4803-9ba7-5814f91de9c2" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'comparedâ£to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="150" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="17_8" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared with</named-content> vehicle in reducing the number of <named-content id="83534a2e-6c04-45c1-af3e-17dd09572129" data-cid="83534a2e-6c04-45c1-af3e-17dd09572129" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="196" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="17_9" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> requiring intravitreal Lucentis<named-content id="8a986536-0db6-4a0d-abac-3da17d64268b" data-cid="8a986536-0db6-4a0d-abac-3da17d64268b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SYM" data-track-detail="" data-tag-desc="SYM" data-tag-type="SYM" data-offset="236" data-match="Â®" data-replace="delete" data-pattern="delete" data-tag-index="17_5" data-time="" data-username="" data-userid=""><named-content id="848d31e1-158c-4fde-ba8c-c2df059c7cde" data-cid="848d31e1-158c-4fde-ba8c-c2df059c7cde" content-type="del cts-1" specific-use="1554794312000 data-cid=" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000 data-cid=">Â®</named-content></named-content> for recurrence of active <named-content data-cid="1555259716" id="d59792f0-e168-4676-81ac-da3949b15b30" content-type="del cts-3" specific-use="1555262129150" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262129150">choroidal neovascularization (</named-content><named-content id="e846bff3-4002-4abc-bb5b-420491e78196" data-cid="e846bff3-4002-4abc-bb5b-420491e78196" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="294" data-match=" (CNV)" data-pattern="" data-tag-index="17_4" data-time="" data-username="" data-userid="">CNV</named-content><named-content data-cid="1555259717" id="765642cb-7100-4279-9c29-6a8b14598a5a" content-type="del cts-3" specific-use="1555262130866" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262130866">)</named-content>. At day 84, <named-content id="570cc0db-a24d-4850-a834-d8b3351222f6" data-cid="570cc0db-a24d-4850-a834-d8b3351222f6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="311" data-match="75.8%" data-replace="75.8" data-pattern="$1" data-tag-index="17_2" data-time="" data-username="" data-userid="">75.8</named-content><named-content id="58201362-904d-441b-8901-cae832a28c61" data-cid="58201362-904d-441b-8901-cae832a28c61" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="315" data-match="75.8%" data-replace="%" data-pattern="%" data-tag-index="17_2" data-time="" data-username="" data-userid="">%</named-content> of eyes in the LHA-510 required Lucentis<named-content id="de541c7d-3247-465b-a9b9-5824ea29f54b" data-cid="de541c7d-3247-465b-a9b9-5824ea29f54b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="SYM" data-track-detail="" data-tag-desc="SYM" data-tag-type="SYM" data-offset="357" data-match="Â®" data-replace="delete" data-pattern="delete" data-tag-index="17_6" data-time="" data-username="" data-userid=""><named-content id="f75e48e6-d4a4-4713-90d4-0f5163a72e82" data-cid="f75e48e6-d4a4-4713-90d4-0f5163a72e82" content-type="del cts-1" specific-use="1554794312000 data-cid=" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000 data-cid=">Â®</named-content></named-content> retreatment, <named-content data-cid="1554794312022" id="ee05314e-5170-45b3-8766-85d7e8ddb604" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared to</named-content><named-content data-cid="1554794312022" id="0ad167ac-2d86-4a2a-ba95-487af221dae3" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'comparedâ£to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="373" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="17_10" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554794312000">compared with</named-content> <named-content id="24c7c689-94f5-4ed6-b052-0d8d89bcbfa5" data-cid="24c7c689-94f5-4ed6-b052-0d8d89bcbfa5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="385" data-match="67.6%" data-replace="67.6" data-pattern="$1" data-tag-index="17_3" data-time="" data-username="" data-userid="">67.6</named-content><named-content id="03b2b6d4-bf0d-41ef-ab60-4e01cd8f0708" data-cid="03b2b6d4-bf0d-41ef-ab60-4e01cd8f0708" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="389" data-match="67.6%" data-replace="%" data-pattern="%" data-tag-index="17_3" data-time="" data-username="" data-userid="">%</named-content> in the control group, thus indicating a lack of efficacy of LHA-510 for the treatment of exudative AMD.<xref id="be8c1073-0d87-418c-9407-58fca8abfda3" ref-type="bibr" rid="R23" data-citation-string=" R23 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="495" data-match="23" data-pattern="" data-tag-index="17_1" data-track-change="23"><sup id="30495b33-e8db-42b1-ad8b-8d061a066b40">23</sup></xref></p><title data-level="2" data-class="jrnlHead2" id="194ce8c7-1b03-47c4-a2a2-79e271ab5568">Nanoparticles</title><title data-level="3" data-class="jrnlHead3" id="7d33b25e-f02b-4bca-aee0-84b38e7bdfe7">Liposomes</title><p data-class="jrnlSecPara" id="4bb7a880-0286-4aec-aebd-1d8389bb9e6a">Liposomes range in size from <named-content id="3fa33545-88ea-4cc1-88cb-b754c27086a9" data-cid="3fa33545-88ea-4cc1-88cb-b754c27086a9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="29" data-match="0.01 to 10 Âµm" data-replace="0.01" data-pattern="$2" data-tag-index="19_5" data-time="" data-username="" data-userid="">0.01</named-content><named-content id="0f8f3ea8-c5ae-446e-81e2-7d7cee38d756" data-cid="0f8f3ea8-c5ae-446e-81e2-7d7cee38d756" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGC" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="33" data-match="0.01 to 10 Âµm" data-replace=" to " data-pattern=" $3 " data-tag-index="19_5" data-time="" data-username="" data-userid=""> to </named-content><named-content id="57e1d993-5ec9-42a7-bba8-adf73fdf3cd6" data-cid="57e1d993-5ec9-42a7-bba8-adf73fdf3cd6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="VAL" data-offset="37" data-match="0.01 to 10 Âµm" data-replace="10" data-pattern="$1" data-tag-index="19_5" data-time="" data-username="" data-userid="">10</named-content><named-content id="157f5ff0-29c5-45f9-8969-65500bc38ef9" data-cid="157f5ff0-29c5-45f9-8969-65500bc38ef9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£Âµm' to 'âÂµm'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="UNT" data-offset="39" data-match="0.01 to 10 Âµm" data-replace="â&amp;#x00B5;m" data-pattern="â$2" data-tag-index="19_5" data-track-change=" Âµm" data-time="" data-username="" data-userid=""> Âµm</named-content> and consist of a single outer lipid bilayer or multiple interwoven lipid bilayers (multilamellar) composed primarily of phospholipids and cholesterol<named-content data-cid="1555259630" id="8c396d46-e230-4586-bff4-3cdc13436fbc" content-type="del cts-3" specific-use="1555260483914" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260483914">,</named-content> and an aqueous internal compartment. Liposomes have several advantages that make them suitable as a drug delivery mechanism, including biocompatibility and biodegradability, amphipathic nature allowing incorporation of both hydrophobic and hydrophilic drug molecules, surface modification to enhance solubility and specificity, and the ability to increase half-life of the encapsulated drug by <named-content id="7938efdc-02d6-4b63-91ef-d886bc3bd39c" data-cid="7938efdc-02d6-4b63-91ef-d886bc3bd39c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="589" data-match="7-11" data-replace="7" data-pattern="$2" data-tag-index="19_6" data-time="" data-username="" data-userid="">7</named-content><named-content id="082c1e65-cd27-495a-b40a-6ed2ef2b99e8" data-cid="082c1e65-cd27-495a-b40a-6ed2ef2b99e8" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to 'â'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="590" data-match="7-11" data-replace="â" data-pattern="â" data-tag-index="19_6" data-track-change="-" data-time="" data-username="" data-userid="">â</named-content><named-content id="7c00f871-ffbd-446c-9cd1-047fd2460caf" data-cid="7c00f871-ffbd-446c-9cd1-047fd2460caf" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGE" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGE" data-offset="591" data-match="7-11" data-replace="11" data-pattern="$4" data-tag-index="19_6" data-time="" data-username="" data-userid="">11</named-content> times.<xref id="c6d66b8c-95f3-43ec-bd11-0b9bee0466fb" ref-type="bibr" rid="R24 R25 R26 R27 R28 R29 R30" data-citation-string=" R24 R25 R26 R27 R28 R29 R30 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="614" data-match="28-30" data-pattern="" data-tag-index="19_3" data-track-change="24-26 27 28-30"><sup id="217a7b52-a28d-44a6-a1c3-3faa21c9fc71">24â30</sup></xref> Because of their amphipathic nature, liposomes can be <named-content data-cid="1555259597" id="469e8aa1-4eff-4ab3-83d4-2eac6443e038" content-type="del cts-3" specific-use="1555260275750" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:14pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260275750">utilised</named-content><named-content data-cid="1555259598" id="450912bf-7cf5-4a00-b8e3-1a4b2aa845fc" content-type="ins cts-3" specific-use="1555260275831" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:14pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260275831">used</named-content> as carriers for both hydrophilic anti-VEGF agents (<named-content id="2b3e52c4-f2b1-4212-9019-0772c848c013" data-cid="2b3e52c4-f2b1-4212-9019-0772c848c013" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="OPR" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="OPR" data-offset="735" data-match="&amp;lt;10nm" data-replace="&lt;" data-pattern="$2" data-tag-index="19_4" data-time="" data-username="" data-userid="">&lt;</named-content><named-content id="fb040779-6c26-4586-8496-54b44a95e60a" data-cid="fb040779-6c26-4586-8496-54b44a95e60a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="VAL" data-offset="736" data-match="&amp;lt;10nm" data-replace="10" data-pattern="$3" data-tag-index="19_4" data-time="" data-username="" data-userid="">10</named-content><named-content id="5987d464-e817-4b4b-8da2-69060fe3e8b3" data-cid="5987d464-e817-4b4b-8da2-69060fe3e8b3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'nm' to 'ânm'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="UNT" data-offset="738" data-match="&amp;lt;10nm" data-replace="ânm" data-pattern="â$6" data-tag-index="19_4" data-track-change="nm" data-time="" data-username="" data-userid=""> nm</named-content>) and hydrophobic corticosteroids. Their small size and modifiable surface charge facilitates their passage through the vitreous to reach the therapeutic target sites in the retina.</p><p data-class="jrnlSecPara" id="6144557d-b12e-4c48-84d6-22f8aac88a8c">Liposome encapsulated anti-VEGF agents have shown promise both in terms of efficient delivery through non-invasive or minimally invasive routes or by increasing drug residency time within the vitreous. Annexin A5 associated liposomes loaded with bevacizumab applied topically once a day for <named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="291" data-match="5 days" data-replace="5" data-pattern="$1" data-tag-index="20_4" id="a71e60be-1bc4-4543-a635-5c3afd5429d5">5</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="292" data-match="5 days" data-replace=" days" data-pattern=" $2" data-tag-index="20_4" id="479a438c-d96c-480e-a74d-b18409de1417"> days</named-content> in New Zealand white rabbits achieved significantly higher concentrations of bevacizumab in the vitreous and retina than an equivalent topical dose of unencapsulated avastin.<xref ref-type="bibr" rid="R31" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="473" data-match="31" data-pattern="" data-tag-index="20_1" data-citation-string=" R31 " data-track-change="31" id="25f8c6aa-4616-4eac-a383-c003bebde2b5"><sup id="46aea5a9-5880-4abc-abc2-ffbfec1b9bf3">31</sup></xref> These liposomes were able to undergo transcytosis across the cornea epithelia and possibly the conjunctiva epithelia as well, allowing them to bypass the corneal barrier. In experimental models, <named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'ex vivo' to 'ex vivo'" data-track-detail="" data-tag-desc="FNW" data-tag-type="FNW" data-offset="672" data-match="ex vivo" data-pattern="" data-tag-index="20_5" data-function="removeItalics" id="ecb8bec8-9838-4c8c-8a1a-629ea9b457fe">ex vivo</named-content> transport of liposome encapsulated ranibizumab across sclera (simulating a subconjunctival injection) occurred in a linear manner for <named-content data-cid="1554794312029" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" id="f4d577e1-c50a-4b10-814a-c3bed69b6c1e">seven</named-content><named-content data-cid="1554794312029" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'seven' to '7'" data-track-detail="" data-tag-desc="NUM,TIME" data-tag-type="NUM" data-offset="814" data-match="seven days" data-pattern="" data-tag-index="20_8" data-function="textToNumber,addTrackChanges" data-track-change="seven" data-userid="preediting" data-username="Exeter" data-time="1554794312000" id="2a4d230d-111c-4b76-b54c-7793969600b4">7</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£days' to 'âdays'" data-track-detail="" data-tag-desc="NUM,TIME" data-tag-type="TIME" data-offset="819" data-match="seven days" data-replace="âdays" data-pattern="â$2" data-tag-index="20_8" data-track-change=" days" id="6c496f81-fd65-4ed6-8b07-5868e478de3c"> days</named-content>, suggesting that the sclera allows diffusion of liposomal-formulated ranibizumab and raises the possibility that subconjunctival injections could serve as long-acting depots for anti-VEGF therapy.<xref ref-type="bibr" rid="R30" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1022" data-match="30" data-pattern="" data-tag-index="20_2" data-citation-string=" R30 " data-track-change="30" id="c178055f-c3db-47d8-a6c5-ac95e5e3db0e"><sup id="676e7378-8995-4569-b304-89664bfa1b58">30</sup></xref> In rabbits, intravitreal injection of liposomal bevacizumab was shown to produce <named-content data-cid="1554794312008" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" id="f6f4feb4-c40f-4aac-b54c-397eeb430283">5</named-content><named-content data-cid="1554794312008" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from '5' to 'five'" data-track-detail="" data-tag-desc="SNUM" data-tag-type="SNUM" data-offset="1107" data-match="5" data-pattern="" data-tag-index="20_6" data-function="numberToText,addTrackChanges" data-track-change="5" data-userid="preediting" data-username="Exeter" data-time="1554794312000" id="ea2dc02f-1181-4b52-918c-5455511ba598">five</named-content> times higher intravitreal concentration of bevacizumab at day 42 <named-content data-cid="1554794312023" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" id="238fd81e-abb4-488a-8952-b618c8fefd1a">compared to</named-content><named-content data-cid="1554794312023" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'comparedâ£to' to 'compared with'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="1174" data-match="compared to" data-replace="compared with" data-pattern="compared with" data-tag-index="20_7" data-function="addTrackChanges" data-track-change="compared to" data-userid="preediting" data-username="Exeter" data-time="1554794312000" id="ffdfe8b9-e0b2-407a-934d-49dc55cfffb4">compared with</named-content> free bevacizumab.<xref ref-type="bibr" rid="R32" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1204" data-match="32" data-pattern="" data-tag-index="20_3" data-citation-string=" R32 " data-track-change="32" id="5c9eb125-ef41-460d-8a56-85419265a04e"><sup id="c6cf2da1-5a04-4dd3-b37a-11acfd587478">32</sup></xref></p><title data-level="3" data-class="jrnlHead3" id="ae368faa-64b0-4ab8-aa03-ef3f4f28df30">Dendrimers</title><p data-class="jrnlSecPara" id="dedddff9-9f30-4134-8249-d29f481b1ccf">Dendrimers are a group of polymeric nanostructures that have been extensively investigated for ocular drug delivery. Their enhanced aqueous solubility, smaller size <named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="165" data-match="(1-100nm" data-replace="(1" data-pattern="$2" data-tag-index="22_2" id="64ad6617-951f-4eb4-922c-481bd67ba73b">(1</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to 'â'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="167" data-match="(1-100nm" data-replace="â" data-pattern="â" data-tag-index="22_2" data-track-change="-" id="aafdd021-8ade-4ecb-9134-99165809c419">â</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGE" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGE" data-offset="168" data-match="(1-100nm" data-replace="100" data-pattern="$4" data-tag-index="22_2" id="41e65ba8-7109-4f21-a51d-4b70edc19a51">100</named-content><named-content content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'nm' to 'ânm'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="UNT" data-offset="171" data-match="(1-100nm" data-replace="ânm" data-pattern="â$5" data-tag-index="22_2" data-track-change="nm" id="59ce1de8-9ed9-4687-84bf-b0a9071965f5"> nm</named-content>) and large variety of surface functional groups that can be modified for targeted delivery makes them ideal as a versatile and biocompatible drug delivery mechanism.<xref ref-type="bibr" rid="R33" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="340" data-match="33" data-pattern="" data-tag-index="22_1" data-citation-string=" R33 " data-track-change="33" id="5b5cef79-def0-4cbe-934c-33e1b2c3bf8c"><sup id="18d58a3f-338b-4a3d-91ca-61d0ce2e9579">33</sup></xref> As with liposomes, the size and charge of dendrimers grants them smooth passage through the vitreous, and they are capable of delivering both hydrophobic and hydrophilic drug molecules.</p><p data-class="jrnlSecPara" id="5ddd04ac-2d27-4e6c-b880-262756818497">In a laser<named-content data-cid="1555259602" id="a96e4d1f-7513-4f35-9609-fdfdd65d9089" content-type="del cts-3" specific-use="1555260341377" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:15pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260341377"> </named-content><named-content data-cid="1555259603" id="6435eb54-be4d-40dc-a36b-98675315637a" content-type="ins cts-3" specific-use="1555260342144" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:15pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260342144">-</named-content>induced CNV rat model, a lipophilic amino acid dendrimer-VEGF oligonucleotide (ODN-1) conjugate significantly inhibited the development of CNV for <named-content id="5b04a31e-0c4a-4071-84a5-d75b146136f0" data-cid="5b04a31e-0c4a-4071-84a5-d75b146136f0" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="158" data-match="4-6 months" data-replace="4" data-pattern="$2" data-tag-index="23_2" data-time="" data-username="" data-userid="">4</named-content><named-content id="e8d5c313-0bc6-4e4b-b214-437fe6b91eb6" data-cid="e8d5c313-0bc6-4e4b-b214-437fe6b91eb6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to 'â'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="159" data-match="4-6 months" data-replace="â" data-pattern="â" data-tag-index="23_2" data-track-change="-" data-time="" data-username="" data-userid="">â</named-content><named-content id="fcfc42a3-73ca-4086-ab9e-dcce57b901f0" data-cid="fcfc42a3-73ca-4086-ab9e-dcce57b901f0" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGE" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGE" data-offset="160" data-match="4-6 months" data-replace="6" data-pattern="$4" data-tag-index="23_2" data-time="" data-username="" data-userid="">6</named-content><named-content id="5af4ba76-f59c-4658-8d2e-72c5305b106f" data-cid="5af4ba76-f59c-4658-8d2e-72c5305b106f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="UNT" data-offset="161" data-match="4-6 months" data-replace=" months" data-pattern=" $5" data-tag-index="23_2" data-time="" data-username="" data-userid=""> months</named-content>, while injection of ODN-1 alone was unable to inhibit CNV activity from month 2 onwards. The dendrimer ODN-1 conjugates were also shown to penetrate all layers of the retina to the <named-content data-cid="1555259695" id="b4e85c25-ab88-415b-b56c-1a934d6b32f9" content-type="ins cts-3" specific-use="1555261829262" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:40pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261829262">RPE</named-content><named-content id="9236b454-c9ae-427b-b79f-940b49c80963" data-cid="9236b454-c9ae-427b-b79f-940b49c80963" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="350" data-match="retinal pigment epithelium" data-pattern="" data-tag-index="" data-abbr="RPE" data-time="" data-username="" data-userid=""><named-content data-cid="1555259698" id="88e66984-7cd1-40ce-a839-d89955aaa333" content-type="del cts-3" specific-use="1555261831677" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:40pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261831677">retinal pigment epithelium</named-content></named-content>.<xref id="e70f9f3c-edd7-4128-820a-b4454e3e422a" ref-type="bibr" rid="R34" data-citation-string=" R34 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="378" data-match="34" data-pattern="" data-tag-index="23_1" data-track-change="34"><sup id="9c04194a-a6fa-46e8-9f72-50a4189f1964">34</sup></xref> The dendrimer in this instance provided a high degree of protection against nucleases and enhanced delivery of the ODN-1 gene into retinal tissues, thereby prolonging its effective lifespan.</p><title data-level="2" data-class="jrnlHead2" id="c167e31f-33cc-439f-a035-b5c2820251fd"><named-content data-cid="1554794312035" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase" id="ad171c50-d6fb-43b6-8c09-5d64b5e4fa35">Port Delivery Systems</named-content><named-content data-cid="1554794312035" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase" id="16c46e9f-8805-4b3b-b5a4-556ea95d4545">Port delivery systems</named-content></title><p data-class="jrnlSecPara" id="d7a46dc6-c18b-496f-9cec-42ac92ccdda0">A refillable ranibizumab port delivery system has been developed to reduce the need for repeated intravitreal anti-VEGF injections. The preloaded implant is surgically implanted beneath the conjunctiva through a <named-content id="9b244708-0183-4dc2-aa72-677e6f045bd6" data-cid="9b244708-0183-4dc2-aa72-677e6f045bd6" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="212" data-match="3.2 mm" data-replace="3.2" data-pattern="$1" data-tag-index="24_3" data-time="" data-username="" data-userid="">3.2</named-content><named-content id="aafed007-4f09-4ade-856e-40f52e61031d" data-cid="aafed007-4f09-4ade-856e-40f52e61031d" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£mm' to 'âmm'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="215" data-match="3.2 mm" data-replace="âmm" data-pattern="â$2" data-tag-index="24_3" data-track-change=" mm" data-time="" data-username="" data-userid=""> mm</named-content> scleral incision over the pars plana,<xref id="4187ccc7-343b-4d99-b6af-bb828da2b9a8" ref-type="bibr" rid="R35" data-citation-string=" R35 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="256" data-match="35" data-pattern="" data-tag-index="24_1" data-track-change="35"><sup id="37df94c7-e3c5-4d15-8363-5e896e0327d5">35</sup></xref> with a reservoir tip that can be accessed easily and refilled through the conjunctiva as needed. This device essentially replaces regular intravitreal injections with a single surgical implantation of the port delivery system. In between refills, the device continuously releases ranibizumab into the vitreous. Following a successful Phase <named-content data-cid="1555259536" id="969dc8e6-02c2-4195-a484-871b24a50f71" content-type="ins cts-3" specific-use="1555259868592" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259868592">I</named-content><named-content data-cid="1555259537" id="817e6fcc-25c5-463e-9ee8-5e00c2379f3e" content-type="del cts-3" specific-use="1555259868899" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259868899">1</named-content> trial in <named-content id="3c3659db-72a9-41d4-be59-f2ab47a6cfe7" data-cid="3c3659db-72a9-41d4-be59-f2ab47a6cfe7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="612" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="24_6" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with neovascular <named-content data-cid="1555259675" id="5175d875-d95d-4f12-a43a-1e511ae13867" content-type="ins cts-3" specific-use="1555261593368" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:36pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261593368">AMD</named-content><named-content data-cid="1555259604" id="39ecc08e-193a-4df0-b6a5-a6daeb884dcb" content-type="del cts-3" specific-use="1555260372958" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:16pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260372958">age </named-content><named-content data-cid="1555259678" content-type="del cts-3" specific-use="1555261596200" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:36pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261596200" id="4e3c257a-6ae5-4852-bcab-2999ef2ae69c">related macular degeneration</named-content>, a multicentre, <named-content data-cid="1554794312026" id="125ed227-4df7-4541-b7f5-08f0970583c2" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">randomized</named-content><named-content data-cid="1554794312026" id="793d1729-0d25-4523-8e3e-7948404860a4" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'randomized' to 'randomised'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="687" data-match="randomized" data-replace="randomised" data-pattern="randomised" data-tag-index="24_8" data-function="addTrackChanges" data-track-change="randomized" data-userid="preediting" data-username="Exeter" data-time="1554794312000">randomised</named-content>, treatment-control, Phase <named-content data-cid="1555259538" id="1ac31f5c-2051-4548-a4a1-5fec2a24f29d" content-type="ins cts-3" specific-use="1555259872256" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259872256">II</named-content><named-content data-cid="1555259540" id="4e925578-e136-446f-a383-f975c5bddb49" content-type="del cts-3" specific-use="1555259872808" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259872808">2</named-content> LADDER trial was conducted and recently announced positive topline results, with the majority of <named-content id="bd4b19ad-266d-4d02-8dcd-4509f24d0851" data-cid="bd4b19ad-266d-4d02-8dcd-4509f24d0851" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="823" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="24_7" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> requiring a refill only after the <named-content id="51c5d6dc-f300-41d6-9c37-6c4f898761d8" data-cid="51c5d6dc-f300-41d6-9c37-6c4f898761d8" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="866" data-match="6 months" data-replace="6" data-pattern="$1" data-tag-index="24_4" data-time="" data-username="" data-userid="">6</named-content><named-content id="7a31aa80-7862-44a1-ad54-61cddf272d86" data-cid="7a31aa80-7862-44a1-ad54-61cddf272d86" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="867" data-match="6 months" data-replace=" months" data-pattern=" $2" data-tag-index="24_4" data-time="" data-username="" data-userid=""> months</named-content> and achieving similar visual outcomes as monthly injections of ranibizumab.<xref id="84bbb43b-6e1f-4896-974b-e0f9c4700680" ref-type="bibr" rid="R36" data-citation-string=" R36 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="951" data-match="36" data-pattern="" data-tag-index="24_2" data-track-change="36"><sup id="67c02b1c-922e-4555-b4d7-76e891e584fc">36</sup></xref></p><p data-class="jrnlSecPara" id="e232b5a4-e0b7-48b2-8ea8-8fe4c27bbca4">Microelectromechanical system <named-content data-cid="1555259722" id="24d950c1-d1b4-45a8-b9b5-1dcfb3c21c37" content-type="del cts-3" specific-use="1555262226512" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:47pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262226512">(</named-content><named-content id="e6a5f801-92be-4b4d-9e87-6970e2bfbd44" data-cid="e6a5f801-92be-4b4d-9e87-6970e2bfbd44" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="31" data-match=" (MEMS)" data-pattern="" data-tag-index="25_2" data-time="" data-username="" data-userid=""><named-content data-cid="1555259722" id="61cb2ca9-e5ca-458d-9b51-9b376cd79949" content-type="del cts-3" specific-use="1555262226512" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:47pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262226512">MEMS</named-content></named-content><named-content data-cid="1555259722" id="90caf3a5-84f0-4221-bcd1-61261691880a" content-type="del cts-3" specific-use="1555262226512" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:47pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262226512">)</named-content>technology is a <named-content data-cid="1554794312027" id="67e7eeb9-e092-40a9-b48d-3e31fdf8d54d" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">miniaturized</named-content><named-content data-cid="1554794312027" id="0a6c451f-b52f-43b3-9fd5-97c787684d91" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'miniaturized' to 'miniaturised'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="53" data-match="miniaturized" data-replace="miniaturised" data-pattern="miniaturised" data-tag-index="25_8" data-function="addTrackChanges" data-track-change="miniaturized" data-userid="preediting" data-username="Exeter" data-time="1554794312000">miniaturised</named-content> system that is currently used in insulin pumps to deliver drug to tissues. The Posterior MicroPump Drug Delivery System (PMP, Replenish<named-content data-cid="1555259612" id="bdfdc5cb-dda1-4d18-863f-6e16f29c91e1" content-type="del cts-3" specific-use="1555260430935" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260430935"> Inc.</named-content>, Pasadena, C<named-content data-cid="1555259613" id="b47ffefd-7ede-49df-97b3-08ebca38bdb8" content-type="ins cts-3" specific-use="1555260433341" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260433341">alifornia</named-content><named-content data-cid="1555259622" id="934cdbb9-d33d-46c7-b52e-b243d5c68e30" content-type="del cts-3" specific-use="1555260435894" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260435894">A</named-content>, USA) prefilled with ranibizumab has been tested in a first human trial of 11 <named-content id="04cbf81b-9b0b-4e65-ab7a-19ebfc0f05dc" data-cid="04cbf81b-9b0b-4e65-ab7a-19ebfc0f05dc" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="299" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="25_5" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content> with DME. The PMP was implanted in the subconjunctival space with an intraocular cannula inserted through the pars plana<named-content data-cid="1555259631" id="2bd3e650-3895-4c76-87bb-f1b5ee34bfe1" content-type="del cts-3" specific-use="1555260492795" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260492795">,</named-content> and delivers a programmed microdose via wireless control. In <named-content data-cid="1554794312011" id="ddbc4d68-119f-46cc-9fd7-a09122d99062" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">7</named-content><named-content data-cid="1554794312011" id="aac682cd-0689-41c4-81d6-1f453e73f2c5" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from '7' to 'seven'" data-track-detail="" data-tag-desc="SNUM" data-tag-type="SNUM" data-offset="491" data-match="7" data-pattern="" data-tag-index="25_3" data-function="numberToText,addTrackChanges" data-track-change="7" data-userid="preediting" data-username="Exeter" data-time="1554794312000">seven</named-content> <named-content id="4c1166f5-8267-4a38-87ac-a949475fe189" data-cid="4c1166f5-8267-4a38-87ac-a949475fe189" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'patients' to 'patients'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="493" data-match="patients" data-replace="patients" data-pattern="$1" data-tag-index="25_6" data-function="addTrackChanges" data-time="" data-username="" data-userid="">patients</named-content>, the PMP delivered the programmed dose of ranibizumab while the remaining <named-content data-cid="1554794312012" id="d9471d31-09e6-4b0e-87fe-94bd0bb76a90" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">4</named-content><named-content data-cid="1554794312012" id="e6181cf3-74b4-4ad6-ad49-30a915e9c7d2" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from '4' to 'four'" data-track-detail="" data-tag-desc="SNUM" data-tag-type="SNUM" data-offset="576" data-match="4" data-pattern="" data-tag-index="25_4" data-function="numberToText,addTrackChanges" data-track-change="4" data-userid="preediting" data-username="Exeter" data-time="1554794312000">four</named-content> received a lower than target dose.<xref id="6198e22d-5448-4876-b66d-f62f91156927" ref-type="bibr" rid="R37" data-citation-string=" R37 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="613" data-match="37" data-pattern="" data-tag-index="25_1" data-track-change="37"><sup id="51939273-8ee4-4639-95bd-b8dfea4e8695">37</sup></xref> The device was well tolerated with no serious adverse events reported during the <named-content data-cid="1554794312024" id="a01daba1-5daf-4bb9-95dd-574a259ba6a6" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">follow up</named-content><named-content data-cid="1554794312024" id="848e5e04-3776-43f7-aaed-600fc88f28ef" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'followâ£up' to 'follow-up'" data-track-detail="" data-tag-desc="HIGH" data-tag-type="HIGH" data-offset="698" data-match="follow up" data-replace="follow-up" data-pattern="follow-up" data-tag-index="25_7" data-function="addTrackChanges" data-track-change="follow up" data-userid="preediting" data-username="Exeter" data-time="1554794312000">follow-up</named-content> period.</p><title data-level="2" data-class="jrnlHead2" id="965a6a5d-0b00-4b9c-8fef-c47916a34d56"><named-content data-cid="1554794312036" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase" id="3627087b-d1fc-49d0-91ec-6fb51a44a68b">Cell Penetrating Peptides (CPPs)</named-content><named-content data-cid="1554794312036" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase" id="63022876-566e-4933-ba7f-2be47996c1b1">Cell penetrating peptides (CPPs)</named-content></title><p data-class="jrnlSecPara" id="b079d0bb-dab4-4c5c-8227-c9925bd35d64">CPPs are a family of various peptides, typically sequences of <named-content id="c2e13d6d-6ccc-4cbd-9aa6-c90af8a1a71f" data-cid="c2e13d6d-6ccc-4cbd-9aa6-c90af8a1a71f" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGS" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGS" data-offset="62" data-match="5-40" data-replace="5" data-pattern="$2" data-tag-index="26_7" data-time="" data-username="" data-userid="">5</named-content><named-content id="5429c35e-bfe8-4625-be23-91f4d563c6f7" data-cid="5429c35e-bfe8-4625-be23-91f4d563c6f7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-' to 'â'" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGC" data-offset="63" data-match="5-40" data-replace="â" data-pattern="â" data-tag-index="26_7" data-track-change="-" data-time="" data-username="" data-userid="">â</named-content><named-content id="40d8d751-c16d-4039-adbd-fc6fd3952755" data-cid="40d8d751-c16d-4039-adbd-fc6fd3952755" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RNGE" data-track-detail="" data-tag-desc="VAL,RNGS,RNGC,RNGE,UNT" data-tag-type="RNGE" data-offset="64" data-match="5-40" data-replace="40" data-pattern="$4" data-tag-index="26_7" data-time="" data-username="" data-userid="">40</named-content> amino acids (aa), also known as <named-content data-cid="1555259623" id="f40ebf33-0871-4544-95d4-d442ec1f13c8" content-type="ins cts-3" specific-use="1555260450422" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260450422">â</named-content><named-content id="ef39ff99-e142-4281-9b40-c4b2c585f8f9" data-cid="ef39ff99-e142-4281-9b40-c4b2c585f8f9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="LQUOTE" data-track-detail="" data-tag-desc="LQUOTE" data-tag-type="LQUOTE" data-offset="99" data-match="â" data-replace="â" data-pattern="â" data-tag-index="26_10" data-time="" data-username="" data-userid=""><named-content data-cid="1555259624" id="b14c0195-cbb9-418e-b794-b19cf2db7971" content-type="del cts-3" specific-use="1555260451150" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260451150">â</named-content></named-content>Trojan horse peptides<named-content data-cid="1555259627" id="6266a2dd-a026-4031-ae31-d654d5904193" content-type="ins cts-3" specific-use="1555260455359" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260455359">â</named-content><named-content id="ccedd691-b3f8-42c8-8e4f-5e1c94016120" data-cid="ccedd691-b3f8-42c8-8e4f-5e1c94016120" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RQUOTE" data-track-detail="" data-tag-desc="RQUOTE" data-tag-type="RQUOTE" data-offset="123" data-match="â" data-replace="â" data-pattern="â" data-tag-index="26_11" data-time="" data-username="" data-userid=""><named-content data-cid="1555259628" id="d24e1bbf-0db3-4be9-86e3-5335446ccedd" content-type="del cts-3" specific-use="1555260455998" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260455998">â</named-content></named-content> for their ability to deliver a wide range of cargo across bio<named-content data-cid="1555259629" id="9c2e3d2a-882d-4925-8773-df3dff4b13b0" content-type="del cts-3" specific-use="1555260460459" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:17pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260460459">-</named-content>barriers via energy-dependent or energy-independent mechanisms with no interaction with specific receptors.<xref id="065b7794-da9a-42a5-9fa7-6af319c89db1" ref-type="bibr" rid="R38 R39" data-citation-string=" R38 R39 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="303" data-match="39" data-pattern="" data-tag-index="26_2" data-track-change="38 39"><sup id="20c45ddb-e8e0-48cd-bf2a-5d9eaba8410e">38 39</sup></xref> CPPs can enhance the cellular <named-content data-cid="1554794312028" id="0b5b6b4e-0c37-42d3-b83e-4bb814e17859" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000">internalization</named-content><named-content data-cid="1554794312028" id="26d24ce9-bc60-4dd9-b306-89364e71561c" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="changed from 'internalization' to 'internalisation'" data-track-detail="" data-tag-desc="SPELL" data-tag-type="SPELL" data-offset="337" data-match="internalization" data-replace="internalisation" data-pattern="internalisation" data-tag-index="26_12" data-function="addTrackChanges" data-track-change="internalization" data-userid="preediting" data-username="Exeter" data-time="1554794312000">internalisation</named-content> of covalently or non<named-content data-cid="1555259657" id="4b736815-d502-4d24-bd33-cf44bb6b86fe" content-type="ins cts-3" specific-use="1555260609732" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:20pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260609732">-</named-content>covalently conjugated therapeutic cargo and thus have received considerable interest as a means of drug delivery.<xref id="6e3d8117-21c1-415f-9ff3-242025a365c3" ref-type="bibr" rid="R38" data-citation-string=" R38 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="487" data-match="38" data-pattern="" data-tag-index="26_3" data-track-change="38"><sup id="63caf9b3-bc1f-4233-a222-9bd0dff70239">38</sup></xref> Examples of CPPs include<named-content data-cid="1555259653" id="8db8116c-7859-4596-8cfa-dc9e1c7ccce0" content-type="del cts-3" specific-use="1555260555394" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:19pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260555394">s</named-content> penetratin, TAT, low molecular weight protamine<named-content data-cid="1555259632" id="294d6765-f3b0-437f-ae6b-bf612901e5d8" content-type="del cts-3" specific-use="1555260496163" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260496163">,</named-content> and poly(arginine)8.<xref id="fef6a465-0cae-4bbc-a1ba-1f38b3cf8db9" ref-type="bibr" rid="R40" data-citation-string=" R40 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="587" data-match="40" data-pattern="" data-tag-index="26_4" data-track-change="40"><sup id="e972f6df-1537-436a-bd98-46c68f02dcce">40</sup></xref> Among these, the permeability of penetratin across the cornea <named-content id="5f826b10-4b5b-44a4-b9cc-dc28aec11284" data-cid="5f826b10-4b5b-44a4-b9cc-dc28aec11284" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'ex vivo' to 'ex vivo'" data-track-detail="" data-tag-desc="FNW" data-tag-type="FNW" data-offset="653" data-match="ex vivo" data-pattern="" data-tag-index="26_9" data-function="removeItalics" data-time="" data-username="" data-userid="">ex vivo</named-content> has been shown to be 87.5 times higher in comparison with a control peptide. After topical instillation in the rat conjunctival sac, a rapid and wide distribution of penetratin in both the anterior and posterior segment of the eye could be observed in the corneal epithelium and retina at least <named-content id="64a79f22-a386-4117-b625-53a97f0c7972" data-cid="64a79f22-a386-4117-b625-53a97f0c7972" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="956" data-match="6 hours" data-replace="6" data-pattern="$1" data-tag-index="26_8" data-time="" data-username="" data-userid="">6</named-content><named-content id="71aa7e5d-d294-4925-ac16-efaed7a8701d" data-cid="71aa7e5d-d294-4925-ac16-efaed7a8701d" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£hours' to 'âhours'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="957" data-match="6 hours" data-replace="âhours" data-pattern="âhours" data-tag-index="26_8" data-track-change=" hours" data-time="" data-username="" data-userid=""> hours</named-content>, while also showing low ocular cellular and tissue toxicity. These data demonstrate that penetratin is potentially a safe and effective absorption enhancer for posterior segment drug delivery.<xref id="9eedbbde-b25b-485b-9342-44cdd26393ce" ref-type="bibr" rid="R40" data-citation-string=" R40 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1157" data-match="40" data-pattern="" data-tag-index="26_5" data-track-change="40"><sup id="63255c62-b18e-4f1b-8fbc-26a23b73e574">40</sup></xref></p><p data-class="jrnlSecPara" data-head-type="bold" id="eae127db-0f98-4375-8f20-e7ea69c54828">XG-102 (Brimapitide)<named-content data-cid="1554804001" id="c6a8c9c6-cca3-4580-8bb2-3e331d314f19" content-type="ins cts-2" specific-use="1554807791790" xlink:title="Asha (PREEDITOR)" alt="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-title="Inserted by Asha (PREEDITOR) - Apr 9 2019 4:33pm" data-track-detail="" data-userid="preeditor 74d455fb-5d27-44fd-a9e5-5e6807bcf916" data-username="Asha (PREEDITOR)" data-time="1554807791790"> </named-content>is a CPP inhibitor of the <named-content id="edfffb6f-a236-4e2f-9217-ece92afcf4b3" data-cid="edfffb6f-a236-4e2f-9217-ece92afcf4b3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="EXPN" data-track-detail="" data-tag-desc="EXPN" data-tag-type="EXPN" data-offset="26" data-match="jun-N-terminal protein kinase" data-pattern="" data-tag-index="" data-abbr="JNK" data-time="" data-username="" data-userid="">jun-N-terminal protein kinase</named-content> (<named-content id="2f1dfdeb-6d8e-4776-a3c4-a7188e592e5a" data-cid="2f1dfdeb-6d8e-4776-a3c4-a7188e592e5a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="57" data-match=" (JNK)" data-pattern="" data-tag-index="27_13" data-time="" data-username="" data-userid="">JNK</named-content>) pathway and is one of the first CPPs in clinical trial for treatment of intraocular inflammation. It has been shown in a Phase <named-content data-cid="1555259541" id="6d9330bc-219e-47f9-85c3-ba185deef747" content-type="ins cts-3" specific-use="1555259876609" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259876609">III</named-content><named-content data-cid="1555259544" id="a0c3d9dd-dee8-47a5-8b45-b8dd9a4a8d88" content-type="del cts-3" specific-use="1555259877799" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:07pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259877799">3</named-content> clinical trial that a single subconjunctival injection of XG-102 administered at the end of a surgical procedure is non-inferior to the administration of dexamethasone eye drops, 4 times a day for <named-content id="011bbc8e-a092-4f0c-a388-c2ea33c02afb" data-cid="011bbc8e-a092-4f0c-a388-c2ea33c02afb" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="388" data-match="21 days" data-replace="21" data-pattern="$1" data-tag-index="27_8" data-time="" data-username="" data-userid="">21</named-content><named-content id="e4e4794d-03f6-4174-93ab-ab7983fb07cc" data-cid="e4e4794d-03f6-4174-93ab-ab7983fb07cc" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="UNT" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="390" data-match="21 days" data-replace=" days" data-pattern=" $2" data-tag-index="27_8" data-time="" data-username="" data-userid=""> days</named-content>.<xref id="44142589-4359-4f9c-a918-b623c25f53cf" ref-type="bibr" rid="R41" data-citation-string=" R41 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="397" data-match="41" data-pattern="" data-tag-index="27_1" data-track-change="41"><sup id="9fdc766b-99a2-43b6-83d3-9ba5c5c3cd90">41</sup></xref> De Cogan <named-content id="c07fb76f-4fce-48be-a625-1dea01d9b873" data-cid="c07fb76f-4fce-48be-a625-1dea01d9b873" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'etâ£al' to '&lt;i&gt;etâ£al&lt;/i&gt;'" data-track-detail="" data-tag-desc="ETL" data-tag-type="ETL" data-offset="410" data-match="et al" data-replace="&lt;i&gt;et al&lt;/i&gt;" data-pattern="&lt;i&gt;et al&lt;/i&gt;" data-tag-index="27_11" data-track-change="et al" data-time="" data-username="" data-userid=""><italic id="51ef1127-da01-40d9-b7a6-696f40937877">et al</italic></named-content> recently reported the possibility of topically delivering anti-VEGF to the posterior segment by conjugating bevacizumab or ranibizumab to a CPP (FAM (5-carboxyfluorescein) polyarginine R6). They reported rapid diffusion of topically administered CPP<named-content id="7e940ce5-112b-485b-8e11-78960f72640a" data-cid="7e940ce5-112b-485b-8e11-78960f72640a" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£+â£' to 'â½+'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="OPR" data-offset="665" data-match="CPP + anti-VEGF" data-replace=" +" data-pattern=" $2" data-tag-index="27_6" data-track-change=" + " data-time="" data-username="" data-userid=""><named-content data-cid="1555259556" id="e2555c6d-da50-41b1-8957-e0b9ca9c0168" content-type="del cts-3" specific-use="1555259934480" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259934480"> </named-content>+</named-content><named-content id="004b5e8d-c5df-4a85-92c1-bcc8dfd0a83b" data-cid="004b5e8d-c5df-4a85-92c1-bcc8dfd0a83b" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="VAL" data-offset="668" data-match="CPP + anti-VEGF" data-replace="anti" data-pattern="$3" data-tag-index="27_6" data-time="" data-username="" data-userid="">anti</named-content><named-content id="0e0ca32f-361b-4c26-9510-a07dabcae1e5" data-cid="0e0ca32f-361b-4c26-9510-a07dabcae1e5" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-VEGF' to 'âVEGF'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="UNT" data-offset="672" data-match="CPP + anti-VEGF" data-replace="âVEGF" data-pattern="â$6" data-tag-index="27_6" data-track-change="-VEGF" data-time="" data-username="" data-userid=""><named-content data-cid="1555259557" id="68d00189-d156-4426-8a16-b718af1c4fc1" content-type="del cts-3" specific-use="1555259936153" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259936153"> </named-content><named-content data-cid="1555259558" id="63b3c45e-8867-4010-b4d0-f0beebfb0e9c" content-type="ins cts-3" specific-use="1555259936992" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259936992">-</named-content>VEGF</named-content> into the anterior chamber (within <named-content id="eac6909f-5e9b-4f47-a534-b248938fe84d" data-cid="eac6909f-5e9b-4f47-a534-b248938fe84d" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="712" data-match="6 minutes" data-replace="6" data-pattern="$1" data-tag-index="27_9" data-time="" data-username="" data-userid="">6</named-content><named-content id="77312a7d-e88e-4ad7-affd-744434f89dc7" data-cid="77312a7d-e88e-4ad7-affd-744434f89dc7" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£minutes' to 'âmin'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="713" data-match="6 minutes" data-replace="âmin" data-pattern="âmin" data-tag-index="27_9" data-track-change=" minutes" data-time="" data-username="" data-userid=""> min</named-content>), reaching maximum tissue concentration in the vitreous and retina after <named-content id="77123c53-5ddd-4a65-b435-5f4f10788fc9" data-cid="77123c53-5ddd-4a65-b435-5f4f10788fc9" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="VAL" data-offset="795" data-match="45 minutes" data-replace="45" data-pattern="$1" data-tag-index="27_10" data-time="" data-username="" data-userid="">45</named-content><named-content id="d936fb10-356c-4b1c-9777-a9fe43b89214" data-cid="d936fb10-356c-4b1c-9777-a9fe43b89214" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£minutes' to 'âmin'" data-track-detail="" data-tag-desc="VAL,UNT" data-tag-type="UNT" data-offset="797" data-match="45 minutes" data-replace="âmin" data-pattern="âmin" data-tag-index="27_10" data-track-change=" minutes" data-time="" data-username="" data-userid=""> min</named-content> in the rat model<named-content data-cid="1555259633" id="aef4d0fb-e58c-4557-982d-50f86befb9fe" content-type="del cts-3" specific-use="1555260500667" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260500667">,</named-content> and demonstrated the same capability in an <named-content id="c756aab4-4389-4820-88ad-c7b7cf0c7393" data-cid="c756aab4-4389-4820-88ad-c7b7cf0c7393" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed from 'ex vivo' to 'ex vivo'" data-track-detail="" data-tag-desc="FNW" data-tag-type="FNW" data-offset="867" data-match="ex vivo" data-pattern="" data-tag-index="27_12" data-function="removeItalics" data-time="" data-username="" data-userid="">ex vivo</named-content> model using the porcine eye. In a mouse model of laser<named-content data-cid="1555259720" id="a3fd0429-a3f1-480e-8094-caedd1547652" content-type="del cts-3" specific-use="1555262139459" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262139459"> </named-content><named-content data-cid="1555259721" id="e7a8639a-e153-45eb-8499-7f9916cb2784" content-type="ins cts-3" specific-use="1555262140479" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262140479">-</named-content>induced <named-content data-cid="1555259718" id="278e6af7-c166-4da3-bb73-290fd8ad3133" content-type="del cts-3" specific-use="1555262135991" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262135991">choroidal neovascularization (</named-content><named-content id="1764eda4-e583-489c-9aec-1430c3769d31" data-cid="1764eda4-e583-489c-9aec-1430c3769d31" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="968" data-match=" (CNV)" data-pattern="" data-tag-index="27_14" data-time="" data-username="" data-userid="">CNV</named-content><named-content data-cid="1555259719" id="10baa563-7e55-491e-9933-35cbe6822273" content-type="del cts-3" specific-use="1555262137630" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:45pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262137630">)</named-content>, <named-content data-cid="1555259635" id="b9c5054a-c2a6-4a6e-80aa-5ce070e18b04" content-type="ins cts-3" specific-use="1555260528442" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260528442">two times a day</named-content><named-content data-cid="1555259652" id="a815c84c-6a80-49d7-a274-625518858dfd" content-type="del cts-3" specific-use="1555260534982" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260534982">twice daily</named-content> CPP<named-content id="55febbb5-ca73-4c29-afef-0af1fb7b7966" data-cid="55febbb5-ca73-4c29-afef-0af1fb7b7966" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed 'â£+â£' to 'â½+'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="OPR" data-offset="989" data-match="CPP + anti-VEGF" data-replace=" +" data-pattern=" $2" data-tag-index="27_7" data-track-change=" + " data-time="" data-username="" data-userid=""><named-content data-cid="1555259559" id="b25396bb-2df2-4a1c-8566-4e71521a1a4a" content-type="del cts-3" specific-use="1555259939601" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259939601"> </named-content>+</named-content><named-content id="59a69829-986e-46ff-b7a5-af9b88e0d42c" data-cid="59a69829-986e-46ff-b7a5-af9b88e0d42c" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="VAL" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="VAL" data-offset="992" data-match="CPP + anti-VEGF" data-replace="anti" data-pattern="$3" data-tag-index="27_7" data-time="" data-username="" data-userid="">anti</named-content><named-content id="d6bc0a1e-7648-4f51-9730-e1045f2a3d26" data-cid="d6bc0a1e-7648-4f51-9730-e1045f2a3d26" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="changed '-VEGF' to 'âVEGF'" data-track-detail="" data-tag-desc="VAR,OPR,VAL,OPRS,VALS,UNT" data-tag-type="UNT" data-offset="996" data-match="CPP + anti-VEGF" data-replace="âVEGF" data-pattern="â$6" data-tag-index="27_7" data-track-change="-VEGF" data-time="" data-username="" data-userid=""><named-content data-cid="1555259560" id="155f823a-8f4e-427c-83ac-b2e2b2c863dd" content-type="del cts-3" specific-use="1555259941025" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259941025"> </named-content><named-content data-cid="1555259561" id="1cf75f60-2289-4cfb-ba89-b5edd2be1f7e" content-type="ins cts-3" specific-use="1555259941756" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:09pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259941756">-</named-content>VEGF</named-content> eye drops was comparable to a single intravitreal injection of anti-VEGF in reducing CNV area.<xref id="b7fb2782-c4c6-4e19-907e-c36484e12096" ref-type="bibr" rid="R42" data-citation-string=" R42 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1097" data-match="42" data-pattern="" data-tag-index="27_2" data-track-change="42"><sup id="48cd94c4-d7cd-434b-be82-da70b24e27ff">42</sup></xref> These are promising results and CPPs conjugated to other anti<named-content data-cid="1555259587" id="fa15c329-e375-47a2-b25f-7bfd524274cc" content-type="del cts-3" specific-use="1555260188167" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260188167">-</named-content>angiogenic agents such as endostatin,<xref id="8b1e9ee5-090a-4d0a-a308-b74428b45809" ref-type="bibr" rid="R43" data-citation-string=" R43 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1201" data-match="43" data-pattern="" data-tag-index="27_3" data-track-change="43"><sup id="12d0fc2f-763e-441f-81cf-913cad722c72">43</sup></xref> KV11<xref id="308fa4a5-fb6f-482b-9317-e170ee67b06a" ref-type="bibr" rid="R44" data-citation-string=" R44 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1210" data-match="44" data-pattern="" data-tag-index="27_4" data-track-change="44"><sup id="f58ee9d1-ad31-4fe7-a633-f6da53a27fae">44</sup></xref> and tyrosine kinase inhibitors (pazopanib)<xref id="abae5c8b-7eb9-41a7-8ec0-6da04d2703e0" ref-type="bibr" rid="R45" data-citation-string=" R45 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1257" data-match="45" data-pattern="" data-tag-index="27_5" data-track-change="45"><sup id="80240100-2ba4-4bb2-aff2-a8c1ee12cc42">45</sup></xref> have demonstrated similar efficacy with non<named-content data-cid="1555259654" id="cf405c3f-6a3c-4817-8037-f06a7894c8f8" content-type="ins cts-3" specific-use="1555260580035" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:19pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260580035">-</named-content>invasive or minimally invasive routes of administration in preclinical models.</p><p data-class="jrnlSecPara" id="fa3fd3ee-6c18-4aa7-9581-282dfbb01ed1">One notable drawback of CPPs is their lack of cell and tissue specificity, which could potentially lead to a wider drug distribution and intracellular accumulation than is desired for the specific indication. Another downside is their rapid degradation by both extracellular and intracellular proteases, releasing the cargo before they reach their target sites and thus reducing their efficacy. It is hoped that ongoing research will be able to address both the specificity and stability concerns of CPPs.<xref ref-type="bibr" rid="R46" data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="506" data-match="46" data-pattern="" data-tag-index="28_1" data-citation-string=" R46 " data-track-change="46" id="8cbd0281-ca00-4762-982c-68e3c01b036e"><sup id="fd33d5be-f42c-4c4e-8e73-1449ce04b5a6">46</sup></xref></p><title data-level="3" data-class="jrnlHead3" id="97ab99a3-481f-46b0-82d2-252f9631c940">Gene therapy</title><p data-class="jrnlSecPara" id="7885e8f8-8696-4f3c-829f-e2603bc88b43">A comprehensive discussion of gene therapy is beyond the scope of this review but a brief overview will be presented here. Gene therapy is being explored as a therapeutic option for AMD to increase anti-VEGF expression within the eye, with hopes of reducing treatment burden of anti-VEGF injections. Transduction of anti<named-content data-cid="1555259588" id="637cd49c-b86b-451e-9d06-4536811e7576" content-type="del cts-3" specific-use="1555260190886" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260190886">-</named-content>angiogenic genetic information into host cells is achieved with viral vectors. These vectors currently used in ocular gene therapy clinical trials include adeno<named-content data-cid="1555259744" id="d9e67328-a007-4284-befa-3309e2bd74d7" content-type="ins cts-3" specific-use="1555263404885" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 11:06pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555263404885">-</named-content>associated virus<named-content data-cid="1555259734" id="8e890485-611f-4042-a370-a4e2c27c1c40" content-type="del cts-3" specific-use="1555262391793" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:49pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262391793"> (</named-content><named-content id="59debdf1-0215-4e19-84f0-d19698b818e3" data-cid="59debdf1-0215-4e19-84f0-d19698b818e3" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="ABBR" data-track-detail="" data-tag-desc="ABBR" data-tag-type="ABBR" data-offset="499" data-match=" (AAV)" data-pattern="" data-tag-index="30_7" data-time="" data-username="" data-userid=""><named-content data-cid="1555259734" id="e6f15ebb-e5c2-41dc-9c23-8de8ece92071" content-type="del cts-3" specific-use="1555262391793" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:49pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262391793">AAV</named-content></named-content><named-content data-cid="1555259734" id="3896896e-dfe9-47e1-b5df-a93fdeb1bbd7" content-type="del cts-3" specific-use="1555262391793" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:49pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262391793">)</named-content>, small single-stranded DNA viruses of the parvovirus family<named-content data-cid="1555259634" id="87a452a7-8b52-42ac-96de-ebd8593029b0" content-type="del cts-3" specific-use="1555260505596" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:18pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260505596">,</named-content> and lentivirus, RNA viruses of the retrovirus family.<xref id="e42ba17b-dd70-4b14-af02-04ce766e7f15" ref-type="bibr" rid="R47" data-citation-string=" R47 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="619" data-match="47" data-pattern="" data-tag-index="30_1" data-track-change="47"><sup id="482e4f01-2c5c-43c6-b4e2-0892eee63ad4">47</sup></xref> With a single subretinal or intravitreal administration, <named-content data-cid="1555259735" id="9381b442-abc0-49a7-9723-00be265403f3" content-type="ins cts-3" specific-use="1555262399890" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:49pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262399890">â</named-content><named-content id="19bc303b-5506-4b64-aa61-08d52ef117cf" data-cid="19bc303b-5506-4b64-aa61-08d52ef117cf" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="LQUOTE" data-track-detail="" data-tag-desc="LQUOTE" data-tag-type="LQUOTE" data-offset="680" data-match="â" data-replace="â" data-pattern="â" data-tag-index="30_8" data-time="" data-username="" data-userid=""><named-content data-cid="1555259736" id="f1622f71-eec3-43ba-a5de-f6f968f4d968" content-type="del cts-3" specific-use="1555262400491" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:50pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262400491">â</named-content></named-content>biofactories<named-content data-cid="1555259737" id="d03ed6ce-8cb3-4aee-aa06-7b2d4deb2edd" content-type="ins cts-3" specific-use="1555262402731" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:50pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262402731">â</named-content><named-content id="42980be8-927d-4563-8a26-7cde1f59abcb" data-cid="42980be8-927d-4563-8a26-7cde1f59abcb" content-type="jrnlPatterns" specific-use="" xlink:title="" alt="" data-title="RQUOTE" data-track-detail="" data-tag-desc="RQUOTE" data-tag-type="RQUOTE" data-offset="695" data-match="â" data-replace="â" data-pattern="â" data-tag-index="30_9" data-time="" data-username="" data-userid=""><named-content data-cid="1555259738" id="e966c587-3447-46ac-bcf4-397644044ae0" content-type="del cts-3" specific-use="1555262403293" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:50pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262403293">â</named-content></named-content> are established which then exert continuous and long-term anti<named-content data-cid="1555259589" id="6ac0d016-dc38-4397-8429-2c538ba3dc2d" content-type="del cts-3" specific-use="1555260193575" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260193575">-</named-content>angiogenic effects. Current trials target VEGF by generating anti<named-content data-cid="1555259590" id="83927248-a4be-42b1-92b2-76bdd07a2c1f" content-type="del cts-3" specific-use="1555260196439" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:13pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555260196439">-</named-content>angiogenics including soluble fms-like tyrosine kinase-1 (sfLT-1),<xref id="12a898ed-3de5-48ce-817d-13a07c773af3" ref-type="bibr" rid="R48 R49" data-citation-string=" R48 R49 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="894" data-match="48 49" data-pattern="" data-tag-index="30_2" data-track-change="48 49"><sup id="1d1c8777-d606-4076-b641-db669f228f6b">48 49</sup></xref> a modified form of sfLT-1 (sFLT01),<xref id="296a055a-a222-4812-9995-076d4f335720" ref-type="bibr" rid="R50" data-citation-string=" R50 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="937" data-match="50" data-pattern="" data-tag-index="30_3" data-track-change="50"><sup id="60072eea-feb9-464d-978a-a0f4684fa40c">50</sup></xref> angiostatin,<xref id="1135e652-5be5-41cd-b66b-91b7e4e7fd10" ref-type="bibr" rid="R51" data-citation-string=" R51 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="954" data-match="51" data-pattern="" data-tag-index="30_4" data-track-change="51"><sup id="2fb76af9-07ef-4d5b-be8c-f103a93dd604">51</sup></xref> endostatin<xref id="28f617a4-6bcf-4d84-8973-34961d4e39ed" ref-type="bibr" rid="R52" data-citation-string=" R52 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="970" data-match="52" data-pattern="" data-tag-index="30_5" data-track-change="52"><sup id="053a9b3a-f6b6-4cee-ad87-41ef26867e16">52</sup></xref> or anti-VEGF monoclonal antibodies.<xref id="2928d1d2-ea42-49aa-aa3f-ee3abb608c2d" ref-type="bibr" rid="R53" data-citation-string=" R53 " data-tag-desc="BIBREF" data-tag-type="BIBREF" data-offset="1010" data-match="53" data-pattern="" data-tag-index="30_6" data-track-change="53"><sup id="35cb1f76-9f87-4fe9-b2c5-ba72e107c3fb">53</sup></xref></p><title data-level="1" data-class="jrnlHead1" id="c569e8a4-37b8-4e8d-9b7f-1f40cfd64243"><named-content data-cid="1554794312037" id="3ee0913d-e638-45b7-b669-0c7982bc4116" content-type="del cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase">CONCLUSIONS AND FUTURE DIRECTIONS</named-content><named-content data-cid="1554794312037" id="986a46cc-c65b-40cb-a618-41694dcfdf71" content-type="ins cts-1" specific-use="1554794312000" xlink:title="Exeter" alt="preediting" data-title="" data-track-detail="" data-userid="preediting" data-username="Exeter" data-time="1554794312000" data-reason="truecase">Conclusion<named-content data-cid="1555259670" id="9e19f735-e736-47e3-bd2c-32c9a56c6375" content-type="del cts-3" specific-use="1555261286237" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:31pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555261286237">s</named-content> and future directions</named-content></title><p data-class="jrnlSecPara" id="e0b31420-c0cd-4000-87a8-896d24eeddc6">Anti-VEGF therapy transformed the treatment of exudative AMD and DME, achieving visual gains not previously attainable. However, the fight against blindness from these conditions is far from over, and real-world long-term studies have starkly revealed the shortcomings of current treatment. The next major step for the field is to develop sustained action therapeutics that can be delivered to target tissue in the least invasive manner. This is an arduous task and many promising technologies have met with premature failure in Phase <named-content data-cid="1555259545" id="76e84e4b-2625-4cdb-a28b-ff89e72f05b8" content-type="ins cts-3" specific-use="1555259881544" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259881544">II</named-content><named-content data-cid="1555259547" id="8125b336-8cb2-4ced-b688-dfc55248bf23" content-type="del cts-3" specific-use="1555259882026" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259882026">2</named-content> or <named-content data-cid="1555259548" id="068b4086-b79c-40ca-baa4-ee2409f55eb6" content-type="ins cts-3" specific-use="1555259883697" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259883697">III</named-content><named-content data-cid="1555259551" id="23d09761-d6ab-4d9b-b1e6-ab3bdec5c847" content-type="del cts-3" specific-use="1555259884866" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259884866">3</named-content> trials. Nevertheless, there have been preclinical successes, and more are on the horizon, such as port delivery systems for the treatment of exudative AMD that have entered Phase <named-content data-cid="1555259552" id="91971cca-fe90-4e33-b68b-9030e921c85a" content-type="ins cts-3" specific-use="1555259888600" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259888600">III</named-content><named-content data-cid="1555259555" id="c563e1c0-5f73-410f-a999-d8e7b746be73" content-type="del cts-3" specific-use="1555259889729" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:08pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259889729">3</named-content> trials. A wide array of preclinical studies have demonstrated the potential for nanoparticles and <named-content data-cid="1555259730" id="f0934ba2-f095-4f50-a7fe-1ae852c1b31c" content-type="ins cts-3" specific-use="1555262272426" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:47pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262272426">CPP</named-content><named-content data-cid="1555259733" id="9358689e-1614-4b01-a2e8-92c284268926" content-type="del cts-3" specific-use="1555262276042" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Deleted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:47pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555262276042">cell penetrating peptide</named-content>s to deliver therapeutics into the posterior segment via minimally invasive routes but translation into human trials remain ponderous and uncertain at every stage toward<named-content data-cid="1555259462" id="59a447e8-9298-4ddd-aa98-81ed5d4ebde1" content-type="ins cts-3" specific-use="1555259729983" xlink:title="Varadaraj (COPYEDITOR)" alt="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-title="Inserted by Varadaraj (COPYEDITOR) - Apr 14 2019 10:05pm" data-track-detail="" data-userid="copyeditor 5cae1647-7e1c-4749-ac72-f68e012b1207" data-username="Varadaraj (COPYEDITOR)" data-time="1555259729983">s</named-content> clinical development. It is a testimony that better, more clinically effective therapies and sustained delivery systems remain a focused area in the advancement of clinical treatment of AMD and DME. Thus, it is imperative for pharmaceutical scientists, ophthalmologists and industry to collaborate and expedite the clinical translation of such promising therapies.</p></body><back data-edited="true" data-edited-version="2" id="a1643c62-8c15-4f7d-88d1-d29bdb1ed142"><ref-list section="back" node-xpath="back" id="a4d362e7-390a-4ee7-ba31-73a18bae9e1b"><title data-level="1" id="c2a9a555-f31d-40cf-a506-f2305173416c">References</title><ref data-class="jrnlRefText" id="R1" data-id="R1" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R1" data-validated="true" data-doi="10.1016/j.ophtha.2016.03.045" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/27156698"><label id="d0da6894-902c-4ff4-993e-f52d936e8aa3">1</label><element-citation publication-type="journal" id="450ed47f-ae75-4693-bfd2-b40cab77aeb7"><person-group person-group-type="author" id="4161358e-9312-4c5e-a5c1-5b8c071aa9bc"><name id="840d479e-ae08-4f0f-a132-c6588a021819"><surname id="69bc50e6-0d25-403e-af24-a6ac853c2dd3">Maguire</surname> <given-names id="661d996d-c398-497f-90f0-cacafc3382b0">MG</given-names></name><x>, </x><name id="ff35476a-7c21-4a59-b9f7-cd308c4f12b4"><surname id="75eb01d4-0adf-401d-97c0-d564b40d2d8a">Martin</surname> <given-names id="e0612d3a-d405-4e71-935d-6b9fb1ce5c87">DF</given-names></name><x>, </x><name id="461adeed-67b2-4c46-b72d-76c45520e4df"><surname id="8710dadd-03ae-4630-99fd-23646435e82c">Ying</surname> <given-names id="974a06da-6265-4a72-a37c-4e6484896856">G-S</given-names></name><x>, </x><etal data-class="RefEtal" id="ad441306-c193-4e0e-8cba-3e0bef9e6760">et al</etal></person-group><x>. </x><article-title id="4bb288ae-99c9-48d3-9b47-dcabc4a9b027">Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials</article-title><x>. </x><source id="84d1c6c9-b6ce-4c09-a34a-e12ae431246b">Ophthalmology</source><x> </x><year id="5fac4ab4-be30-452a-b640-2d1ddabb7f74">2016</year><x>;</x><volume id="b7928fb3-ef0a-4f93-a26c-4fcc273eaaa5">123</volume><x>:</x><fpage id="481ccea7-31bc-47ce-9d8c-1dcb04aab017">1751</fpage><x>â</x><lpage id="e8c8f1b2-f907-44ab-802d-36d084e83bfa">61</lpage><x>.</x><pub-id pub-id-type="doi" id="f0ef39da-306a-4412-86ee-47816f516620">10.1016/j.ophtha.2016.03.045</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R2" data-id="R2" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R2" data-validated="true" data-doi="10.1016/j.ophtha.2013.03.046" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/23642856"><label id="59909b32-f546-4960-8ca2-41127482d426">2</label><element-citation publication-type="journal" id="dd632512-2e9a-4eb7-a7fc-9f04994e5770"><person-group person-group-type="author" id="9bb7752b-673b-4895-9c04-616f3f8f2628"><name id="2a0829b8-03a8-4ed9-80fe-9176763e386c"><surname id="e86c62cf-07c5-482d-a07b-c564d00801fd">Rofagha</surname> <given-names id="3e56d790-0674-4ea5-ab19-93b657c8230d">S</given-names></name><x>, </x><name id="73decc4c-351d-4c1d-8785-492e26ee6901"><surname id="4b4fd915-b573-4075-a2b3-06e26e4f81f3">Bhisitkul</surname> <given-names id="d28e592a-e093-49d6-991c-20f9011524ff">RB</given-names></name><x>, </x><name id="11946cc4-b1d0-4c2e-a65d-53ac640373ae"><surname id="fd98c68d-6c9f-425c-8b0d-67e68424fe4e">Boyer</surname> <given-names id="fe927f32-93ad-45ca-b1f5-39c320aabd70">DS</given-names></name><x>, </x><etal data-class="RefEtal" id="70491b92-4219-40a4-8f59-6db5476cb0e6">et al</etal></person-group><x>. </x><article-title id="fa111f00-a045-4617-ba08-1f814942d39e">Seven-year outcomes in ranibizumab-treated patients in anchor, marina, and horizon: a multicenter cohort Study (seven-up)</article-title><x>. </x><source id="ed1d9e48-c367-48d5-86e2-5b7cf01809fb">Ophthalmology</source><x> </x><year id="2118831a-bb21-473a-af78-db2742c8e95e">2013</year><x>;</x><volume id="03f7d575-ce07-459b-bb1a-5e7568d3683e">120</volume><x>:</x><fpage id="10f6251a-8801-4789-880a-0bab91e596e2">2292</fpage><x>â</x><lpage id="d281e824-c7af-4eec-8772-dd7225a35152">9</lpage><x>.</x><pub-id pub-id-type="doi" id="572ee793-c7c0-4505-9309-aff2bc951546">10.1016/j.ophtha.2013.03.046</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R3" data-id="R3" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R3" data-doi="10.1016/0039-6257(93)90141-S" data-validated="true"><label id="5b27ff1f-8304-4113-ba47-7b7b88a0f5eb">3</label><element-citation publication-type="journal" id="002cea3e-ae04-487c-9ec9-8a09b39e0f32"><person-group person-group-type="author" id="43441be1-d820-4ab5-b489-b76abe8e32f8"><name id="41268a69-0364-4de4-8375-5538d4db120c"><surname id="5a90c0f4-79c5-4eef-af1a-ad27a1f7d385">Urtti</surname> <given-names id="22c5b323-91cf-4feb-a8b8-30e6cbdb80b4">A</given-names></name><x>, </x><name id="426e4dee-0e9a-4706-ac38-61adaa132a06"><surname id="2dadeb79-8307-44a6-9f31-fdad276a1385">Salminen</surname> <given-names id="e4c5993d-424d-43c4-85d4-ab81bc2ce387">L</given-names></name></person-group><x>. </x><article-title id="d40bc42d-d3dd-4834-b60a-4710315b2aae">Minimizing systemic absorption of topically administered ophthalmic drugs</article-title><x>. </x><source id="d2f6318b-2aa4-41b8-894b-d8ceb4963cf6">Surv Ophthalmol</source><x> </x><year id="dfd64ced-6ac7-4956-91fd-f7cc31872c7f">1993</year><x>;</x><volume id="233f87bf-4e51-4660-8416-2ba3d6253812">37</volume><x>:</x><fpage id="e9fe82cc-cf50-49f2-83cb-022f8a45579d">435</fpage><x>â</x><lpage id="bb4014ab-204d-4a3e-ae8a-6da3524c0b45">56</lpage><x>.</x><pub-id pub-id-type="doi" id="75040bcd-51d1-471a-8abf-ec3d833e8fb1">10.1016/0039-6257(93)90141-S</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R4" data-id="R4" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R4" data-doi="10.1089/jop.1986.2.67" data-validated="true"><label id="274b4805-22f5-41eb-b8d5-a9f554c5855c">4</label><element-citation publication-type="journal" id="f9ffa4fa-9576-42ea-b7aa-3f39bba948ab"><person-group person-group-type="author" id="685ed9ce-5e30-48cf-beb8-2587ee3c5fbe"><name id="46763bff-3b7d-4e5d-bb8d-1db094efe80f"><surname id="421eca21-eef6-4dc5-9127-57fa2045aa08">Lee</surname> <given-names id="7d0ae5c5-af7f-4141-b676-19131f42793f"><named-content data-cid="1554794355031" id="b3043996-6bdc-47ee-b4fa-a887e70fa1f3" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000">VH</named-content><named-content data-cid="1554794355031" id="192c5830-1f54-4d40-87cd-09f1a0ea2821" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000">VHL</named-content></given-names></name><x>, </x><name id="162d1844-d15f-4a97-9259-783919e92923"><surname id="f8e713a0-adb8-4f3d-8ddf-43bd851be372">Robinson</surname> <given-names id="84a2e428-99e5-4e99-bb8b-581ec1c18e48">JR</given-names></name></person-group><x>. </x><article-title id="41029ce4-72fe-4389-a9ba-9c4fc20ca24b">Topical ocular drug delivery: recent developments and future challenges</article-title><x>. </x><source id="70f5df56-dbda-4dd7-a0f9-7bbaf530eacc">J Ocul Pharmacol</source><x> </x><year id="8629aef5-0119-46d7-a520-2c9a853a671b">1986</year><x>;</x><volume id="fe0d0eed-9470-4e4f-8ff0-5b94d5bcf1aa">2</volume><x>:</x><fpage id="18a76f1c-2bf4-4e18-90fc-1be884e359ab">67</fpage><x>â</x><lpage id="cf1535af-ed4d-4825-8515-fb67c78e84fb">108</lpage><x>.</x><pub-id pub-id-type="doi" id="3d341aad-f2f2-49ac-9724-189f3bc937fe">10.1089/jop.1986.2.67</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R5" id="R5" data-id="R5" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R5" data-validated="true"><label id="06b460a6-0ea6-4317-bfe7-749aea674ffa">5</label><element-citation publication-type="journal" id="3e3c8919-e67f-424e-a5da-5bb63c258b8a"><person-group person-group-type="author" id="0a7a0dbb-de8d-4a61-b897-b82fb76eabff"><name id="7d8ddeee-ac8f-499e-bbb3-778c66b06fe7"><surname id="b1baf69d-cf28-450f-90d9-8a464bbc5320">Rajapakshal</surname> <given-names id="ba1f07f7-746f-42d0-bcd1-bff6a3e7e074">A</given-names></name><x>, </x><name id="d942d999-2439-42fa-a696-ebc0006e938a"><surname id="a1596d28-9fa7-4de8-8972-b47f74d59d47">Fink</surname> <given-names id="e7099021-20cc-434c-83fa-e6a2715e052e">M</given-names></name><x>, </x><name id="722c0432-a8b5-4235-b118-9473be615462"><surname id="382073cf-d73f-4291-a5a9-a016394a0121">Todd</surname> <given-names id="634ae1ba-4f8a-430a-a3df-7dde60e8c5b9">BA</given-names></name></person-group><x>. </x><article-title id="45492da0-cc57-44a1-ab1b-109491cb3df6">Size-<named-content data-cid="1554794355035" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="04e86592-8cc3-4c21-9ddb-563c9c30f1a4">Dependent</named-content><named-content data-cid="1554794355035" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="71b6c51c-2f7b-40ad-bc73-42f525edd00c">dependent</named-content> <named-content data-cid="1554794355036" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="9165dea2-206a-498b-b96c-ff9ac15f5848">Diffusion</named-content><named-content data-cid="1554794355036" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="8f74ba01-2aff-4fc5-8080-b2db1e20a57f">diffusion</named-content> of <named-content data-cid="1554794355037" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="bb8ce1cd-62a3-4966-9ec5-6db030dae289">Dextrans</named-content><named-content data-cid="1554794355037" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="679257bb-9940-4a4b-abdb-0d03486aa42f">dextrans</named-content> in <named-content data-cid="1554794355038" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="6a8ef464-2568-4da9-b09f-5f7a460af910">Excised</named-content><named-content data-cid="1554794355038" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="9ddee003-c992-4410-94d4-0d0584efcc38">excised</named-content> <named-content data-cid="1554794355039" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="19673663-f595-4c51-9524-519f04b36df6">Porcine</named-content><named-content data-cid="1554794355039" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="f3e0bf61-11f9-4152-bee0-80594b180be4">porcine</named-content> <named-content data-cid="1554794355040" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="c0f52fdd-99b4-454d-9402-054d21fe8d70">Corneal</named-content><named-content data-cid="1554794355040" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="a870921f-b29f-4127-9b4c-a75ee830e192">corneal</named-content> <named-content data-cid="1554794355041" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="cbcfd993-38d3-4daf-a48d-e640ff124596">Stroma</named-content><named-content data-cid="1554794355041" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="ccc4b9de-cb3f-4380-b0ba-8dcef07bd374">stroma</named-content></article-title><x>. </x><source id="1b9e87c1-0e3d-4057-8bc4-2a1578e1b272">Mol Cell Biomech</source><x> </x><year id="e432ac71-ad02-4c09-a3ef-a8a2f731b87e">2015</year><x>;</x><volume id="6ca7c73a-99b5-4861-8ad8-abb247776e59">12</volume><x>:</x><fpage id="ecfc8fee-a9e7-431d-bb25-724bf4ad6bea">215</fpage><x>â</x><lpage id="0801b723-3e71-4aea-8d56-3b1a57412ec5">30</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" id="R6" data-id="R6" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R6" data-doi="10.1089/jop.2015.0047" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/26666398"><label id="80b020e3-e471-46eb-b794-069d470f972e">6</label><element-citation publication-type="journal" id="a9e8e908-74eb-46fe-bfe3-e92c06e12bd5"><person-group person-group-type="author" id="6b3d932a-f58f-49b7-808d-34b74905a0cc"><name id="76a11789-727d-4d09-8906-48a1687ece8d"><surname id="b96712c4-e8ec-416a-b6c5-6d60c2c6d0a6">Yellepeddi</surname> <given-names id="38fde71e-bdaa-4dab-98a8-31a7fed31340">VK</given-names></name><x>, </x><name id="4e703259-050e-4ab2-82b7-200e7ad0f7f5"><surname id="e93f7e0c-499a-4cd0-8321-f4a85593c24c">Palakurthi</surname> <given-names id="98aab7db-26dc-432c-a14f-f4ce0ba07ec7">S</given-names></name></person-group><x>. </x><article-title id="7cdeefea-4cca-4097-90c9-de4b37fbd79a">Recent advances in topical ocular drug delivery</article-title><x>. </x><source id="6f07bb60-a98b-4b62-a087-12ff19be1528"><named-content data-cid="1554805094002" id="5ca8a61d-57a9-4d71-b37d-b546a71b6687" content-type="del cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">Journal</named-content><named-content data-cid="1554805094002" id="2102231d-99f2-472c-8749-6975ab42dd40" content-type="ins cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">J</named-content> <named-content data-cid="1554805094003" id="9ca41643-706e-4eef-b0e9-18a606db505f" content-type="del cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">of</named-content><named-content data-cid="1554805094003" id="5f78b8c5-15b5-43fd-a28c-43ea63a387bd" content-type="ins cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">Ocul</named-content> <named-content data-cid="1554805094004" id="807e1df5-205a-4976-9068-fa26f4eed1dd" content-type="del cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">Ocular</named-content><named-content data-cid="1554805094004" id="90aef08e-18c7-4a10-919b-a0475b7ce551" content-type="ins cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">Pharmacol</named-content> <named-content data-cid="1554805094005" id="d2d1ca58-e354-48d2-b9ce-ea44f3341672" content-type="del cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R94" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">Pharmacology and Therapeutics</named-content><named-content data-cid="1554805094005" id="0cc83912-4f19-455c-beac-0df481672be3" content-type="ins cts-1" specific-use="1554805094000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R94" data-userid="cross-ref" data-username="cross-ref" data-time="1554805094000">Ther</named-content></source><x> </x><year id="680efcd1-a94d-408e-8910-2a36759b55e8">2016</year><x>;</x><volume id="31686078-afee-41a1-9f03-677375403a87">32</volume><x>:</x><fpage id="9c690716-6fe9-4d62-8b50-58df0fa198ba">67</fpage><x>â</x><lpage id="524e6a21-5c37-4239-b896-8db53add3100">82</lpage><x>.</x><pub-id pub-id-type="doi" id="1be8fb76-0211-4560-b5ce-2197bf6ae24e">10.1089/jop.2015.0047</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R7" data-id="R7" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R7" data-doi="10.1517/17425247.5.5.567" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/18491982"><label id="1c2d02a4-0a99-4f17-b34e-8e9294cee0d0">7</label><element-citation publication-type="journal" id="ea15f04e-a01b-4886-be12-206a04026fd6"><person-group person-group-type="author" id="1d6fa043-9b66-4239-bb64-89fb2c541917"><name id="0bdc0771-8739-4915-b716-68ff5fb4f9e4"><surname id="7b0ca1d7-93cd-4cea-8603-b886653decf2">Barar</surname> <given-names id="0fd59686-d91d-4426-8977-a3e97094e6e5">J</given-names></name><x>, </x><name id="25f5bad2-9bc3-45e9-9921-bcab02e3ec43"><surname id="a4657b04-c8da-46ad-b0a4-228520d04e01">Javadzadeh</surname> <given-names id="328a671b-9a95-4627-9439-089e6aa12c06">AR</given-names></name><x>, </x><name id="e2f8c980-2bd2-42da-9154-3445eda46d6c"><surname id="1b817ccd-4dfd-4ea0-8683-e44c99afc717">Omidi</surname> <given-names id="1ed9e061-a53c-429f-aecd-4aa679c2ec31">Y</given-names></name></person-group><x>. </x><article-title id="4632ee42-0b65-4db0-a8dd-1832498fc23c">Ocular novel drug delivery: impacts of membranes and barriers</article-title><x>. </x><source id="797e58c0-1c4c-47bc-96ff-060e5155b26d">Expert <named-content data-cid="1554805105002" id="25122a25-e358-45ac-89ad-9e8ab76399b8" content-type="del cts-1" specific-use="1554805105000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805105000">Opinion on</named-content><named-content data-cid="1554805105002" id="dc27df04-c202-4c6b-9114-1df7f795bb5d" content-type="ins cts-1" specific-use="1554805105000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805105000">Opin</named-content> Drug <named-content data-cid="1554805105003" id="1059d8c6-301f-4732-a34f-7ddccf344374" content-type="del cts-1" specific-use="1554805105000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805105000">Delivery</named-content><named-content data-cid="1554805105003" id="1aff1106-1d91-46e3-bfa4-38b797a07f70" content-type="ins cts-1" specific-use="1554805105000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:48 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805105000">Deliv</named-content></source><x> </x><year id="25e0bd68-2e83-42e8-ae83-8ae5ccb09ed1">2008</year><x>;</x><volume id="d256a522-4bb5-4dad-a544-d22bf39e4f28">5</volume><x>:</x><fpage id="acdcb37d-1205-4c61-8096-639e9bb4058f">567</fpage><x>â</x><lpage id="5a42849b-3f5b-49e0-b0da-92b88f077bed">81</lpage><x>.</x><pub-id pub-id-type="doi" id="08b96346-e09e-41c9-a7e7-ba0bcff18630">10.1517/17425247.5.5.567</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R8" data-id="R8" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R8" data-doi="10.1016/S0002-9394(99)00129-4" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/10458175"><label id="0c277876-7887-452b-b2c7-e1cb1190d79f">8</label><element-citation publication-type="journal" id="c3b28779-4edd-4e84-8165-9094acedb606"><person-group person-group-type="author" id="34097d3d-e7e2-4125-b390-594de8a9cdaf"><name id="38bebbf0-d85d-49f2-9793-e3c5547d76d2"><surname id="8155f7b8-8798-45bc-965b-5fa4c1ce3d42">Weijtens</surname> <given-names id="d4c96979-5cd0-4309-8dbe-2a32a512d527">O</given-names></name><x>, </x><name id="f37badab-66fc-4878-8bd4-36cf62167d43"><surname id="1e8168b6-d856-4ef7-ba04-d6549ca1f8bd">Feron</surname> <given-names id="05fd4c3a-9947-47b1-96c2-57e31f617b5b">EJ</given-names></name><x>, </x><name id="2596a7e3-3dcc-4b1c-bb8f-b88a9778b824"><surname id="64adb19e-af7a-4f46-92d2-f85e0ed369f6">Schoemaker</surname> <given-names id="126b0bd0-b1d6-4a0c-bcad-a9bcef5cb62b">RC</given-names></name><x>, </x><etal data-class="RefEtal" id="ed08e963-57b8-4774-929b-431dbb3264c7">et al</etal></person-group><x>. </x><article-title id="6af008a7-c2c3-442f-a098-1aa93e7f34b5">High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection</article-title><x>. </x><source id="1020ce05-20b6-434a-9899-c8fa67937e59"><named-content data-cid="1554805186002" id="5190e3d4-fe63-4017-85d9-6ae9a8809734" content-type="del cts-1" specific-use="1554805186000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805186000">American</named-content><named-content data-cid="1554805186002" id="57fe26da-3d4e-4938-b708-c7cf5f34a90c" content-type="ins cts-1" specific-use="1554805186000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805186000">Am</named-content> <named-content data-cid="1554805186003" id="9c708363-52ee-4f0d-ac79-99553510583a" content-type="del cts-1" specific-use="1554805186000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:49 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805186000">Journal</named-content><named-content data-cid="1554805186003" id="3fca511e-dfbe-48b2-ab6b-3bfa48733e40" content-type="ins cts-1" specific-use="1554805186000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:49 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805186000">J</named-content> <named-content data-cid="1554805186004" id="f4718e38-d04f-40b0-b354-dc56f18a89ba" content-type="del cts-1" specific-use="1554805186000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:49 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554805186000">of Ophthalmology</named-content><named-content data-cid="1554805186004" id="d0687653-5b3b-460f-87c2-2e41f8c23064" content-type="ins cts-1" specific-use="1554805186000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:49 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554805186000">Ophthalmol</named-content></source><x> </x><year id="472b7f07-f218-4b28-8d77-1738a6b21012">1999</year><x>;</x><volume id="8dcb457b-5f3b-4f2c-bdd5-e95c4d60ad41">128</volume><x>:</x><fpage id="e56d2cb2-e969-46d5-b83e-e7de9f80709c">192</fpage><x>â</x><lpage id="a53c7ecd-086e-4ec0-8148-9250c4a017f1">7</lpage><x>.</x><pub-id pub-id-type="doi" id="016b4c2b-86d7-4270-8e13-183e5b7fbf0d">10.1016/S0002-9394(99)00129-4</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R9" id="R9" data-id="R9" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R9" data-doi="10.1016/S0161-6420(00)00344-4" data-validated="true"><label id="51460507-b184-4120-8611-58bcb616169c">9</label><element-citation publication-type="journal" id="a393e5ba-1b28-48bc-92a1-8ab086c599fa"><person-group person-group-type="author" id="1afa32e3-cace-4610-9657-65c78d5ef032"><name data-repeated-author="true" id="0216b3b1-ee42-4df1-8dce-c252186fff2e"><surname id="e023ac36-8439-4bd1-91ba-003a3e186871">Weijtens</surname> <given-names id="2d3ed2b3-e6c4-412f-b365-87630cf32a8b">O</given-names></name><x>, </x><name id="92534ba8-ecb8-458a-8183-c6e890dee3bf"><surname id="b4faf4d5-90a0-4f7a-a149-567288533e21">Schoemaker</surname> <given-names id="e214a224-36b9-4338-a4dd-11f2bd41b45a">RC</given-names></name><x>, </x><name id="bf1fe61f-96f1-4712-8777-1a352d099c26"><surname id="6e3b39ba-a0fd-4374-a7d9-e715f5e89445">Lentjes</surname> <given-names id="f0c8b332-e2c0-4656-a64d-bfa86dcde365"><named-content data-cid="1554794355056" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="86a85832-0935-4de3-a5ab-ef4172c975f6">EG</named-content><named-content data-cid="1554794355056" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="c9eca7c4-fccb-4aa5-a87c-4a6dc6736815">EGWM</named-content></given-names></name><x>, </x><etal data-class="RefEtal" id="0bee0181-4cb5-4758-b1da-e4aa035467e7">et al</etal></person-group><x>. </x><article-title id="22fde62e-b770-4839-b3d2-cf58711093ad">Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose</article-title><x>. </x><source id="4a93298d-1dfc-4ede-a060-c7af0fdd7e6f">Ophthalmology</source><x> </x><year id="c2eab167-e40a-405d-9e57-4bbf4fae207f">2000</year><x>;</x><volume id="52dbd780-6d85-4926-af56-85cb14e70605">107</volume><x>:</x><fpage id="aa640737-e21f-45e6-97f0-ccd4997c4531">1932</fpage><x>â</x><lpage id="6a406705-a65f-46bb-a150-cdb00549e4b4">8</lpage><x>.</x><pub-id pub-id-type="doi" id="8a789759-794d-46b6-86b5-f0ee9dd46b4f">10.1016/S0161-6420(00)00344-4</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R10" data-id="R10" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R10" data-doi="10.1021/js9802594" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/10189253"><label id="cb5c43a1-0153-469d-9369-8d879513f58f">10</label><element-citation publication-type="journal" id="9fd11dec-27bc-4cce-b1cd-e965cd33b22b"><person-group person-group-type="author" id="d2ac057f-b9ad-4ef8-8f2c-d7fae65228d9"><name id="624a4b38-be5a-455e-ba49-4bc06e1951cf"><surname id="8cf92761-490a-4cee-b54d-f2529e64fab0">Prausnitz</surname> <given-names id="81ad3dd8-4db9-4032-afe2-30a01108a97d">MR</given-names></name><x>, </x><name id="2d3f601a-b079-47dd-8bf1-2e6fc5c4dbba"><surname id="ee0510ad-2c84-4327-9c57-e6f7d240938a">Noonan</surname> <given-names id="ed3605f1-db8e-4bdd-a051-f7fba41a5e1a">JS</given-names></name></person-group><x>. </x><article-title id="01849fef-dd2d-44b8-8911-e8c72b717f86">Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye</article-title><x>. </x><source id="f57e0a71-e588-43b4-9d03-c0743e4853f7"><named-content data-cid="1554805223002" id="5353faeb-18cf-4820-bed8-a621e3948d73" content-type="del cts-1" specific-use="1554805223000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:50 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554805223000">Journal</named-content><named-content data-cid="1554805223002" id="b12e3451-ce7d-4195-942a-9dbcb4942312" content-type="ins cts-1" specific-use="1554805223000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:50 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554805223000">J</named-content> <named-content data-cid="1554805223003" id="aeb9ab48-d7d6-461c-91d9-c7c177c77dd4" content-type="del cts-1" specific-use="1554805223000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:50 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554805223000">of</named-content><named-content data-cid="1554805223003" id="9e0311d5-b890-4bee-8a84-241daa56cfbd" content-type="ins cts-1" specific-use="1554805223000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:50 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554805223000">Pharm</named-content> <named-content data-cid="1554805223004" id="bf75adf4-d6d5-49ad-a2c8-627216a1572e" content-type="del cts-1" specific-use="1554805223000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:50 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554805223000">Pharmaceutical Sciences</named-content><named-content data-cid="1554805223004" id="399de1c5-3780-4ac4-aa5c-276fdf972578" content-type="ins cts-1" specific-use="1554805223000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:50 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554805223000">Sci</named-content></source><x> </x><year id="92b7c99c-3e92-47a0-8f4c-264e8426cc6e">1998</year><x>;</x><volume id="2bd26a64-e20d-4ca3-a7f4-896d31852fa8">87</volume><x>:</x><fpage id="8b2667b4-83b3-4180-9bc1-8a0f93db9d0e">1479</fpage><x>â</x><lpage id="2a361fab-03a7-4833-8e35-616f8a0e9894">88</lpage><x>.</x><pub-id pub-id-type="doi" id="7da33e83-91c8-4878-91da-0c2bd6b690b5">10.1021/js9802594</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R11" data-id="R11" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R11" data-doi="10.1016/j.preteyeres.2016.12.001" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/28028001"><label id="c99a2493-6dc3-40d4-a95e-d718f1bc19be">11</label><element-citation publication-type="journal" id="38e0be77-8dc8-48db-8ce9-810f661ac6da"><person-group person-group-type="author" id="89b26109-28b9-49e6-a068-3f045e1b2ca2"><name id="3b196f54-eeaf-46b3-913a-2527ea083333"><surname id="00ed868a-0458-46af-a526-63a7f7c4263f">Del Amo</surname> <given-names id="62a84f37-db7e-4aef-a0d4-cbe310928bdc">EM</given-names></name><x>, </x><name id="d2439d37-1ff3-411b-b882-16b1672f7e89"><surname id="7400fc76-2747-40ed-8de4-bba3bb6cdb8f">RimpelÃ¤</surname> <given-names id="208a52af-c5e8-4aae-b2cb-5bde1b34513c">A-K</given-names></name><x>, </x><name id="8b7f7c43-2916-4e3e-87ad-e53df340d005"><surname id="85f652a2-a76a-4aed-9f0f-9ec9548e0082">Heikkinen</surname> <given-names id="49ea4969-f1b1-4655-9a4f-7c707e99d9f5">E</given-names></name><x>, </x><etal data-class="RefEtal" id="af892532-929b-480d-b98c-80a4c60de106">et al</etal></person-group><x>. </x><article-title id="a1e18d00-a15c-4d53-b375-290b531ee423">Pharmacokinetic aspects of retinal drug delivery</article-title><x>. </x><source id="07f409f3-6b77-4f6d-96da-65bac894e317">Prog Retin Eye Res</source><x> </x><year id="f8db895b-8a5b-4798-8b01-b39b1b6eb2e7">2017</year><x>;</x><volume id="7b2a31b6-9526-4471-9932-bcbe6b046a04">57</volume><x>:</x><fpage id="9715c6f7-5fec-4417-8ed0-6dd107bc7f79">134</fpage><x>â</x><lpage id="727fd368-eb23-4aea-b079-33d6f0ee6f6b">85</lpage><x>.</x><pub-id pub-id-type="doi" id="d6cb912e-78d0-40b2-8c15-7ca3bfbda0c5">10.1016/j.preteyeres.2016.12.001</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R12" data-id="R12" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R12" data-doi="10.1089/jop.2012.0138" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/23113646"><label id="5f15e2e5-d39f-4195-882a-a0cf5d38decf">12</label><element-citation publication-type="journal" id="93d98a66-278e-43fb-abe5-c92acf79ef22"><person-group person-group-type="author" id="2bae479d-c72a-4c45-98b2-64934d1c5054"><name id="114c882d-6106-4339-835c-d8af6ca760d7"><surname id="d832574c-d675-4465-b50d-3524eeb5512f">Mains</surname> <given-names id="571cd3af-2082-4f1e-9c9e-923c8c371054">J</given-names></name><x>, </x><name id="556de849-3f13-4632-b802-23570d9ee618"><surname id="ae496ffe-3ebb-46e3-bed5-cb357e8ca973">Wilson</surname> <given-names id="96c3705f-8d11-4bd0-ad39-6f225bff04fc">CG</given-names></name></person-group><x>. </x><article-title id="5b7a65b3-6dd4-40b1-8bd3-bd61c8aff561">The vitreous humor as a barrier to nanoparticle distribution</article-title><x>. </x><source id="a1bce18b-9001-492b-8f5f-c010e0de9429"><named-content data-cid="1554805501002" id="14a7ec71-b5c5-4f4b-9098-5f8743729d76" content-type="del cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">Journal</named-content><named-content data-cid="1554805501002" id="57bfe51c-debd-45ef-b8cb-484e314dd525" content-type="ins cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">J</named-content> <named-content data-cid="1554805501003" id="c19f707b-85c5-46b9-a3f7-40551685622e" content-type="del cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">of</named-content><named-content data-cid="1554805501003" id="18c27021-d9a9-4678-814a-7ec30d4dfb0d" content-type="ins cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">Ocul</named-content> <named-content data-cid="1554805501004" id="7cb40f6e-ed46-4156-9917-cab45e8bb50d" content-type="del cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">Ocular</named-content><named-content data-cid="1554805501004" id="a57dc4ff-351b-4941-ba25-63e53a120145" content-type="ins cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R93" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">Pharmacol</named-content> <named-content data-cid="1554805501005" id="90a7ebb7-dad2-4382-8436-198cfa4046a7" content-type="del cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R94" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">Pharmacology and Therapeutics</named-content><named-content data-cid="1554805501005" id="66c9754b-d931-4fa1-aad5-3344a2553d7e" content-type="ins cts-1" specific-use="1554805501000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R94" data-userid="cross-ref" data-username="cross-ref" data-time="1554805501000">Ther</named-content></source><x> </x><year id="55907e0c-0d09-4dbd-ab0f-51fee7a08d55">2013</year><x>;</x><volume id="973c6084-dc04-483b-9624-f5b6ffd536d8">29</volume><x>:</x><fpage id="f3d47885-6433-42f6-8daa-1dee9fccf03f">143</fpage><x>â</x><lpage id="d6aa6a3e-76ca-45e7-8c17-2aa8fc496ac4">50</lpage><x>.</x><pub-id pub-id-type="doi" id="9d9731a2-4e29-4acf-8b35-7aeff97c9989">10.1089/jop.2012.0138</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R13" data-id="R13" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R13" data-doi="10.1016/j.ymthe.2016.10.008" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/28129123"><label id="6f5b3129-1377-4b32-8232-1f21a8e90d23">13</label><element-citation publication-type="journal" id="15443aac-6e66-4781-92cd-b33d07157ee0"><person-group person-group-type="author" id="9b8e82dd-0294-4637-8c41-15bd0199ccd9"><name id="8e91eeff-c6ec-4ef8-b861-a54cdb039e75"><surname id="a8c4e669-83d3-4fb8-b444-51f728b9bb2a">Takahashi</surname> <given-names id="6c5e14d5-399f-45dc-ab0a-c1098f974c98">K</given-names></name><x>, </x><name id="a3c7c293-2397-44ac-8c8b-b1999188fe41"><surname id="0a549498-29a9-4299-99de-dbed4ab2cf90">Igarashi</surname> <given-names id="594188bb-3e0e-4a7b-847c-cbabe1394d35">T</given-names></name><x>, </x><name id="4ec6dd29-2c00-4757-a498-9888afa094ea"><surname id="7e0502ba-43f8-41b2-a549-b4bd73667349">Miyake</surname> <given-names id="0151c175-f8d4-4a31-bebc-119e36af7a58">K</given-names></name><x>, </x><etal data-class="RefEtal" id="ef1f1efd-f6c9-44e9-b33f-9f9e1c606aee">et al</etal></person-group><x>. </x><article-title id="54bc44ae-8812-4dda-832a-c01e8c49a42e">Improved intravitreal AAV-mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys</article-title><x>. </x><source id="09e8391a-393a-45b8-8d3d-2fe4d4100d26"><named-content data-cid="1554805517002" id="800be76d-3403-4586-b749-aa34a25c0a1e" content-type="del cts-1" specific-use="1554805517000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805517000">Molecular</named-content><named-content data-cid="1554805517002" id="062cd468-5b88-413b-9f59-7a0d16595c1a" content-type="ins cts-1" specific-use="1554805517000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805517000">Mol</named-content> <named-content data-cid="1554805517003" id="02a857e0-1e5c-402e-8e84-0f648624f9f4" content-type="del cts-1" specific-use="1554805517000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805517000">Therapy</named-content><named-content data-cid="1554805517003" id="13b9414f-b106-43c3-97d8-67fbdc86aafa" content-type="ins cts-1" specific-use="1554805517000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805517000">Ther</named-content></source><x> </x><year id="67b098fc-00fd-4438-967f-8cfb7a2e2ee9">2017</year><x>;</x><volume id="b47b5b41-d640-4b2e-9e5a-ac104473cf8b">25</volume><x>:</x><fpage id="e91130b9-722d-4811-9a88-63c00781a914">296</fpage><x>â</x><lpage id="d1ced474-24b1-445b-854d-1c1d9e0e9ee3">302</lpage><x>.</x><pub-id pub-id-type="doi" id="34ef9f4d-b812-41d0-b5cf-6c0aa679440f">10.1016/j.ymthe.2016.10.008</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R14" id="R14" data-id="R14" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R14" data-validated="true"><label id="c2481935-35f4-4df3-bebf-e698d7b9a4a9">14</label><element-citation publication-type="journal" id="1dc2cff5-cc1c-4f66-b5b8-a3a25592f62b"><person-group person-group-type="author" id="fb4d8760-5b41-43b8-b611-e2877eb75d86"><name id="82170a5e-547a-45a2-867c-96b519ceb00a"><surname id="223b55e9-b48f-4179-8dd5-0994a06e6773">Campbell</surname> <given-names id="84158850-5632-4bc6-b7bf-1434884f2cdc">M</given-names></name><x>, </x><name id="a2752c93-a5b6-442d-8cba-dbe455fd9155"><surname id="5a370f37-4bf8-4f29-b682-a8bc58319722">Humphries</surname> <given-names id="26b9818f-2898-4b79-88f0-121fee9b1129">P</given-names></name></person-group><x>. </x><article-title id="6321283d-16a2-47fa-9225-513239dd57fc">The <named-content data-cid="1554794355086" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="7c2c9651-37aa-4636-8d93-b5083ff7f01d">blood</named-content><named-content data-cid="1554794355086" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="01d14b83-448b-4cdd-a26c-43a191ca90c4">Blood</named-content>-<named-content data-cid="1554794355087" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="74184606-2202-484d-a5e3-cd1799700e64">retina</named-content><named-content data-cid="1554794355087" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="607d9ae3-fda4-46e4-b86f-6243b25f502d">Retina</named-content> barrier: tight junctions and barrier modulation</article-title><x>. </x><source id="2f3ad9be-9eec-467c-beee-983490937c0e">Adv Exp Med Biol</source><x> </x><year id="b1208cea-adb3-4f5f-94eb-57603eae516a">2012</year><x>;</x><volume id="802678f5-6330-43a2-bc55-ce45d8edcd48">763</volume><x>:</x><fpage id="8751d47b-5b04-4629-ad7a-d49a74737b7c">70</fpage><x>â</x><lpage id="f8671859-e042-464d-9d9a-1294a9b49730">84</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" id="R15" data-id="R15" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R15" data-doi="10.3390/jfb4010014" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/24955828"><label id="3762e1f0-4174-4a02-b72b-44cae63c6efc">15</label><element-citation publication-type="journal" id="45e559d1-aec6-4366-b853-0599d5ad8f82"><person-group person-group-type="author" id="1951d2e8-78e6-4140-8af6-67a920756cf8"><name id="549ec44c-37dc-4412-a3fe-ec031efd34c0"><surname id="b32cc366-019c-4c37-8e02-a7b96a5ddeea">Gooch</surname> <given-names id="6a1be7e7-52e5-41b4-82c0-acb073c63218">N</given-names></name><x>, </x><name id="1fc5dae0-8c65-468a-88d9-58605d2e759d"><surname id="94bb94b0-d7d9-4258-90c0-5baa6d6b46b7">Burr</surname> <given-names id="e5027fb5-7ad4-4e6b-ac5f-2c3dfe93289a"><named-content data-cid="1554805535002" id="f640bc20-b46d-4dd4-a1ff-e263195966f3" content-type="del cts-1" specific-use="1554805535000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805535000">R</named-content><named-content data-cid="1554805535002" id="1918a83c-5750-47d5-99ff-5a669becbc97" content-type="ins cts-1" specific-use="1554805535000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554805535000">RM</named-content></given-names></name><x>, </x><name id="96bb9ee5-6d90-4d71-b01b-7fc5487d49c5"><surname id="c01f79b6-0718-433c-ae9f-5915505c9623">Holt</surname> <given-names id="526870d7-00ef-4876-9a8d-9d39ce579fda"><named-content data-cid="1554805535003" id="e9920835-83bf-48f4-8fe5-38f27cbd6416" content-type="del cts-1" specific-use="1554805535000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805535000">D</named-content><named-content data-cid="1554805535003" id="2caef350-e710-492a-9f2a-47cb974fd292" content-type="ins cts-1" specific-use="1554805535000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554805535000">DJ</named-content></given-names></name><x>, </x><etal data-class="RefEtal" id="7b26c622-07fe-4a62-99c0-305f299dfb5e">et al</etal></person-group><x>. </x><article-title id="ef076182-1860-44b8-9b67-309c258a8103">Design and in vitro biocompatibility of a novel ocular drug delivery device</article-title><x>. </x><source id="1a4381cd-514d-43e6-8c0a-f327b3c9f011"><named-content data-cid="1554805535004" id="d42c22ca-e787-4678-bd42-1dac35228d60" content-type="del cts-1" specific-use="1554805535000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554805535000">JFB</named-content><named-content data-cid="1554805535004" id="94888759-ceb3-4f43-9008-2b8609514263" content-type="ins cts-1" specific-use="1554805535000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 15:55 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554805535000">J Funct Biomater</named-content></source><x> </x><year id="f91ae8ac-9ad8-401c-a03f-6b8e4e93dc57">2013</year><x>;</x><volume id="c93e7ddc-c467-4fd4-a3ff-3fd5310e2854">4</volume><x>:</x><fpage id="61c42c34-086d-4d4d-9ab4-0f47915829dd">14</fpage><x>â</x><lpage id="ff1b7f9c-fadc-42b1-a7ec-27b3e6b956e6">26</lpage><x>.</x><pub-id pub-id-type="doi" id="cdf914f8-de7c-40ae-a24d-41370394ed56">10.3390/jfb4010014</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R16" id="R16" data-id="R16" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R16" data-validated="true"><label id="86ccd46c-9a4b-41d3-be86-e523a7d565cb">16</label><element-citation publication-type="journal" id="f3d6283e-ae0c-4575-9dd3-31c0270ce8e6"><person-group person-group-type="author" id="1138e4e6-4b31-402c-9053-43213a192ec0"><name id="02960922-c476-483b-bb55-a653026e7bdc"><surname id="80da0029-4fce-4b44-8932-81a2e44af377">Emerich</surname> <given-names id="34ed48a8-e524-4132-a625-538e4c349a48">DF</given-names></name><x>, </x><name id="a8e9e62e-8229-4194-be36-9965aa2a2c39"><surname id="84eb9127-9e04-45f5-ae2f-38b40f9727e0">Thanos</surname> <given-names id="4ab6a9c4-7788-4939-8b59-fc50023dee01">CG</given-names></name></person-group><x>. </x><article-title id="4dbb3bc8-eecc-45ae-a06e-37742d64c6f5">NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells</article-title><x>. </x><source id="dcfc86e8-f778-4cf0-ab59-0786deee93e0">Curr Opin Mol Ther</source><x> </x><year id="2b61b036-70c6-44f4-933c-05fa74a66d2d">2008</year><x>;</x><volume id="8499e37f-b150-43b9-92ed-122a9255450e">10</volume><x>:</x><fpage id="5720e915-35fd-4d56-b44f-5334b65bed37">506</fpage><x>â</x><lpage id="66d3d496-baff-4950-a345-b528acf7e183">15</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" id="R17" data-id="R17" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R17" data-validated="true"><label id="de86d228-92a1-487b-8e97-a8eb96020b98">17</label><element-citation publication-type="website" id="3b8c09be-9d6a-4252-aaa9-2c0455e1cda8"><person-group person-group-type="author" id="53ff02fb-88ed-425b-aecf-91159dea1626"><collab id="eb40c572-ecbb-4709-ba71-c52dc5dd85d9">U.S. Department of Health and Human Services</collab></person-group><x>. </x><article-title id="98331e68-f98a-4bb5-b15f-d1fe2439f581">Study of the intravitreal implantation of NT-503-3 encapsulated cell technology (ECT) for the treatment of recurrent choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)</article-title><x>. Available: </x><uri id="17ef8846-fb9f-4636-a44d-62b7502deb04" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02228304">https://clinicaltrials.gov/ct2/show/NCT02228304</uri><x> [Accessed </x><comment data-class="RefLAD" id="06c57001-7599-4a0e-811c-4750fc08d827">19th Feb 2019</comment><x>].</x></element-citation></ref><ref data-class="jrnlRefText" id="R18" data-id="R18" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R18" data-validated="true"><label id="a93996ec-cec7-46af-9ff7-436af2baadd4">18</label><element-citation publication-type="website" id="09672365-a98c-4aed-aaa2-8ca65e32e091"><person-group person-group-type="author" id="9f794e9e-5d2f-4ad6-92ab-d352d4c70079"><collab id="b466ab19-5098-4457-9fa5-fe6603253a64">U.S. Department of Health and Human Services</collab></person-group><x>. </x><article-title id="3d7561ad-6f0a-40f8-b4da-0ac3ecc75c5d">A depot formulation of sunitinib malate (GB-102) in subjects with neovascular (Wet) age-related macular degeneration</article-title><x>. Available: </x><uri id="08d54350-87c7-478b-b4d8-71e319ce0a84" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03249740">https://clinicaltrials.gov/ct2/show/NCT03249740</uri><x> [Accessed </x><comment data-class="RefLAD" id="f1987f89-72f0-494b-a5e8-015bbdfdfef4">21st Feb 2019</comment><x>].</x></element-citation></ref><ref data-class="jrnlRefText" id="R19" data-id="R19" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R19" data-doi="10.1016/j.ophtha.2014.09.036" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/25432081"><label id="ae5fbd46-d54a-4033-8871-70519eddb145">19</label><element-citation publication-type="journal" id="cdc105bc-64fd-44d8-b49d-99a6b9cbf858"><person-group person-group-type="author" id="efa02c65-ab7c-4fca-aca0-a6813adfc733"><name id="41707587-f24d-42de-ae0b-bc63eb7576d6"><surname id="ba22d1f2-7eb2-4f39-af33-06cffc1a3950">Csaky</surname> <given-names id="6a55f6db-4bf6-4fc1-9943-9c3535ce5129">KG</given-names></name><x>, </x><name id="2924019d-692d-44b1-a782-6bd6e9b7f9e2"><surname id="e842e57d-9175-4335-ab66-9cff47cd5618">Dugel</surname> <given-names id="f9b8062e-ec88-4570-b95c-7c155c9668e1">PU</given-names></name><x>, </x><name id="5e3d35ee-c588-4864-a74b-3dc070322c1b"><surname id="001d05df-1563-455d-a20d-86f9cb1f07ed">Pierce</surname> <given-names id="b10332db-59ca-4f29-b06a-e8e8713b888c">AJ</given-names></name><x>, </x><etal data-class="RefEtal" id="a6357420-6a18-4ea1-954d-5927b071d12d">et al</etal></person-group><x>. </x><article-title id="8429d464-1f37-4a9e-9025-bc6bdf9d56f3">Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration</article-title><x>. </x><source id="472e274c-1290-4693-8172-f724f92f87cc">Ophthalmology</source><x> </x><year id="b4168f6a-5fdd-49de-96e7-74e7c141964a">2015</year><x>;</x><volume id="19b05239-2f7d-4cf1-ba34-5ee9be4364fc">122</volume><x>:</x><fpage id="d4cc5600-5653-4be5-afe6-f22f37392448">579</fpage><x>â</x><lpage id="6326e78a-db69-469f-8b5b-db4135093df5">88</lpage><x>.</x><pub-id pub-id-type="doi" id="e5881cf3-507b-47f7-ad07-5a2084e1b122">10.1016/j.ophtha.2014.09.036</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R20" data-id="R20" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R20" data-doi="10.1111/bcp.13794" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/30341774"><label id="140aeb7a-eca8-4ed2-9fb8-eed9dc745435">20</label><element-citation publication-type="journal" id="ec9d1670-34fa-470f-aeb1-124084e443ae"><person-group person-group-type="author" id="fd66fc1b-af2d-45ae-a40d-fde4439251c2"><name id="6146934b-057a-490e-b8e4-4ef135b41f66"><surname id="71cf2ecb-a354-46f3-b1ad-a3dcbb744384">Joussen</surname> <given-names id="fb2c64ab-8a48-4733-86ef-4f28c696205a">AM</given-names></name><x>, </x><name id="e54f70c1-1fd4-4329-9187-56c16deacca9"><surname id="d8d4a1ca-37f8-4e3a-88d2-386b3b505877">Wolf</surname> <given-names id="c3cd1ec3-3c0b-4fbf-a535-f5470ea35276">S</given-names></name><x>, </x><name id="e38db70a-1fab-4e47-beb8-9db44671535a"><surname id="d17c42fb-20a8-4aad-a015-fa2e606ab42b">Kaiser</surname> <given-names id="e6c89362-3e41-4092-b6ea-cf50d7b2131e">PK</given-names></name><x>, </x><etal data-class="RefEtal" id="d8f9db60-d6a0-4f9c-93c5-7f46af4a3b5e">et al</etal></person-group><x>. </x><article-title id="424af800-4a31-47b9-a6dc-2e3ef5cf607f">The developing regorafenib eye drops for neovascular age-related macular degeneration (DREAM) study: an open-label phase II trial</article-title><x>. </x><source id="c08b759f-048b-47bc-bcff-c3740660b9a7">Br J Clin Pharmacol</source><x> </x><year id="ae73db40-7661-4a8b-acc1-c2068e128e5d">2019</year><x>;</x><volume id="7e5989e2-1f6b-4c13-9683-6e1150387c95">85</volume><x>:</x><fpage id="11eb4923-71c9-4476-8f86-4b547cf20675">347</fpage><x>â</x><lpage id="5c50f20e-b485-426b-bc25-402e92166219">55</lpage><x>.</x><pub-id pub-id-type="doi" id="39458479-30cf-40c5-bf3b-5bab9c827505">10.1111/bcp.13794</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R21" data-id="R21" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R21" data-validated="true"><label id="24776f2f-3dda-496f-9f22-36151dd8ace0">21</label><element-citation publication-type="website" id="7ab21a71-d5c5-4a1b-8f65-e2e3c31d8dda"><person-group person-group-type="author" id="b4fd6bfc-d65a-48ed-a7ee-e6cde07aed75"><collab id="a6beb015-5945-4324-9294-4178a94356b5">GlobeNewswire, Inc</collab></person-group><x>. </x><article-title id="dc4ea30f-b3e5-41ca-9cc9-6e70a6a7bb0f">Ohr pharmaceutical Announces efficacy results from the MAKO study in Wet-AMD</article-title><x>. Available: </x><uri id="fc719554-54c5-4941-8be6-4f4869ccab4d" xlink:href="https://globenewswire.com/news-release/2018/01/05/1284092/0/en/Ohr-Pharmaceutical-Announces-Efficacy-Results-from-the-MAKO-Study-in-Wet-AMD.html">https://globenewswire.com/news-release/2018/01/05/1284092/0/en/Ohr-Pharmaceutical-Announces-Efficacy-Results-from-the-MAKO-Study-in-Wet-AMD.html</uri></element-citation></ref><ref data-class="jrnlRefText" id="R22" data-id="R22" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R22" data-doi="10.1517/13543784.2015.961601" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/25243494"><label id="6037d1a9-9e66-452f-887c-c6df6678a3b5">22</label><element-citation publication-type="journal" id="1d8346ff-a155-4458-8a7a-2d65a016a301"><person-group person-group-type="author" id="d2924fb9-6f83-446f-b889-d24a39f0808d"><name id="bb61face-f44e-4cbe-955b-865070865d2c"><surname id="b415b1e6-8255-446e-b1be-90721a9f0c28">Tolentino</surname> <given-names id="e72b2e95-134b-4575-b05d-78e2489fca68">MJ</given-names></name><x>, </x><name id="5e35f715-d957-4f04-b80c-69c895c3738e"><surname id="f9e2364a-db49-4a74-92ae-b24497f4a086">Dennrick</surname> <given-names id="4e8c9c0e-a7c6-41b4-a5bb-fb4453188b56">A</given-names></name><x>, </x><name id="28d1d9df-9b63-41f5-b225-6ee1eb525e7b"><surname id="74d76ab9-8cda-42e7-8954-daf8975df2aa">John</surname> <given-names id="5f5105d5-c6b8-4a63-b45f-1e7b16e96f37">E</given-names></name><x>, </x><etal data-class="RefEtal" id="9ffd53a9-e172-4876-a7ec-0c0a9060b403">et al</etal></person-group><x>. </x><article-title id="574583b4-9c7e-4add-9bd3-4d276aad24d3">Drugs in phase II clinical trials for the treatment of age-related macular degeneration</article-title><x>. </x><source id="3d5c12dd-2280-4669-90b8-323287f3f36c">Expert <named-content data-cid="1554806233002" id="8682d0f6-4411-432a-b976-2474918bdf3c" content-type="del cts-1" specific-use="1554806233000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:07 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806233000">Opinion</named-content><named-content data-cid="1554806233002" id="57c090bc-107c-4521-8575-b50b6181c888" content-type="ins cts-1" specific-use="1554806233000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:07 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806233000">Opin</named-content> <named-content data-cid="1554806233003" id="edafded9-738e-4856-874f-b9ed612514b2" content-type="del cts-1" specific-use="1554806233000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:07 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806233000">on Investigational</named-content><named-content data-cid="1554806233003" id="44d0acc8-d7f2-47d8-9090-92ee46d1ae16" content-type="ins cts-1" specific-use="1554806233000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:07 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806233000">Investig</named-content> Drugs</source><x> </x><year id="03e07190-6dc5-4d7d-9729-a0d8a71c8318">2015</year><x>;</x><volume id="416b4a7e-ed9c-4f7d-8fd6-8d563039feec">24</volume><x>:</x><fpage id="b94bf087-9f58-4bc0-af37-bade1f70c731">183</fpage><x>â</x><lpage id="5c054b19-af62-41ef-9512-65f5865eefc9">99</lpage><x>.</x><pub-id pub-id-type="doi" id="6b5d19b4-d6a5-4be2-9dde-20d42db20473">10.1517/13543784.2015.961601</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R23" data-id="R23" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R23" data-validated="true"><label id="cec3daad-9715-4c4e-977d-438cc5cd7d33">23</label><element-citation publication-type="website" id="40e720c2-1636-4012-b50b-0f1c9995e3db"><person-group person-group-type="author" id="3ef91df3-ec31-4c62-bfe6-78ed7cec640f"><collab id="59ee6099-4141-4189-99bb-40d15c603d99">U.S. Department of Health and Human Services</collab></person-group><x>. </x><article-title id="81554607-3498-4f8a-919c-486d736cd089">LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration</article-title><x>. Available: </x><uri id="8903c3a0-58ee-4457-b92e-a6c71a603729" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT02355028">https://clinicaltrials.gov/ct2/show/results/NCT02355028</uri><x> [Accessed </x><comment data-class="RefLAD" id="b74ac555-f02e-459d-be80-8389ccacddd8">20th Feb 2019</comment><x>].</x></element-citation></ref><ref data-class="jrnlRefText" seqid="R24" id="R24" data-id="R24" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R24" data-doi="10.18433/J3CP55" data-validated="true"><label id="48d36a59-ca64-4c0e-a829-380aa6b61bf7">24</label><element-citation publication-type="journal" id="3ad39985-effe-478f-ba80-a5c95269c808"><person-group person-group-type="author" id="03ff53f1-f058-4916-ab71-e93850b0c265"><name id="9d1479cb-7140-47b1-8ea9-0bfddcb1c632"><surname id="842802f0-c942-4912-887a-29811b7c82f8">Madni</surname> <given-names id="2fb7c9d5-aeec-4c04-bd50-2f88dad5d21e">A</given-names></name><x>, </x><name id="effbce18-1116-441f-a843-9ee39f30dea2"><surname id="51ff5e15-2070-4705-949f-ebf4c7a1e31f">Sarfraz</surname> <given-names id="4b86e386-1d1f-49a9-8ae0-3a4be62330a1">M</given-names></name><x>, </x><name id="5a2a2339-96ff-4a69-b3d4-3d092ce1fb46"><surname id="aa0086c4-448e-4fe3-a57d-a66664234e07">Rehman</surname> <given-names id="7f8cf4a8-4f80-4474-b441-bb4fd4fcbe31">M</given-names></name><x>, </x><etal data-class="RefEtal" id="ce56d267-3283-4e34-a4da-d6a479346739">et al</etal></person-group><x>. </x><article-title id="0ef995a7-bd45-4430-aa51-603e56b36410">Liposomal drug delivery: a versatile platform for challenging clinical applications</article-title><x>. </x><source id="10e4c1b4-cbb2-4191-9109-fe689818c78a">J Pharm Pharm Sci</source><x> </x><year id="413a1ecc-de94-4ba4-be89-1dad8b5b8abe">2014</year><x>;</x><volume id="ca3bc90c-707c-43ec-9ceb-1419e6e76faa">17</volume><x>:</x><fpage id="84cd8702-1be9-4266-93dd-3033b720c1f6">401</fpage><x>â</x><lpage id="043a3fe8-d107-4346-8f8a-88b4ef29147b">26</lpage><x>.</x><pub-id pub-id-type="doi" id="05546c6a-5d92-4a86-a9bd-7b18b5ea3d1d">10.18433/J3CP55</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R25" data-id="R25" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R25" data-doi="10.3109/08820138009065997" data-validated="true"><label id="8c8e07b4-f3b7-451c-bc1a-c90b0af0b2c5">25</label><element-citation publication-type="journal" id="b603f976-3f0a-476a-834b-cb3121f5c065"><person-group person-group-type="author" id="8f7aa7cb-50a8-4621-b738-b0b5cf6d3534"><name id="9c7d0ba0-309f-4d0d-8a01-ae17bf2e7dfa"><surname id="fef020bd-ca52-4a94-a8a9-fe66d7f25212">van Rooijen</surname> <given-names id="032c8ea7-c2e1-4edd-87c7-18697326bd13">N</given-names></name><x>, </x><name id="75aa3f10-ab92-4540-b61e-daa6a88efbb2"><surname id="10ead7a4-bc6d-4278-87c4-0bd497947a96">van Nieuwmegen</surname> <given-names id="bd5ca3fe-30b2-4d4f-92c0-0a03deba1b4c">R</given-names></name></person-group><x>. </x><article-title id="07b3971c-33c2-4123-a74f-b2f132b0d520">Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own</article-title><x>. </x><source id="5b183ca5-b6e1-4e62-aa19-fda0691bc0d8">Immunol Commun</source><x> </x><year id="3075ee04-6863-4436-8096-d44be8a928cd">1980</year><x>;</x><volume id="85114ff9-3957-4589-a18c-e595dfec93f9">9</volume><x>:</x><fpage id="1b0cab46-e6a1-4c0f-8bfe-b34db7ee96c2">243</fpage><x>â</x><lpage id="9009c692-60c1-49c0-9159-aef737b41d03">56</lpage><x>.</x><pub-id pub-id-type="doi" id="78d5f2a1-8691-4590-8fbc-40ff8dedef46">10.3109/08820138009065997</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R26" id="R26" data-id="R26" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R26" data-validated="true"><label id="bf280aa2-8650-4f29-be93-24e12ed2a142">26</label><element-citation publication-type="journal" id="4abcf48f-5776-48e2-85b7-6a2a59e8a6d5"><person-group person-group-type="author" id="bf51d953-8c7d-4a42-a123-b8f5ada0253e"><name id="6c39bc05-0aa7-4138-bee0-390f022b0032"><surname id="ad6d7505-1bcf-492e-9e47-f2290855e9c9">Ahmad</surname> <given-names id="9027b804-a982-4060-bcfa-1b82cfaf710d">I</given-names></name><x>, </x><name id="37062f23-12f6-4e0a-82e2-be7eb7bea8ea"><surname id="0df4578b-2558-46e4-9e07-3d9a588bc6c6">Allen</surname> <given-names id="7d1780bd-4d41-4d34-ad92-87c9ef7f6eeb">TM</given-names></name></person-group><x>. </x><article-title id="b59fa338-c1ec-4137-8053-7cd82fd518e0">Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro</article-title><x>. </x><source id="4ebbf5f2-044a-42e8-8aa8-1173c9c54d5a">Cancer Res</source><x> </x><year id="2e5594e9-35f2-4115-bd81-d41871bf567c">1992</year><x>;</x><volume id="97171dc7-a485-4097-8075-c17addfd61fc">52</volume><x>:</x><fpage id="e7172623-1572-47dd-a765-9f81196c1cad">4817</fpage><x>â</x><lpage id="1467d524-8fec-45ba-bca1-ec98db4b6d8c">20</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" seqid="R27" id="R27" data-id="R27" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R27" data-doi="10.2174/138920012798356934" data-validated="true"><label id="52ae2cb5-8bf5-4dd9-9424-a5f1227e9b00">27</label><element-citation publication-type="journal" id="ef45ba47-4111-4ba6-a859-45604c337bab"><person-group person-group-type="author" id="e2add00a-0991-4b4d-8186-6ec02963697d"><name id="2bc9545f-ffd3-4797-b956-83ae2b294848"><surname id="800d068b-f01e-4105-b0ac-626704d6a9c5">Milla</surname> <given-names id="d9bb741d-1704-46b8-9490-56f5e914fa12">P</given-names></name><x>, </x><name id="ce8156ac-17ff-435a-b3d2-a1f0cb79d517"><surname id="cc2fd3b4-483d-44a1-9b69-90c1566f822d">Dosio</surname> <given-names id="a0a3720d-6d20-464b-994c-656af9b83a64">F</given-names></name><x>, </x><name id="d4234ac9-767e-4d64-81c4-976fe0ea9f66"><surname id="321b82f9-57c4-4e71-ae3b-8dcb8592eff7">Cattel</surname> <given-names id="c5132fc0-3905-4a0d-8442-ccaf07e4addb">L</given-names></name></person-group><x>. </x><article-title id="979d4648-d942-4ab1-a2ca-378c8db3a966">PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery</article-title><x>. </x><source id="e663db0b-919e-4e4b-9f56-e61fa6ecf2a4">Curr Drug Metab</source><x> </x><year id="6e742931-a7ac-44bb-8baa-9c0397c7c1ab">2012</year><x>;</x><volume id="f04a7ef9-9251-4097-a28c-b4651a694411">13</volume><x>:</x><fpage id="c225d44d-4283-42f2-919d-a2488d3ad5a4">105</fpage><x>â</x><lpage id="241252bd-b031-41ee-82e5-a3ac0eeb6d9f">19</lpage><x>.</x><pub-id pub-id-type="doi" id="8115236f-3e1f-4ec8-a810-fd030fe5ebba">10.2174/138920012798356934</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R28" id="R28" data-id="R28" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R28" data-validated="true"><label id="603ad28a-7660-418f-8703-896e8e0c8012">28</label><element-citation publication-type="journal" id="e31cbbf2-07af-43fd-becb-866d00178871"><person-group person-group-type="author" id="c9e257e0-7d81-4dbe-a04b-6578a7153fcc"><name id="6a1c8871-577b-4c43-84b3-2fdd0c903eb9"><surname id="03bb1648-1f92-4f30-9919-8d2960542b2e">Barza</surname> <given-names id="29776d1c-a5a2-4617-a098-73e88b7372bd">M</given-names></name><x>, </x><name id="d72b3452-4e6c-4f8f-bec8-c0d47ab4c2a2"><surname id="9165086c-13f5-442f-97d7-0444fa757e57">Stuart</surname> <given-names id="9e6cbd39-f079-426d-bae6-0ce51d05ca8e">M</given-names></name><x>, </x><name id="7daaf3e4-e1a6-4385-8212-43c9b4dacb4d"><given-names id="ee2c959b-7ec8-4e0a-ae84-af3873fb16e6">Szoka F, Jr</given-names></name></person-group><x>. </x><article-title id="8f171514-1a5a-4c0e-9f32-470bdd8d55e5">Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes</article-title><x>. </x><source id="db578228-de69-4f3b-b097-fa77673815b3">Invest Ophthalmol Vis Sci</source><x> </x><year id="3530de40-3365-4537-9508-8ba74fe43df6">1987</year><x>;</x><volume id="2e39fef1-b4a9-4e29-ac0f-7f4cb3d6c776">28</volume><x>:</x><fpage id="9edcdebd-23a6-4f75-951e-4a55c8045e64">893</fpage><x>â</x><lpage id="0a5c7297-be80-489d-b1f7-b5f28edb45e1">900</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" id="R29" data-id="R29" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R29" data-doi="10.1089/jop.2000.16.511" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/11132898"><label id="1bf931ad-285b-4b7d-b762-5bb1d555f6c8">29</label><element-citation publication-type="journal" id="eca59bf3-7022-45c2-96fb-2261cd069e38"><person-group person-group-type="author" id="37083bee-e595-4ea0-9b3b-bfc4c58a9a0b"><name id="28130a0b-298e-4ff4-9a7f-5938b0c1e70b"><surname id="d2b25347-dbc8-4dae-926c-7c5c59b5f64a">Gupta</surname> <given-names id="c700438f-0321-4c2c-b8d5-adb9a394dbc4">SK</given-names></name><x>, </x><name id="8f881c8a-c71d-41a7-8e9c-94e138cff02d"><surname id="0e30cc63-c209-4b81-87da-49cb115a2624">Velpandian</surname> <given-names id="8c7c908f-9234-4e85-a86b-401ce94b7760">T</given-names></name><x>, </x><name id="9fcfd1a4-833e-4424-b56c-d958ccb89d2b"><surname id="1f695102-0124-425b-a0c3-b6e01689a532">Dhingra</surname> <given-names id="f2483685-63b6-4742-96f5-df7dd5f71fee">N</given-names></name><x>, </x><etal data-class="RefEtal" id="71e43613-dad1-46e1-8219-a8c4deb60aaa">et al</etal></person-group><x>. </x><article-title id="6f4dee64-36cf-40f0-9f06-2750cfaefff1">Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes</article-title><x>. </x><source id="958c5e38-d016-425a-baf2-0727c0b5fbef"><named-content data-cid="1554806335002" id="52c6d535-959a-4218-99af-2091258270f9" content-type="del cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">Journal</named-content><named-content data-cid="1554806335002" id="887f64de-b38f-4082-81f9-922e6fd5703d" content-type="ins cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">J</named-content> <named-content data-cid="1554806335003" id="de05889f-2fdc-46c9-b008-4b63ba9cbdd1" content-type="del cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">of</named-content><named-content data-cid="1554806335003" id="cdb14e4e-b80f-41eb-b3c9-6b0d6fdb89b1" content-type="ins cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">Ocul</named-content> <named-content data-cid="1554806335004" id="8bfc8317-0ca7-453b-92b5-99a95f049db7" content-type="del cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">Ocular</named-content><named-content data-cid="1554806335004" id="9ab69dfe-fbbf-4175-8b7e-8c3d9d5d32c1" content-type="ins cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">Pharmacol</named-content> <named-content data-cid="1554806335005" id="c73697b6-911e-48c8-837f-763cf0860949" content-type="del cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">Pharmacology and Therapeutics</named-content><named-content data-cid="1554806335005" id="50a627c0-44f9-4e66-a070-1c5468c594d5" content-type="ins cts-1" specific-use="1554806335000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:08 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554806335000">Ther</named-content></source><x> </x><year id="1f12f5d2-181e-4e64-8076-957f96c4606c">2000</year><x>;</x><volume id="92ae37b8-83f9-45f8-9a81-ddc1e478cc67">16</volume><x>:</x><fpage id="29c31c6f-e9bd-4996-b72a-68f38c1a0070">511</fpage><x>â</x><lpage id="7b4fd6dc-c320-4f91-8e5e-9293e9c8c8ef">8</lpage><x>.</x><pub-id pub-id-type="doi" id="ac3d2050-827f-4250-ba23-4fa1c4f0d664">10.1089/jop.2000.16.511</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R30" data-id="R30" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R30" data-doi="10.1038/s41598-017-16791-7" data-validated="true"><label id="dfeab506-dfe8-474c-97a5-70d96fd278a3">30</label><element-citation publication-type="journal" id="6ada108b-4346-4d8d-b027-08f21a1b3ea3"><person-group person-group-type="author" id="19bfb8dc-1b1c-4c96-816f-0656f7502eef"><name id="4d39108b-04da-497b-8ace-87f6cfc7cf4b"><surname id="69de0804-db8f-40be-82df-a5e9d8875b23">Joseph</surname> <given-names id="c0ad0f93-39e1-4353-8126-2af11ad9bdc8">RR</given-names></name><x>, </x><name id="7308c813-3de5-444f-a846-b02b0e66a97e"><surname id="49dd3746-d579-4765-9ace-b28af50be4f9">Tan</surname> <given-names id="189384fa-86dd-43e2-ac04-c5e3572019dd">DWN</given-names></name><x>, </x><name id="d337a3ae-1781-486b-bbbe-765435c08d1b"><surname id="7d3aa9b2-5721-4c38-9261-f4c7e4b6c440">Ramon</surname> <given-names id="3776a44c-f4d6-4174-a6df-654be9375008">MRM</given-names></name><x>, </x><etal data-class="RefEtal" id="001dc26a-9c6d-42d0-a499-5a265ae527a8">et al</etal></person-group><x>. </x><article-title id="08c7b55c-be87-4733-9c0f-8664f459f0ac">Characterization of liposomal carriers for the trans-scleral transport of ranibizumab</article-title><x>. </x><source id="70c00902-34e4-4f0e-9f3e-e87294b435dc">Sci Rep</source><x> </x><year id="31f9fded-9e30-4ba4-a98f-f9631144344a">2017</year><x>;</x><volume id="7ee474f2-0877-4d92-b0df-bb31df50182b">7</volume><x>.</x><pub-id pub-id-type="doi" id="5a41eb11-00f6-48a5-9999-0aefd3f46c3f">10.1038/s41598-017-16791-7</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R31" data-id="R31" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R31" data-doi="10.1002/smll.201303433" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/24596245"><label id="464c4885-9d37-49cc-baea-d46eaca34ede">31</label><element-citation publication-type="journal" id="5eec4705-da3b-4bd4-b237-6eebf313abae"><person-group person-group-type="author" id="0c1b310a-d3ab-44f1-ad8c-c1282929bbbe"><name id="70c1a2c3-f6db-4982-9735-4da56042cc15"><surname id="03485bff-e682-497b-9ffa-085a49d2f26f">Davis</surname> <given-names id="77fe1ef7-6280-48e5-a843-cbead9f16340">BM</given-names></name><x>, </x><name id="40331836-d399-489c-8446-5b49431f3d79"><surname id="c0f4e0fd-41c0-446c-9763-50ca7db006e2">Normando</surname> <given-names id="a79ef6ff-c9a8-4964-9bf5-1d1ef8598e93">EM</given-names></name><x>, </x><name id="7d4d869a-1aac-4a93-8b4b-b9bec3f2ce4b"><surname id="9f80f2e5-fddd-4dcd-9fe8-2e6f18f4b5f3">Guo</surname> <given-names id="1f301ab0-dfb9-4eb7-a8a4-58d537a4e00d">L</given-names></name><x>, </x><etal data-class="RefEtal" id="dadad554-7568-4ccb-82ed-4111c65faf17">et al</etal></person-group><x>. </x><article-title id="4e41dc55-82f9-4bde-963a-773618765b4c">Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes</article-title><x>. </x><source id="a0b045dc-2842-4e5a-8618-8c1488411894">Small</source><x> </x><year id="3b9b1734-da50-4e9d-83f8-e2ae4ce5580c">2014</year><x>;</x><volume id="d7f92fed-7bab-4cee-aa04-3871e2b2f772">10</volume><x>:</x><fpage id="0d459b43-2bd0-4039-9fa4-c022972aa948">1575</fpage><x>â</x><lpage id="ae2808d1-fbef-4a2c-be5f-d6fcc5be93b0">84</lpage><x>.</x><pub-id pub-id-type="doi" id="3e862dd9-9a43-43e2-9401-1aeac5c6069a">10.1002/smll.201303433</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R32" data-id="R32" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R32" data-doi="10.1097/IAE.0b013e3181a2f42a" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/19430280"><label id="f4c16f79-105c-479b-b6ef-d107cc116535">32</label><element-citation publication-type="journal" id="af7aef1d-9d03-4004-8dd7-6dab9db7be2f"><person-group person-group-type="author" id="7fced78f-9845-4309-99cf-0d5695db67d6"><name id="b964f621-7d2b-46dc-8ed0-d391d976de8a"><surname id="9ae8d117-3081-4ea7-bf92-d4209b995ab8">Abrishami</surname> <given-names id="08807894-c040-4ec2-8e79-538729870b65">M</given-names></name><x>, </x><name id="d2aa3bf8-6949-42d4-9025-5170d5247d57"><named-content data-cid="1554806590002" id="5f5d225d-7330-4a08-a332-d072bdcfac53" content-type="ins cts-1" specific-use="1554806590000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806590000"><surname id="ffe57b36-b4d6-44a4-abc9-8ae28471edb2">Zarei-Ghanavati</surname> <given-names id="60f37596-e877-48bc-ab1a-f3a3fe6e505c">S</given-names></named-content></name><x>, </x><name id="e72f3b1d-7e59-471b-8ad1-32912804a35c"><surname id="9f8cce37-f538-4fa7-b509-51bcca0d925a">Soroush</surname> <given-names id="fa1c9bc8-4b7c-4b26-8f63-f4181fa10cad">D</given-names></name><x>, </x><etal data-class="RefEtal" id="c7a1e923-45f3-40e2-aa98-dd516db86ff6">et al</etal></person-group><x>. </x><article-title id="0b13439a-2c04-4abf-a21f-19a66d9e8225">Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration</article-title><x>. </x><source id="3e3e0f26-f893-42ea-a3ba-7402e4b5f43a">Retina</source><x> </x><year id="8dc7029f-c1e1-4c39-acfa-49ce55e3c9c0">2009</year><x>;</x><volume id="68e9e867-cbfb-41a2-9c36-34f77248c1a1">29</volume><x>:</x><fpage id="fca66ed3-4d1d-4bbc-8cae-df2eddbf674e">699</fpage><x>â</x><lpage id="17cdbc3f-bfbb-4856-821e-0af937f90860">703</lpage><x>.</x><pub-id pub-id-type="doi" id="d55983b0-e569-4af7-822a-74f6fbc73ae7">10.1097/IAE.0b013e3181a2f42a</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R33" data-id="R33" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R33" data-doi="10.1016/j.ijpharm.2018.07.030" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/30012508"><label id="72b2bf5b-8b50-48a5-9ebd-d1a9bd7acd6f">33</label><element-citation publication-type="journal" id="65dc444a-0d61-410e-b16b-c5af7b7642ae"><person-group person-group-type="author" id="44e8c945-fd45-4faa-a4a8-9043c13450ed"><name id="e027136a-6e58-48c9-a905-c29e32bcbf93"><surname id="925712a4-09ad-4b7f-8f16-fc8752954063">Sherje</surname> <given-names id="15b7778d-401e-4fb8-96ac-98d11ca6d877">AP</given-names></name><x>, </x><name id="9251dcbf-e45a-47f8-b6ee-36a2d5e74eb6"><surname id="d6440fa3-432d-4bab-ba04-9502411e715a">Jadhav</surname> <given-names id="f2ebf13d-924b-4280-9e12-f527050df89c">M</given-names></name><x>, </x><name id="2eca198e-4293-4ce5-9a52-831696d068f3"><surname id="d16386e0-70e2-4288-8f23-13a666648e09">Dravyakar</surname> <given-names id="90c7ea2d-7c89-47bc-8bd6-da4d217e9951">BR</given-names></name><x>, </x><etal data-class="RefEtal" id="4b62fe13-55d7-4b56-b363-00124845273e">et al</etal></person-group><x>. </x><article-title id="e5dfc181-5009-4dd3-9482-936a22c7ca2e">Dendrimers: a versatile nanocarrier for drug delivery and targeting</article-title><x>. </x><source id="8470a9b8-dd24-4d37-81d4-336d4257a38b"><named-content data-cid="1554806609002" id="bfd795f7-7158-4b07-9cdb-dc0446e1a708" content-type="del cts-1" specific-use="1554806609000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806609000">International</named-content><named-content data-cid="1554806609002" id="3afafca0-1107-4828-80f1-91dde47a2786" content-type="ins cts-1" specific-use="1554806609000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806609000">Int</named-content> <named-content data-cid="1554806609003" id="25f24ad8-5564-47e0-9f0e-fdd440c5e23f" content-type="del cts-1" specific-use="1554806609000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806609000">Journal</named-content><named-content data-cid="1554806609003" id="2d94e0d5-e705-40a9-b26c-c816487845ce" content-type="ins cts-1" specific-use="1554806609000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806609000">J</named-content> <named-content data-cid="1554806609004" id="bd44ac6c-4c9e-4412-bae0-4671f6540685" content-type="del cts-1" specific-use="1554806609000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806609000">of Pharmaceutics</named-content><named-content data-cid="1554806609004" id="d626b4db-f965-4471-b577-57721a31903f" content-type="ins cts-1" specific-use="1554806609000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:13 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806609000">Pharm</named-content></source><x> </x><year id="3c841af1-b5e4-44c1-a776-8d6b001d1ee8">2018</year><x>;</x><volume id="9d82b973-e07a-4a3c-9b3e-c4a94b375e78">548</volume><x>:</x><fpage id="9260f4aa-6f28-4097-8646-35bf0bd2018b">707</fpage><x>â</x><lpage id="18cb36dc-faab-4f51-948c-6ae9ff842972">20</lpage><x>.</x><pub-id pub-id-type="doi" id="d601e620-5b5c-4c25-9db7-c602e601adf5">10.1016/j.ijpharm.2018.07.030</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R34" data-id="R34" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R34" data-doi="10.1038/sj.gt.3302579" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/16034458"><label id="6b8658ad-a1b2-448c-ae1f-198c043bafed">34</label><element-citation publication-type="journal" id="1d8569c7-dcea-4fdd-a301-7d517ca566b2"><person-group person-group-type="author" id="d8d1191f-cc2e-40c6-9f19-a96f8d810fac"><name id="de7358f6-3306-4b3d-b575-d16e24de52cc"><surname id="474ec295-54ef-4147-b3ab-d838cf823bc1">Marano</surname> <given-names id="16891992-dd67-4a56-ba2f-292ec3000b0f">RJ</given-names></name><x>, </x><name id="4a54ad84-0487-4527-81ca-92a465931c36"><surname id="d4b39e86-9ed2-4c2c-991c-ed18a55e5215">Toth</surname> <given-names id="3d198cf7-6b5b-4990-b489-d611ed705d67">I</given-names></name><x>, </x><name id="ad9fec5c-97cc-4876-b3fb-04f03781425f"><surname id="a12ffc2a-7600-4529-a9e7-874bd4821fde">Wimmer</surname> <given-names id="de9d858a-afb9-42d4-9712-1712be7ed0fa">N</given-names></name><x>, </x><etal data-class="RefEtal" id="7b346c52-1f32-43f0-a26a-44b54fdcb5e9">et al</etal></person-group><x>. </x><article-title id="ad17a0c6-7c3f-4a20-9b73-76b17078751c">Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity</article-title><x>. </x><source id="c60f178f-8173-4b52-9f42-2f273ff40fe5">Gene Ther</source><x> </x><year id="0e7c2964-ac96-4058-831f-fc8bd33d5d25">2005</year><x>;</x><volume id="f405dc26-cef0-445e-b697-6b5ea6a011d2">12</volume><x>:</x><fpage id="baa3377f-2931-420c-8033-bcbf7eb741fd">1544</fpage><x>â</x><lpage id="764075c1-e388-4aa2-887a-bc868e475f99">50</lpage><x>.</x><pub-id pub-id-type="doi" id="2d1bfd17-b609-441e-a070-87acdf0ce677">10.1038/sj.gt.3302579</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R35" data-id="R35" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R35" data-validated="true"><label id="6de49176-5e64-4d5b-9363-5f0b76524dbf">35</label><element-citation publication-type="website" id="2be5abe5-a900-402b-b0e6-03ab5eeb9245"><person-group person-group-type="author" id="e50e9e63-62af-4ddf-8590-0f01dd4d8f8f"><collab id="cc89e4a0-59f5-466d-a350-b1315d2a4a86">Retina Today</collab></person-group><x>. </x><article-title id="d8d4f41b-3ca5-4c8c-8153-fce520e87dd4">Long-<named-content data-cid="1554806668002" id="48603f0f-fe92-4c9d-bf86-b3bdc626e5b6" content-type="del cts-1" specific-use="1554806668000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:14 pm" data-track-detail="" data-diff-rid="R51" data-userid="cross-ref" data-username="cross-ref" data-time="1554806668000">Acting</named-content><named-content data-cid="1554806668002" id="01dde84a-1819-4347-b192-54d694d94d9c" content-type="ins cts-1" specific-use="1554806668000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:14 pm" data-track-detail="" data-diff-rid="R51" data-userid="cross-ref" data-username="cross-ref" data-time="1554806668000">acting</named-content> <named-content data-cid="1554806668003" id="c1012af6-ea4e-48be-a47c-567b59ac38a0" content-type="del cts-1" specific-use="1554806668000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:14 pm" data-track-detail="" data-diff-rid="R52" data-userid="cross-ref" data-username="cross-ref" data-time="1554806668000">Anti</named-content><named-content data-cid="1554806668003" id="e701be97-a6ff-4e2a-8ba8-29cda68e3e66" content-type="ins cts-1" specific-use="1554806668000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:14 pm" data-track-detail="" data-diff-rid="R52" data-userid="cross-ref" data-username="cross-ref" data-time="1554806668000">anti</named-content>-VEGF <named-content data-cid="1554806668004" id="c5bb3188-3a52-4548-8f60-d1023b8e0e3e" content-type="del cts-1" specific-use="1554806668000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:14 pm" data-track-detail="" data-diff-rid="R53" data-userid="cross-ref" data-username="cross-ref" data-time="1554806668000">Delivery</named-content><named-content data-cid="1554806668004" id="df554c3e-0225-483d-8d43-c402fbb6c435" content-type="ins cts-1" specific-use="1554806668000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:14 pm" data-track-detail="" data-diff-rid="R53" data-userid="cross-ref" data-username="cross-ref" data-time="1554806668000">delivery</named-content></article-title><x>. Available: </x><uri id="4209597f-c1f9-4f4a-a5f4-e4eb5da829a3" xlink:href="http://retinatoday.com/2014/08/long-acting-anti-vegf-delivery">http://retinatoday.com/2014/08/long-acting-anti-vegf-delivery</uri><x> [Accessed </x><comment data-class="RefLAD" id="b52f4694-451b-4f60-bacb-87ccf14caeba">19th Feb 2019</comment><x>].</x></element-citation></ref><ref data-class="jrnlRefText" id="R36" data-id="R36" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R36" data-validated="true"><label id="c92b1632-b159-4441-86d1-53f845d695a2">36</label><element-citation publication-type="website" id="33c7855d-4444-4a15-967c-71e90d6847ac"><person-group person-group-type="author" id="72992ecb-9011-4f0e-a897-97aa8d8d8ad7"><collab id="fd3737db-3a96-48ce-b7ed-54f3494deb2c">Hoffmann-La Roche Ltd</collab></person-group><x>. </x><article-title id="83f64677-3aca-431f-978b-6068aaf529e7">Investor <named-content data-cid="1554806716002" id="4bff8506-23fb-433e-8733-2ec246514a4d" content-type="del cts-1" specific-use="1554806716000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:15 pm" data-track-detail="" data-diff-rid="R51" data-userid="cross-ref" data-username="cross-ref" data-time="1554806716000">Update</named-content><named-content data-cid="1554806716002" id="35e144f0-c54d-4d74-8f6b-835c36a8b2c2" content-type="ins cts-1" specific-use="1554806716000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:15 pm" data-track-detail="" data-diff-rid="R51" data-userid="cross-ref" data-username="cross-ref" data-time="1554806716000">update</named-content></article-title><x>. Available: </x><uri id="d05015bf-b72d-4045-b4f5-ad9cc7dfa15a" xlink:href="https://www.roche.com/investors/updates/inv-update-2018-07-26b.htm">https://www.roche.com/investors/updates/inv-update-2018-07-26b.htm</uri><x> [Accessed </x><comment data-class="RefLAD" id="52605aab-9d4c-4929-a262-2b820d7aad0e">19th Feb 2019</comment><x>].</x></element-citation></ref><ref data-class="jrnlRefText" id="R37" data-id="R37" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R37" data-doi="10.1167/tvst.3.6.5" data-validated="true"><label id="f1d5e587-2466-420d-8723-2bdabf66833e">37</label><element-citation publication-type="journal" id="cf280483-dacb-4cff-a6ca-0fb389478d51"><person-group person-group-type="author" id="f699f4d2-c854-4331-bd26-73aafb074ee3"><name id="38c9da07-2595-473c-84f9-0d106836bc55"><surname id="69d20c9b-387d-4269-9369-fc6cff8d1036">Humayun</surname> <given-names id="d8a70c72-da7a-46e2-8344-760e0975e990">M</given-names></name><x>, </x><name id="681ff17e-b68d-45fc-a533-08fd76f278de"><surname id="3ea145d6-adc3-4e6a-be16-e0e3afdbe841">Santos</surname> <given-names id="63afb42b-9b2a-4ed5-ae7f-b56fb2648d6b">A</given-names></name><x>, </x><name id="52120447-fe69-4862-9ec1-24329ec282ca"><surname id="1da7f3c6-2bbd-44e3-a020-83ccf9661dae">Altamirano</surname> <given-names id="46a9be04-5300-43d2-b105-69b8d74983d8">JC</given-names></name><x>, </x><etal data-class="RefEtal" id="d64ed041-6fed-4435-aab0-e27ee845f40b">et al</etal></person-group><x>. </x><article-title id="95e430da-b566-44c1-8164-78f4ef0b62b8">Implantable MicroPump for drug delivery in patients with diabetic macular edema</article-title><x>. </x><source id="db51a70d-ae95-43b3-9f36-18bf1a03d2a7"><named-content data-cid="1554806777002" id="8d6b1c57-2ea0-479e-a954-f93469b1ae44" content-type="del cts-1" specific-use="1554806777000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R81" data-userid="cross-ref" data-username="cross-ref" data-time="1554806777000">Trans.</named-content><named-content data-cid="1554806777002" id="037e0292-8557-43d0-97a6-dd243a73650b" content-type="ins cts-1" specific-use="1554806777000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R81" data-userid="cross-ref" data-username="cross-ref" data-time="1554806777000">Transl</named-content> Vis<named-content data-cid="1554806777003" id="9163f04b-6fd5-44ba-b2a9-6f30fe010a9b" content-type="del cts-1" specific-use="1554806777000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806777000">.</named-content> Sci<named-content data-cid="1554806777004" id="6379c8c1-2ba3-4a52-9d42-1c2efcea9a74" content-type="del cts-1" specific-use="1554806777000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806777000">.</named-content> <named-content data-cid="1554806777005" id="0cc04940-a740-42a8-9a7a-0f99a8f9d153" content-type="del cts-1" specific-use="1554806777000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R82" data-userid="cross-ref" data-username="cross-ref" data-time="1554806777000">Tech.</named-content><named-content data-cid="1554806777005" id="d087191f-eead-4ee1-aaa4-94ef1d694bb6" content-type="ins cts-1" specific-use="1554806777000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R82" data-userid="cross-ref" data-username="cross-ref" data-time="1554806777000">Technol</named-content></source><x> </x><year id="03322ac8-2e01-4e52-84ff-3f0d9d309b21">2014</year><x>;</x><volume id="2023d495-8088-454a-93bf-6d8b39950d49">3</volume><x>.</x><pub-id pub-id-type="doi" id="c4bf530d-1e7b-4f9e-9f1c-895366a5179f">10.1167/tvst.3.6.5</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R38" data-id="R38" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R38" data-doi="10.1016/j.tips.2017.01.003" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/28209404"><label id="5ca71e2d-0563-4db0-a2eb-4d6547ca0f82">38</label><element-citation publication-type="journal" id="d2a683f8-a164-4ed8-8a2f-cc72dfc1c2de"><person-group person-group-type="author" id="383646c5-920d-464c-8bf4-291db14e4602"><name id="3f0db85e-4f88-4b25-92d2-2856b2e8379b"><surname id="2ed8231a-dc7f-4567-b84c-ee2523921e2d">Guidotti</surname> <given-names id="2c2e5cee-2bb5-42dc-92c0-3e169972804a">G</given-names></name><x>, </x><name id="1b6e09fa-0d5a-4365-b454-bec85e69cc78"><surname id="ece08692-ceb9-4f21-9083-1ac5f37fbba0">Brambilla</surname> <given-names id="053a81d2-7d76-46f0-b295-1194b799fa6f">L</given-names></name><x>, </x><name id="92516fe5-eb20-4327-b68f-bf6557d27af4"><surname id="2d309deb-f3e7-4dad-8b8d-74c3d014985b">Rossi</surname> <given-names id="5ec873ef-c4aa-4060-b79b-e4465e5a7648">D</given-names></name></person-group><x>. </x><article-title id="00050e79-a7da-4883-a9d6-3b280cbeb7c1">Cell-penetrating peptides: from basic research to clinics</article-title><x>. </x><source id="178a6de5-5e4f-4722-b17c-08d39dff7a62">Trends <named-content data-cid="1554806803002" id="19216b87-0c1a-4794-a41a-cd4eb63318be" content-type="del cts-1" specific-use="1554806803000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806803000">in</named-content><named-content data-cid="1554806803002" id="540c24e4-7625-4e8e-a615-1a99f0a7d220" content-type="ins cts-1" specific-use="1554806803000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806803000">Pharmacol</named-content> <named-content data-cid="1554806803003" id="6afd592b-c72d-455b-a8ea-02958f2287d4" content-type="del cts-1" specific-use="1554806803000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806803000">Pharmacological Sciences</named-content><named-content data-cid="1554806803003" id="b2b6d804-8fd1-44cd-9d8f-92d97fe5c626" content-type="ins cts-1" specific-use="1554806803000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806803000">Sci</named-content></source><x> </x><year id="c400aca6-6ab1-4b86-ab15-826f48168af3">2017</year><x>;</x><volume id="ce8ad3bd-8590-44d1-904a-0956f5bd3080">38</volume><x>:</x><fpage id="3af83272-6f9b-445a-94b3-4b0f92eb645c">406</fpage><x>â</x><lpage id="338e1cd5-1c45-4a30-8edf-d7a46115522b">24</lpage><x>.</x><pub-id pub-id-type="doi" id="8d22a575-3ea2-4d05-87a0-d30d4b6353fb">10.1016/j.tips.2017.01.003</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R39" id="R39" data-id="R39" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R39" data-doi="10.1002/psc.2672" data-validated="true"><label id="0468f8a5-939f-4032-b9d9-8afc80a02014">39</label><element-citation publication-type="journal" id="c1655329-6544-4273-b82a-092926af1bc5"><person-group person-group-type="author" id="051aa12d-0f6a-452d-98ae-eb561fe0e743"><name id="8113e68c-2292-41ea-845c-290f072bba69"><surname id="2ef8456e-f810-44a0-9d60-40c9ebfdb75a">Reissmann</surname> <given-names id="ea2e17f1-6c54-461d-9375-20d03a3294b7">S</given-names></name></person-group><x>. </x><article-title id="566c38e8-a2c4-4bd6-a25a-0738518d6b80">Cell penetration: scope and limitations by the application of cell-penetrating peptides</article-title><x>. </x><source id="815de265-ef8c-4dcf-bfea-eedd30b32e01">J<named-content data-cid="1554794355137" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="bb500441-d823-4b48-9687-9373ae3727d8">.</named-content> Pept<named-content data-cid="1554794355138" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="68b82af3-2757-4932-aa73-9a36aa3468d1">.</named-content> Sci<named-content data-cid="1554794355139" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="229149cc-25b1-42e0-88cb-28112f843f1d">.</named-content></source><x> </x><year id="32e06ef3-7373-473a-b524-05037f08136f">2014</year><x>;</x><volume id="c5e862f4-f1c6-40c7-85c8-4a88430b71e3">20</volume><x>:</x><fpage id="8ac54370-fa70-4abf-ba79-fb0a215788b4">760</fpage><x>â</x><lpage id="9e289de5-3a85-41f4-b765-2be3d99e0ddb">84</lpage><x>. </x><comment data-class="RefComments" id="07934dbf-0a51-4cc6-b69f-425944213a3a">Online First: Epub Date]</comment><x>.</x><pub-id pub-id-type="doi" id="bc559ed7-3dc0-4fcc-97e5-cceaab919949">10.1002/psc.2672</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R40" id="R40" data-id="R40" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R40" data-doi="10.1021/mp400681n" data-validated="true"><label id="7f153989-8536-430c-87b7-64f3be783f57">40</label><element-citation publication-type="journal" id="93268733-6301-4590-b642-2b82216a2003"><person-group person-group-type="author" id="104d335c-66ac-4dd2-94bc-8999c73c76c0"><name id="d466ba55-fbe5-44bc-a72f-d2b46ea9d1e2"><surname id="6f95f44d-be0f-4c18-86fd-30697f3d9443">Liu</surname> <given-names id="9779f4bf-2c19-4b28-ab22-47e79e431e24">C</given-names></name><x>, </x><name id="a423672a-783b-4862-bf83-5832b408216a"><surname id="1c8cdbdc-8708-47fb-ba48-dbde79de464a">Tai</surname> <given-names id="9bde7069-c57b-4dcb-8375-30de736f2b62">L</given-names></name><x>, </x><name id="606a12f1-b103-4d87-883e-62f18e56144d"><surname id="62bba960-e28d-4794-bdb1-c3ed57afbacf">Zhang</surname> <given-names id="8ce402be-5ac6-4388-aad1-bf4aa2ecbe3e">W</given-names></name><x>, </x><etal data-class="RefEtal" id="e5e49358-e5c8-47d7-a411-c3b46863ce23">et al</etal></person-group><x>. </x><article-title id="526ab643-a29a-4c7b-a04f-c4e386d0d871"><named-content data-cid="1554794355140" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="bcd29b37-1749-4065-9c5c-e684d1399b9a">Penetratin, </named-content>a potentially powerful absorption enhancer for noninvasive intraocular drug delivery</article-title><x>. </x><source id="b62d9a21-022b-422f-b020-27695c22d84c">Mol<named-content data-cid="1554794355141" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="38429550-fdd6-4df7-b040-5ac61a6afe77">.</named-content> <named-content data-cid="1554794355142" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="d0036c4a-11a5-4ea1-92b2-c0ba1334e9e9">Pharm</named-content><named-content data-cid="1554794355142" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="11d41c33-a40c-4076-aa82-dcda228a28e3">Pharmaceutics</named-content></source><x> </x><year id="f767acb2-8bac-443e-9a2a-9afe9d7f90a7">2014</year><x>;</x><volume id="35806e47-71d2-4d60-9ac6-c8b35346d87c">11</volume><x>:</x><fpage id="f33bc3b5-84a9-4018-bc65-bfc62824f290">1218</fpage><x>â</x><lpage id="841ea3a0-a2ea-4b8c-ab0a-da0821ed0459">27</lpage><x>.</x><pub-id pub-id-type="doi" id="561bb83a-9872-4ee0-8a34-d1c35ef159e3">10.1021/mp400681n</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R41" data-id="R41" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R41" data-doi="10.1089/jop.2013.0247" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/25347151"><label id="a5d0a8b3-32d9-4f75-b03d-84f8f452d568">41</label><element-citation publication-type="journal" id="d4938826-4573-41f3-812d-c018d8830e83"><person-group person-group-type="author" id="aef7f1c4-e9ac-4e64-865b-a4ae05f55f66"><name id="b3825c84-8c98-40ac-aadd-cb653b1a04a8"><surname id="9c8dd966-d309-48f0-9ff7-87201cd8bcd3">Beydoun</surname> <given-names id="24e5bd13-3397-4054-91cb-de012a92ad61">T</given-names></name><x>, </x><name id="10e9832e-a766-4940-8482-2281c5157d2e"><surname id="6df65f09-ee0f-488e-95ee-a9ec05743723">Deloche</surname> <given-names id="29f2b290-ce32-472d-866b-09e90509f02c">C</given-names></name><x>, </x><name id="a5058324-813e-4939-ac73-2c49876453dc"><surname id="6f764f19-846b-4429-80f0-6f11c35cdbff">Perino</surname> <given-names id="f632ff0b-ab4e-4335-bd17-a818f07454b1">J</given-names></name><x>, </x><etal data-class="RefEtal" id="f79fdff2-471c-4087-9570-d6cffc3b3904">et al</etal></person-group><x>. </x><article-title id="927ce515-814c-4d28-bcd8-07507de0b017">Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation: a safety and tolerability study</article-title><x>. </x><source id="ddbe2bb4-5afa-4484-a9de-d9beb42688ba"><named-content data-cid="1554806812002" id="42bc2faa-b3b0-4cb1-a53f-9f4210272370" content-type="del cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">Journal</named-content><named-content data-cid="1554806812002" id="5962f71a-f657-432a-beda-324dcf521aec" content-type="ins cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">J</named-content> <named-content data-cid="1554806812003" id="9e10f5f8-8dd2-4349-9067-4c7a67d6334d" content-type="del cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">of</named-content><named-content data-cid="1554806812003" id="2482ed54-2b54-4d88-b201-510a95a0274a" content-type="ins cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">Ocul</named-content> <named-content data-cid="1554806812004" id="8b57da6e-3da1-43bd-b522-762a3929f85e" content-type="del cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">Ocular</named-content><named-content data-cid="1554806812004" id="21d751bd-c259-43fd-8789-e20b5c418413" content-type="ins cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">Pharmacol</named-content> <named-content data-cid="1554806812005" id="0476764a-a7c3-4e0c-a312-b9f50aeeb04b" content-type="del cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">Pharmacology and Therapeutics</named-content><named-content data-cid="1554806812005" id="3b7e76c4-db04-4821-baf1-f99c281d538b" content-type="ins cts-1" specific-use="1554806812000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:16 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554806812000">Ther</named-content></source><x> </x><year id="ae791652-3334-4419-b9d3-1f31a32eed7c">2015</year><x>;</x><volume id="d25613c8-86a5-47ed-a91b-b43619ecff30">31</volume><x>:</x><fpage id="49c4b1de-4269-42ae-81fe-de594dfc03c2">93</fpage><x>â</x><lpage id="737e649f-eb74-4839-9f55-bed1e2793b37">9</lpage><x>.</x><pub-id pub-id-type="doi" id="42332828-1a54-4cd8-a2b2-a6ecb9a8ef76">10.1089/jop.2013.0247</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R42" data-id="R42" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R42" data-doi="10.1167/iovs.16-20072" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/28494491"><label id="377baa5e-ee5f-4287-b4b1-a283a3f1b461">42</label><element-citation publication-type="journal" id="1d48e535-1440-4cfa-a773-42535673c8fc"><person-group person-group-type="author" id="bde4f7e7-64a3-409e-a000-9a94ca9da9e5"><name id="b661b561-e644-43f6-91e1-8123650a4150"><surname id="1d6bda6e-971d-42cd-9b04-9f69b6f74c45">de Cogan</surname> <given-names id="06c8cbed-2c48-464a-9e9f-fbcdf37a573e">F</given-names></name><x>, </x><name id="b263d2d6-0d76-4b89-bc4e-758d71042674"><surname id="d7324477-2ed2-4190-981a-b8a78bd5cd4f">Hill</surname> <given-names id="bb1b2cca-a120-4dac-85c6-467f8db39a16">LJ</given-names></name><x>, </x><name id="7d7bfac3-6f16-4fb9-90a1-3a7bc1f94306"><surname id="820b3b69-66c9-48ae-b42f-9c0c7985e43a">Lynch</surname> <given-names id="bd993ed1-c404-41fa-8edb-f15dfb4ae96c">A</given-names></name><x>, </x><etal data-class="RefEtal" id="e8786889-b005-467d-9a2f-11733f036b6f">et al</etal></person-group><x>. </x><article-title id="3e9cffb3-7481-43fa-92ac-cff9432d59a7">Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides</article-title><x>. </x><source id="36ce952c-cbe6-4521-828c-fb8600b241b9">Invest<named-content data-cid="1554806843002" id="288372d7-13b0-4399-8cf0-e1d644d606bb" content-type="del cts-1" specific-use="1554806843000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806843000">.</named-content> Ophthalmol<named-content data-cid="1554806843003" id="cfdb9c7e-dea5-49ad-b3ae-a2353f41d764" content-type="del cts-1" specific-use="1554806843000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806843000">.</named-content> Vis<named-content data-cid="1554806843004" id="7e74a62e-e5a7-4580-9611-80257bb2e303" content-type="del cts-1" specific-use="1554806843000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806843000">.</named-content> Sci<named-content data-cid="1554806843005" id="8d2a3423-5765-4e76-9885-8a4e70461d41" content-type="del cts-1" specific-use="1554806843000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-userid="cross-ref" data-username="cross-ref" data-time="1554806843000">.</named-content></source><x> </x><year id="7787c991-a535-4d36-88b0-6e4c68d5095a">2017</year><x>;</x><volume id="a1bd2f6e-740d-4c73-9f98-d3dff4a7e16b">58</volume><x>:</x><fpage id="32f3c4a6-8699-4417-9107-d691c4157ba3">2578</fpage><x>â</x><lpage id="62a9d4df-4da7-4306-9b15-66624177d614">90</lpage><x>.</x><pub-id pub-id-type="doi" id="56f3b643-40fd-44ac-9316-1c09fd385611">10.1167/iovs.16-20072</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R43" id="R43" data-id="R43" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R43" data-validated="true"><label id="c5d9f676-b961-4f57-8a95-8cbb3ffb6fe7">43</label><element-citation publication-type="journal" id="88c7d9b3-d050-437a-af70-e337d42d1cc9"><person-group person-group-type="author" id="2f9a0bc6-cebd-44c7-9cd8-83969ba24221"><name id="3628903c-7ad0-4145-8d9a-7fda1b8257d0"><surname id="bed0878a-4737-4fca-90b6-ee6c19b95227">Zhang</surname> <given-names id="a788f562-5d90-4bd0-b145-5ed2398d3edf">X</given-names></name><x>, </x><name id="cd9e8c12-b178-4173-af2a-65992636cded"><surname id="bb31d94a-5472-4178-b16c-ad95f3ac97b2">Li</surname> <given-names id="62a7419b-8ecd-4ca1-9df5-5855af487410">Y</given-names></name><x>, </x><name id="eda79eac-1288-4bc7-b9eb-6116b05e5c16"><surname id="4878fff4-c72e-4b0c-93bb-14db688f0d58">Cheng</surname> <given-names id="6dc03853-c4b4-47eb-9053-53de872f19a5">Y</given-names></name><x>, </x><etal data-class="RefEtal" id="d2a36207-9e29-4061-ad7f-5e40c6f2300f">et al</etal></person-group><x>. </x><article-title id="0314ba98-82ff-4da0-883d-e894ec6cbffb">Tat PTD-endostatin: <named-content data-cid="1554794355161" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="5d28e29e-1e0d-43ed-84e3-879cb735c828">A</named-content><named-content data-cid="1554794355161" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="052ffb22-027c-4bc3-b77d-b76c0fc3c998">a</named-content> novel anti-angiogenesis protein with ocular barrier permeability via eye-drops</article-title><x>. </x><source id="cf87b4c2-3c09-4a0e-820a-80e7179e23b4">Biochim Biophys Acta</source><x> </x><year id="1960c8aa-5a0b-43a5-982e-6a9d2c407a86">1850</year><x>;</x><volume id="99aa2165-bf78-4035-95f8-9f4a85175283">2015</volume><x>:</x><fpage id="5bfd4fcc-581a-47bc-9ba6-553c1242e267">1140</fpage><x>â</x><lpage id="2428b17a-a873-4861-af31-2e67eb254e3c">9</lpage><x>.</x></element-citation></ref><ref data-class="jrnlRefText" seqid="R44" id="R44" data-id="R44" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R44" data-doi="10.1016/j.biomaterials.2016.09.022" data-validated="true"><label id="a62b2874-17ca-4693-bbc1-88e0906cbfe0">44</label><element-citation publication-type="journal" id="d7dbbdd6-dea3-41b1-a378-587d3977f711"><person-group person-group-type="author" id="2256dca8-8249-4fdb-b964-6ccde30ff62a"><name id="2edf6945-60d7-4f27-8a49-a406231169d3"><surname id="3bc1d758-f251-41f6-949b-075f8bab46b9">Chen</surname> <given-names id="68a442d8-900f-4e43-8303-7f4df48d89cf">C</given-names></name><x>, </x><name id="9a3e7d90-279e-46ab-94af-27ef7c8019ec"><surname id="6410577c-7aac-45b4-8145-fb43dbfdfb77">Liu</surname> <given-names id="50a53140-ac54-43fe-9bf0-006ffa92dba5">K</given-names></name><x>, </x><name id="15f1a3ef-2f2e-4fa2-879b-37eadab18bb0"><surname id="28ee914d-cd93-43a7-964b-4102fd69cf9b">Xu</surname> <given-names id="a65416ad-1fdc-41d0-810d-21cb3cfd7f95">Y</given-names></name><x>, </x><etal data-class="RefEtal" id="bcc80654-5ea7-49e6-83a1-fb55f74f26e6">et al</etal></person-group><x>. </x><article-title id="e0166673-0414-4abb-b997-546063b8bdd8">Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in<named-content data-cid="1554794355162" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="222b0424-1264-460e-a1ae-4d1f25140626"> </named-content><named-content data-cid="1554794355162" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="2c981c81-d1e1-41b6-93c9-6cebe4fd1d2d"> </named-content>vivo-directed evolution</article-title><x>. </x><source id="88285272-b7df-4ee4-b169-a876eb403605">Biomaterials</source><x> </x><year id="d1779699-110a-427a-b4c1-9cf945ed6e6b">2017</year><x>;</x><volume id="17496657-f8fd-414a-bbaf-73b7c29a2cb9">112</volume><x>:</x><fpage id="3b8c40d6-d616-4346-9311-82a7327b81b6">218</fpage><x>â</x><lpage id="32ca1acd-8ea3-4f54-887a-132508a51236">33</lpage><x>.</x><pub-id pub-id-type="doi" id="83e0aa4d-72ca-432b-86a7-ce2f40f2f03f">10.1016/j.biomaterials.2016.09.022</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R45" data-id="R45" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R45" data-doi="10.1016/j.jconrel.2017.09.036" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/28987881"><label id="39d896d9-bd9b-4736-820b-28dce2f45553">45</label><element-citation publication-type="journal" id="2d4849c9-67bb-4aa8-99b8-2cdd57913764"><person-group person-group-type="author" id="76b69d83-3852-4434-a57a-68d480a1bb20"><name id="7fed7b0b-8e91-4512-92cb-d9c4624aa656"><surname id="c2fc69ed-23b2-4f45-9e2f-e44177a63b8a">Suda</surname> <given-names id="bb49bf1b-a6d7-4f61-b325-31a1d1911cba">K</given-names></name><x>, </x><name id="2779eef6-4383-4b2e-a72e-da0a7df8646c"><surname id="27aa2652-9960-414c-ac78-0237a42a5371">Murakami</surname> <given-names id="3c4f8e39-29a1-445c-b052-458259341b62">T</given-names></name><x>, </x><name id="309f38af-e8e0-48ca-a0ed-8a6e1ded1533"><surname id="386e75ba-bc77-476e-944d-ddaef9711c4d">Gotoh</surname> <given-names id="945e1586-a116-4e26-85d8-d41c13bcdac3">N</given-names></name><x>, </x><etal data-class="RefEtal" id="24ab479b-0537-407c-927d-301a0f68cb04">et al</etal></person-group><x>. </x><article-title id="d35c27fa-a4b0-4d46-a5df-3bf557bb0ca1">High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases</article-title><x>. </x><source id="6431ab8a-8943-4b3f-8333-b8af2ba056ff"><named-content data-cid="1554806852002" id="a532a776-a20c-4bf5-b291-7ac000b5f16e" content-type="del cts-1" specific-use="1554806852000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806852000">Journal</named-content><named-content data-cid="1554806852002" id="6cfdca1d-4ee8-4166-8021-8623f068940d" content-type="ins cts-1" specific-use="1554806852000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806852000">J</named-content> <named-content data-cid="1554806852003" id="932c4744-e422-42a1-84cc-66e752de641a" content-type="del cts-1" specific-use="1554806852000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806852000">of Controlled</named-content><named-content data-cid="1554806852003" id="154915c3-ed65-4ed7-a13b-89c73aceb71f" content-type="ins cts-1" specific-use="1554806852000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806852000">Control</named-content> Release</source><x> </x><year id="58b7448a-5245-4062-8a8e-70317630c0d8">2017</year><x>;</x><volume id="af82bc14-86e3-49b0-b5de-916ee952171e">266</volume><x>:</x><fpage id="1a7de169-fef2-4b37-a1b8-bf224ca24ed8">301</fpage><x>â</x><lpage id="cdf70f3f-2e26-4a5a-b72d-e6c38721ebca">9</lpage><x>.</x><pub-id pub-id-type="doi" id="504e7c1a-6a8b-4c38-b8ce-12e58df836d3">10.1016/j.jconrel.2017.09.036</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R46" data-id="R46" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R46" data-doi="10.1016/j.jconrel.2018.06.023" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/29913221"><label id="b9e33cbe-abee-44c1-b82e-c91355b31ac5">46</label><element-citation publication-type="journal" id="f1689bcf-f267-4ec4-940f-64839c2ba3b4"><person-group person-group-type="author" id="d1f0ee45-95c1-4532-b9af-2a933436ab50"><name id="cbc14156-2789-43ac-afa4-c0dbe581de82"><surname id="1ce7424e-d91e-4a26-88e4-32a363de58b4">Pescina</surname> <given-names id="281427ec-00f0-4ce9-ab88-722fb5f3db20">S</given-names></name><x>, </x><name id="d5095dcb-fd48-4591-a1d5-c89abbf83272"><surname id="9373eb0c-6905-43b3-8b18-6876187acdeb">Ostacolo</surname> <given-names id="b49ef3d1-6d16-43d2-8130-8063d7b8c589">C</given-names></name><x>, </x><name id="1d459b77-e36a-4e6e-844c-02623a240f01"><surname id="9d8daf1a-c13d-40a9-b93f-1d2509da371c">Gomez-Monterrey</surname> <given-names id="3f9d8de2-d708-4455-bdcd-5bd35cb09355">IM</given-names></name><x>, </x><etal data-class="RefEtal" id="b6f5b008-eebb-47a9-a088-78889e007d6b">et al</etal></person-group><x>. </x><article-title id="3c1f302a-9fdd-45ae-b8b2-c6c55ae652e9">Cell penetrating peptides in ocular drug delivery: state of the art</article-title><x>. </x><source id="57091c25-ccd9-430b-8a23-f9217cfc699d"><named-content data-cid="1554806876002" id="94633669-4fd1-401a-ab9f-d4057d5abffb" content-type="del cts-1" specific-use="1554806876000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806876000">Journal</named-content><named-content data-cid="1554806876002" id="fa9250a4-4e4e-426b-a8a2-e6a074fa0f91" content-type="ins cts-1" specific-use="1554806876000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806876000">J</named-content> <named-content data-cid="1554806876003" id="897a3656-ccd7-4776-b69c-c0d35c92af33" content-type="del cts-1" specific-use="1554806876000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806876000">of Controlled</named-content><named-content data-cid="1554806876003" id="25b4ab18-58e1-4fd3-b58d-bc8af987ae98" content-type="ins cts-1" specific-use="1554806876000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:17 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806876000">Control</named-content> Release</source><x> </x><year id="ee433c06-4b20-4c1c-a4cd-18a416a8fe24">2018</year><x>;</x><volume id="a4295459-038f-4516-a9bf-3b9e722cfee9">284</volume><x>:</x><fpage id="1da0bafa-8730-4439-8688-fb28ba98c458">84</fpage><x>â</x><lpage id="4bb46fa1-a996-45ed-b564-aac9b53ecfc5">102</lpage><x>.</x><pub-id pub-id-type="doi" id="4d21a207-faec-4290-9ea4-3572d3d13967">10.1016/j.jconrel.2018.06.023</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R47" id="R47" data-id="R47" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R47" data-doi="10.1080/14728214.2017.1362390" data-validated="true"><label id="6c4a1a74-d9a8-4c0d-a407-be916e8c1bca">47</label><element-citation publication-type="journal" id="bab76179-5fe4-4944-8132-bd0321cefeae"><person-group person-group-type="author" id="0c263b34-1f5f-4dd3-b8e4-70657164caa9"><name id="65f8fbd2-14b9-4373-ae84-839cd154d990"><surname id="c0b65f3a-2836-47c0-9c57-24fa299f456b">Hussain</surname> <given-names id="5b5fa3ac-ba2f-4e0f-9396-95db9f6f2d48">RM</given-names></name><x>, </x><name id="f68e695b-f9cd-44fd-9b9e-0a4fceb2b053"><surname id="5591813b-55e8-4a77-b3dd-052c2f33d02c">Ciulla</surname> <given-names id="403b7b66-ef75-484b-9a82-ee8acb3238ba">TA</given-names></name></person-group><x>. </x><article-title id="4ef6e1f0-a863-482b-a33d-eb59f75ed546">Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration</article-title><x>. </x><source id="7e0148df-90ce-4ea7-81b1-fc09a4fceacd">Expert <named-content data-cid="1554794355168" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="77dafbe6-063c-4bef-a71e-d2a38fac4ba5">Opin</named-content><named-content data-cid="1554794355168" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R91" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="4ce0a8d0-1763-4ef9-9901-416e8a703f2e">Opinion</named-content> <named-content data-cid="1554794355169" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="9e852d2b-b084-4cc4-9c03-dd5283ad9899">Emerg</named-content><named-content data-cid="1554794355169" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R92" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="85d80f74-e6d2-404e-8746-eede8f4c9d39">on Emerging</named-content> Drugs</source><x> </x><year id="ffa6742f-ee0f-4767-863d-297f73fb960a">2017</year><x>;</x><volume id="219028d9-9570-4b4a-a747-9be70ac0ec25">22</volume><x>:</x><fpage id="607cc9d9-b342-4ada-9b43-5a0e0d44b7af">235</fpage><x>â</x><lpage id="abfdf18d-1daa-4bea-b89e-d9cd90ea7307">46</lpage><x>.</x><pub-id pub-id-type="doi" id="41d7aebb-65f1-4f34-9ff1-c12e40d8dc9c">10.1080/14728214.2017.1362390</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R48" data-id="R48" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R48" data-doi="10.1016/S0140-6736(15)00345-1" data-validated="true"><label id="61409f5e-1646-4215-b24b-ebd7054f6f56">48</label><element-citation publication-type="journal" id="218f56d7-721b-4968-ba4b-44a086f804ec"><person-group person-group-type="author" id="f3b0c3c0-3c62-4ab2-9d7e-9a5ebb1529a9"><name id="7c6b0fe3-c1fa-467a-ba02-eecf9649855b"><surname id="c78a973e-ba00-4127-9c37-9b021cbff881">Rakoczy</surname> <given-names id="52f3dec0-aeff-4c5b-8a1c-d85be0a3f0fc">EP</given-names></name><x>, </x><name id="0af3a676-5770-4170-8572-3d0757b07d9c"><surname id="4cbd716b-6f4e-4c89-960c-1bf50706ff4e">Lai</surname> <given-names id="c015083d-3a4f-436b-a2c9-aea37236ab51"><named-content data-cid="1554794355170" id="0c573036-cb9e-4a09-96fd-591423640bed" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000">CM</named-content><named-content data-cid="1554794355170" id="a2baca3d-ef62-43d5-8785-61c767ef225c" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000">C-M</named-content></given-names></name><x>, </x><name id="93a16bf8-b2f6-4b6d-9007-24f224fb60ef"><surname id="430c1b85-91c0-4bd0-bf5b-cf10133a67c3">Magno</surname> <given-names id="76cf1e89-6a78-4de1-b18e-1667454fb3f3">AL</given-names></name><x>, </x><etal data-class="RefEtal" id="39b16a28-d64a-4746-90bc-008489461002">et al</etal></person-group><x>. </x><article-title id="28947c50-cc9a-450e-b296-bb37ed3cbf48">Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial</article-title><x>. </x><source id="a0b347de-1cbf-4cc5-9334-f86536d96fc3">Lancet</source><x> </x><year id="79e2f54b-1eb8-4fb0-83b8-834ac87a7980">2015</year><x>;</x><volume id="09e23672-5824-4173-9f67-e69696aca05b">386</volume><x>:</x><fpage id="d313f2bf-5fde-48cb-8530-4e6d55b260db">2395</fpage><x>â</x><lpage id="126d8e9c-64f1-4079-a5f1-05b5ded7b968">403</lpage><x>.</x><pub-id pub-id-type="doi" id="3e73da22-2eed-4412-a225-e33c29605ffa">10.1016/S0140-6736(15)00345-1</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R49" data-id="R49" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R49" data-doi="10.1016/j.ajo.2017.02.018" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/28245970"><label id="f495b9c8-7c57-4e4e-8ebf-66b70b9aa372">49</label><element-citation publication-type="journal" id="8e2a9318-153f-4d4b-b03d-7084b6c438c3"><person-group person-group-type="author" id="5128bb2d-0fdc-40fb-86ad-100cf1e3c811"><name id="9ac917e3-4fec-4006-bde1-38beaf0f584b"><surname id="6a6a164c-57e3-4fd0-8ab0-a08663606d6a">Constable</surname> <given-names id="3c9bbca6-4128-4577-8b38-958b6d06122f">IJ</given-names></name><x>, </x><name id="63a4722a-3ea9-4fb7-a2d2-b03edc3b93fd"><surname id="6a0dda9e-0995-49f4-887f-3db73f9edf72">Lai</surname> <given-names id="324013b4-aa5a-4ad0-bae7-f1b9d2dc1882">C-M</given-names></name><x>, </x><name id="4cecb445-1af8-41e9-8f15-3c82f65b9aa8"><surname id="b7d91461-1910-43b1-a471-e42951327861">Magno</surname> <given-names id="3f9da9ec-c08c-483d-b1b1-152bf57b7511">AL</given-names></name><x>, </x><etal data-class="RefEtal" id="613049b7-4e14-4791-a396-a0e4de26aecd">et al</etal></person-group><x>. </x><article-title id="390f6cad-3e33-467e-ae69-aa73480e81c8">Gene therapy in neovascular age-related macular degeneration: three-year follow-up of a phase 1 randomized dose escalation trial</article-title><x>. </x><source id="3681a1da-858b-4d38-be02-7b359b330fb5"><named-content data-cid="1554806888002" id="8f9f05d0-bf4b-48fa-aff9-921e0c963082" content-type="del cts-1" specific-use="1554806888000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:18 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806888000">American</named-content><named-content data-cid="1554806888002" id="bff12199-645a-4d12-ae83-738346f49a89" content-type="ins cts-1" specific-use="1554806888000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:18 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554806888000">Am</named-content> <named-content data-cid="1554806888003" id="50ff9280-8c91-4581-be99-196c082cfa75" content-type="del cts-1" specific-use="1554806888000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:18 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806888000">Journal</named-content><named-content data-cid="1554806888003" id="943ce481-56c6-4b71-a41d-03e08e17ca11" content-type="ins cts-1" specific-use="1554806888000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:18 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554806888000">J</named-content> <named-content data-cid="1554806888004" id="1d076c09-6131-480c-b3c4-30c65a405bd6" content-type="del cts-1" specific-use="1554806888000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:18 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806888000">of Ophthalmology</named-content><named-content data-cid="1554806888004" id="07be02c9-5383-4b25-810b-1cc8c2c7160f" content-type="ins cts-1" specific-use="1554806888000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:18 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554806888000">Ophthalmol</named-content></source><x> </x><year id="5f2e1289-10d4-44cd-be16-503bea5c4df5">2017</year><x>;</x><volume id="17e1eff7-8514-4cab-80d2-ea3c4e8c91cf">177</volume><x>:</x><fpage id="4e0a953b-3c92-4a6d-a080-4b2d23ceb9c6">150</fpage><x>â</x><lpage id="0f4aae34-8e38-42a2-a31d-a8ea7c080b30">8</lpage><x>.</x><pub-id pub-id-type="doi" id="4629f9f6-36c0-447a-8f7e-92d5326d1eaf">10.1016/j.ajo.2017.02.018</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R50" data-id="R50" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R50" data-doi="10.1016/S0140-6736(17)30979-0" data-validated="true"><label id="a98b46e5-127a-4483-a491-95966b5c7e2b">50</label><element-citation publication-type="journal" id="77afc708-3573-4748-9d42-358ca6b363af"><person-group person-group-type="author" id="8ab9cb1c-2fd3-4cc4-bbdf-e591e2b32a60"><name id="425a7e31-579e-4c97-af25-7d4d10f5f95d"><surname id="6f1ae961-9b67-4bc0-9dcd-5439903d7c9c">Heier</surname> <given-names id="c5ee3d75-2642-4354-9128-73db5ca95db5">JS</given-names></name><x>, </x><name id="56eaa8ef-8412-4a81-b283-a349ad3290d3"><surname id="693b8192-948a-4b09-a0fe-ff311b038f12">Kherani</surname> <given-names id="8c7ee525-2f4b-4f36-bbfd-07a85270f05b">S</given-names></name><x>, </x><name id="3b37c571-9186-4df2-8a7b-9aaa4301960c"><surname id="4458b394-3f9e-4e3f-861e-8ed8294bd2a7">Desai</surname> <given-names id="3ea9ba4e-68f4-431f-8eb8-edf1fd307cdb">S</given-names></name><x>, </x><etal data-class="RefEtal" id="7e6d94cd-b1f7-42cb-8b2b-c567c3f619be">et al</etal></person-group><x>. </x><article-title id="3df9245b-020b-4aba-8bb2-bba50aec2234">Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial</article-title><x>. </x><source id="df6f1dd2-cc16-47a8-9539-e09d5dd565d5">Lancet</source><x> </x><year id="79dbd6c2-4ba6-4cb3-a013-4515cd063592">2017</year><x>;</x><volume id="a7d71fbc-084f-429d-86fe-cf57625e9d3c">390</volume><x>:</x><fpage id="f0c2d79b-7f62-43ee-aaa6-f287530e2680">50</fpage><x>â</x><lpage id="972db421-f823-4a9c-91f9-0e58cf540fce">61</lpage><x>.</x><pub-id pub-id-type="doi" id="8483f88e-7480-48fd-a5c4-32ebfa16aad5">10.1016/S0140-6736(17)30979-0</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R51" data-id="R51" data-styled="RefText" data-class-name="RefText" data-reftype="journal" data-valid-id="R51" data-doi="10.1038/sj.gt.3301878" data-validated="true" data-pmid="http://www.ncbi.nlm.nih.gov/pubmed/12571629"><label id="88be3193-698b-4434-870f-67e4d2b7c637">51</label><element-citation publication-type="journal" id="15728a67-0fcd-49ce-8d69-0f7db4562637"><person-group person-group-type="author" id="a3f30267-42e3-414c-8488-d2924b810098"><name id="64ba8eb3-d1d8-419d-8cdc-2e8112adb630"><surname id="3b87994e-fc10-4d9a-8710-72f60f4af34c">Igarashi</surname> <given-names id="dc159f03-75ea-4b9e-b351-01987df0d908">T</given-names></name><x>, </x><name id="5218373e-d077-466d-b510-73bb6716af69"><surname id="aa58072d-e99c-4b4b-9dd7-8708265e5c44">Miyake</surname> <given-names id="bd72e019-153a-4140-a659-7fb85902983b">K</given-names></name><x>, </x><name id="19a20af9-9afb-4649-9f1f-7ea66f62f331"><surname id="8ae9d2ce-36c6-4ff5-88e6-621892322634">Kato</surname> <given-names id="1c70ddba-1352-4b0d-b9d6-e1ae7adc1129">K</given-names></name><x>, </x><etal data-class="RefEtal" id="c1fc2025-23bf-4cd5-aa4c-6adc0af29605">et al</etal></person-group><x>. </x><article-title id="a1086f04-f421-46f7-8c8a-21d3eda9a873">Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model</article-title><x>. </x><source id="2c7006a5-d091-4a58-8b3c-c2d451d16596">Gene Ther</source><x>. </x><comment data-class="RefInPress" id="7de8acfb-f728-4fe7-9e89-316c344e852a">In Press</comment><x> </x><year id="5d010337-0f80-4e36-b2e3-a426e42a3b14">2003</year><x>;</x><volume id="6695bd2c-2c5a-46ff-971d-e07f04a3d281">10</volume><x>:</x><fpage id="cd5dd2e0-c71a-43f4-aead-b276396dbda0">219</fpage><x>â</x><lpage id="35fa756c-9033-46e6-9f65-4177ba7e9910">26</lpage><x>.</x><pub-id pub-id-type="doi" id="146d3c30-e050-4b92-a145-0f6ef8b1ad9f">10.1038/sj.gt.3301878</pub-id></element-citation></ref><ref data-class="jrnlRefText" seqid="R52" id="R52" data-id="R52" data-styled="RefText" data-class-name="RefText" data-reftype="Journal" data-valid-id="R52" data-doi="10.1089/hum.2016.117" data-validated="true"><label id="d03b6eaa-7db3-4435-8674-3a7ca0bacf17">52</label><element-citation publication-type="journal" id="9a11bc97-37dd-479c-a31c-bf3201748bc8"><person-group person-group-type="author" id="36fb08fd-a74d-4d05-9b29-fe5305d4f201"><name id="41550c81-d211-40a6-8674-ba18f9dadcad"><surname id="82f42ebe-2dee-4acd-896d-b64e2d8fae20">Campochiaro</surname> <given-names id="6f549d72-f925-4355-8262-e8bd7a9ff882">PA</given-names></name><x>, </x><name id="02fb0429-235b-4697-b308-db66c343ffdb"><surname id="ebff487d-87b4-41d8-9be3-961e2d7fda2b">Lauer</surname> <given-names id="aab8d149-eee8-4f1a-b17e-14d359d6a9b7">AK</given-names></name><x>, </x><name id="f54e7054-0c67-492d-af7e-ae6011f25051"><surname id="edf2dd2d-1a2f-4cdb-b102-d9d1cc040e7f">Sohn</surname> <given-names id="8ca89362-1b70-46f1-8550-31cf55fe2ab9">EH</given-names></name><x>, </x><etal data-class="RefEtal" id="f77e6329-e6aa-46a9-9802-c027f5633645">et al</etal></person-group><x>. </x><article-title id="84814628-6d2f-4758-bdc8-06ef0ad98883">Lentiviral <named-content data-cid="1554794355192" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="e0eac688-d7af-43fb-a773-b89c1ba10061">Vector</named-content><named-content data-cid="1554794355192" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R101" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="6c9902f1-5fe8-4e7d-9672-ba8cb6e60d62">vector</named-content> <named-content data-cid="1554794355193" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="0f64e1f4-c0f5-42cb-a112-0f5c42264efc">Gene</named-content><named-content data-cid="1554794355193" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R102" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="ae0eea7a-9215-44d5-8e55-c70a6e5f39bb">gene</named-content> <named-content data-cid="1554794355194" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="f2cfb876-96bf-405a-9fdb-2a0bab700687">Transfer</named-content><named-content data-cid="1554794355194" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R103" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="d25a26a0-39b2-4856-9b69-12084537c047">transfer</named-content> of Endostatin/Angiostatin for <named-content data-cid="1554794355195" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="42fb3284-54b1-497c-98e3-f77b6b388a03">Macular</named-content><named-content data-cid="1554794355195" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R104" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="fa8392d0-295c-4321-b028-3e1c04201d48">macular</named-content> <named-content data-cid="1554794355196" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="94243227-63c3-4cba-ba5c-19dc515fe7a7">Degeneration</named-content><named-content data-cid="1554794355196" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R105" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="40087448-96f8-4113-b742-c37bc26ae76b">degeneration</named-content> (GEM) <named-content data-cid="1554794355197" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="86edc0bd-6209-4dd7-94fd-bf943d811b11">Study</named-content><named-content data-cid="1554794355197" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R106" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="684c2eea-386a-4ba1-b2bd-10af9312ad35">study</named-content></article-title><x>. </x><source id="6a1d9708-7056-4143-ba95-8ce234522231"><named-content data-cid="1554794355198" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="ad6dd438-97bd-4135-8dbf-20ec6cee9ffc">Hum</named-content><named-content data-cid="1554794355198" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R107" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="cd2e3da0-2733-4757-b6e3-8e5cd9269f09">Human</named-content> Gene <named-content data-cid="1554794355199" content-type="del cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R108" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="05be7197-a881-468a-b6f6-45aa4927f7b4">Ther</named-content><named-content data-cid="1554794355199" content-type="ins cts-1" specific-use="1554794355000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 12:49 pm" data-track-detail="" data-diff-rid="R108" data-userid="cross-ref" data-username="cross-ref" data-time="1554794355000" id="ad7a0ca3-a9cf-494a-bc87-8e8a32529ae1">Therapy</named-content></source><x> </x><year id="446f2535-fae6-45b8-aed1-b3a15d33a3a4">2017</year><x>;</x><volume id="4082eb84-7005-4a2c-ae37-fe0ca6f5e4e9">28</volume><x>:</x><fpage id="1a9719d6-9ba1-4604-8efc-f663ee6fe62c">99</fpage><x>â</x><lpage id="69fc2fa5-0227-411b-be69-31731ca941ba">111</lpage><x>.</x><pub-id pub-id-type="doi" id="bc990dc8-a59d-4b31-bf94-a85dc22145f1">10.1089/hum.2016.117</pub-id></element-citation></ref><ref data-class="jrnlRefText" id="R53" data-id="R53" data-styled="RefText" data-class-name="RefText" data-reftype="website" data-valid-id="R53" data-validated="true"><label id="9e1b4bbf-c24b-420f-acb3-513be45535bf">53</label><element-citation publication-type="website" id="b9a6b1b9-0b50-4efd-9cac-c34ee7730864"><person-group person-group-type="author" id="68818eb3-816b-4629-9a56-2c8b5b8c8756"><collab id="b3e83fe0-0330-46ea-adc8-58d64f9d450d">U.S. Department of Health and Human Services</collab></person-group><x>. </x><article-title id="0fe1e9fb-8f09-40b9-8d4d-a2171a3eefee">RGX-314 <named-content data-cid="1554806991002" id="73fb0de5-8dbe-4536-9f53-4d9b095d82cc" content-type="del cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R51" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">Gene</named-content><named-content data-cid="1554806991002" id="1ff07d68-1236-4c92-8575-2bebb0759d4c" content-type="ins cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R51" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">gene</named-content> <named-content data-cid="1554806991003" id="117f17d7-cad9-4ed8-b888-64d7ff72e7fd" content-type="del cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R52" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">Therapy</named-content><named-content data-cid="1554806991003" id="09864a60-41e9-4960-8a5e-75a8799c7df4" content-type="ins cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R52" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">therapy</named-content> for <named-content data-cid="1554806991004" id="c623273c-d246-47b6-9841-6ba57330b212" content-type="del cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R53" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">Neovascular</named-content><named-content data-cid="1554806991004" id="b4cc92c3-214f-4144-9e46-ce0f5ad63345" content-type="ins cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R53" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">neovascular</named-content> AMD <named-content data-cid="1554806991005" id="5b90be5f-deeb-4db7-be27-c4bd1bcf12da" content-type="del cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Deleted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R54" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">Trial</named-content><named-content data-cid="1554806991005" id="f0a9dfbb-de1a-40ad-aa9e-2638e2235e09" content-type="ins cts-1" specific-use="1554806991000" xlink:title="cross-ref" alt="cross-ref" data-title="Inserted by cross-ref - 2019/04/09 16:19 pm" data-track-detail="" data-diff-rid="R54" data-userid="cross-ref" data-username="cross-ref" data-time="1554806991000">trial</named-content></article-title><x>. Available: </x><uri id="f673b4d0-5a1b-4b04-85ae-93ba6f8930de" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03066258">https://clinicaltrials.gov/ct2/show/NCT03066258</uri><x> [Accessed </x><comment data-class="RefLAD" id="dc01445c-f482-4faa-81a6-0029ae123f15">21st Feb 2019</comment><x>].</x></element-citation></ref></ref-list></back><workflow ftp-file-name="bjophthalmol-2018-313462" data-job-id="4d4e3ab7-8580-4c18-aa71-24d5d8e82ea0"><priority>priority</priority><current-stage>Archive</current-stage><paw-stage><previous>Upload for Online First</previous><current>Article Bank</current></paw-stage><word-count/><word-count-without-ref>3576</word-count-without-ref><stage><name>addJob</name><customer-stage-name>Add Job</customer-stage-name><start-date-time/><end-date-time/><start-date>2019-04-08 09:00:36</start-date><duration>0</duration><end-word-count>30</end-word-count><end-word-count-without-ref>30</end-word-count-without-ref><end-date>2019-04-08 09:00:45</end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on/><reason/></assigned><time-log><log><start/><end/><duration/><status/></log></time-log></stage><stage><iteration>1</iteration><start-word-count>30</start-word-count><start-word-count-without-ref>30</start-word-count-without-ref><name>File download</name><customer-stage-name>Clean up</customer-stage-name><start-date>2019-04-08 09:00:45</start-date><duration>0</duration><end-word-count>30</end-word-count><end-word-count-without-ref>30</end-word-count-without-ref><end-date>2019-04-08 09:01:03</end-date><sla-start-date>2019-04-08 09:00:45</sla-start-date><sla-end-date>2019-04-09 09:00:45</sla-end-date><planned-start-date>2019-04-08 09:00:45</planned-start-date><planned-end-date>2019-04-09 09:00:45</planned-end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on>0</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage><stage><iteration>1</iteration><start-word-count>30</start-word-count><start-word-count-without-ref>30</start-word-count-without-ref><name>Convert Files</name><customer-stage-name>Clean up</customer-stage-name><start-date>2019-04-08 09:01:03</start-date><duration>0</duration><end-word-count>316</end-word-count><end-word-count-without-ref>316</end-word-count-without-ref><end-date>2019-04-08 09:01:14</end-date><sla-start-date>2019-04-08 09:00:45</sla-start-date><sla-end-date>2019-04-09 09:00:45</sla-end-date><planned-start-date>2019-04-08 09:01:03</planned-start-date><planned-end-date>2019-04-09 09:01:03</planned-end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on>0</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage><stage><iteration>1</iteration><start-word-count>316</start-word-count><start-word-count-without-ref>316</start-word-count-without-ref><name>Pre-editing</name><customer-stage-name>Clean up</customer-stage-name><start-date>2019-04-08 09:01:15</start-date><duration>61</duration><end-word-count>5318</end-word-count><end-word-count-without-ref>3588</end-word-count-without-ref><end-date>2019-04-09 11:11:29</end-date><sla-start-date>2019-04-08 09:00:45</sla-start-date><sla-end-date>2019-04-09 09:00:45</sla-end-date><planned-start-date>2019-04-08 09:01:15</planned-start-date><planned-end-date>2019-04-10 09:01:15</planned-end-date><status>completed</status><comments/><assigned><to>Asha Narayanan, ashan@exeterpm.com</to><by>System, Exeter</by><on>2019-04-09 06:59:54</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Asha (PREEDITOR)" role="preeditor" time="1554807097769" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/><pdf user="Asha (PREEDITOR)" role="preeditor" time="1554807955937" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/></proof></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha Narayanan</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>06:59:54</start-time><end-date>2019-04-09</end-date><end-time>07:20:58</end-time><status type="user">logged-off</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha Narayanan</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>09:58:33</start-time><end-date>2019-04-09</end-date><end-time>10:04:18</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:10:17</start-time><end-date>2019-04-09</end-date><end-time>10:11:58</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:12:43</start-time><end-date>2019-04-09</end-date><end-time>10:15:52</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:17:56</start-time><end-date>2019-04-09</end-date><end-time>10:19:34</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:19:39</start-time><end-date>2019-04-09</end-date><end-time>10:22:17</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:24:43</start-time><end-date>2019-04-09</end-date><end-time>10:28:45</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:34:34</start-time><end-date>2019-04-09</end-date><end-time>10:36:23</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:36:24</start-time><end-date>2019-04-09</end-date><end-time>10:37:29</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:37:46</start-time><end-date>2019-04-09</end-date><end-time>10:41:57</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:43:01</start-time><end-date>2019-04-09</end-date><end-time>10:44:33</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:44:38</start-time><end-date>2019-04-09</end-date><end-time>10:44:53</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:45:04</start-time><end-date>2019-04-09</end-date><end-time>10:50:39</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:51:43</start-time><end-date>2019-04-09</end-date><end-time>10:51:43</end-time><status type="system">open</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:51:43</start-time><end-date>2019-04-09</end-date><end-time>10:53:01</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:54:43</start-time><end-date>2019-04-09</end-date><end-time>10:55:44</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:57:13</start-time><end-date>2019-04-09</end-date><end-time>10:57:13</end-time><status type="system">open</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>10:57:13</start-time><end-date>2019-04-09</end-date><end-time>11:05:08</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>11:05:12</start-time><end-date>2019-04-09</end-date><end-time>11:05:25</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>11:05:27</start-time><end-date>2019-04-09</end-date><end-time>11:06:13</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>11:06:40</start-time><end-date>2019-04-09</end-date><end-time>11:09:44</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>11:10:05</start-time><end-date>2019-04-09</end-date><end-time>11:10:41</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-09</start-date><start-time>11:11:24</start-time><end-date>2019-04-09</end-date><end-time>11:11:24</end-time><status type="system">signed-off</status></log></job-logs><time-tracker><process type="styling">10</process><process type="author-details">10</process><process type="footnotes">0</process><process type="figure-upload">0</process><process type="table-setting">0</process><process type="supplements">0</process><process type="references">0</process><process type="check-rulesets">0</process><process type="others">0</process></time-tracker></stage><stage><iteration>1</iteration><start-word-count>5318</start-word-count><start-word-count-without-ref>3588</start-word-count-without-ref><name>Waiting for CE</name><customer-stage-name>Copy edit</customer-stage-name><start-date>2019-04-09 11:11:29</start-date><duration>0</duration><end-word-count>5318</end-word-count><end-word-count-without-ref>3588</end-word-count-without-ref><end-date>2019-04-10 14:15:05</end-date><sla-start-date>2019-04-09 11:11:29</sla-start-date><sla-end-date>2019-04-10 11:11:29</sla-end-date><planned-start-date>2019-04-09 11:11:29</planned-start-date><planned-end-date>2019-04-10 11:11:29</planned-end-date><status>completed</status><comments/><assigned><to>Exeter</to><by>Exeter</by><on>0</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage><stage><iteration>1</iteration><start-word-count>5318</start-word-count><start-word-count-without-ref>3588</start-word-count-without-ref><name>Copyediting</name><customer-stage-name>Copy edit</customer-stage-name><start-date>2019-04-10 14:15:05</start-date><duration>65</duration><end-word-count>5302</end-word-count><end-word-count-without-ref>3572</end-word-count-without-ref><end-date>2019-04-14 17:42:00</end-date><sla-start-date>2019-04-10 14:15:05</sla-start-date><sla-end-date>2019-04-11 14:15:05</sla-end-date><planned-start-date>2019-04-10 14:15:05</planned-start-date><planned-end-date>2019-04-11 14:15:05</planned-end-date><status>completed</status><comments/><assigned><to>Varadaraj B, bvaradaraj1976@gmail.com</to><by>Satish Raju, satishraju@exeterpm.com</by><on>2019-04-13 04:32:50</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Varadaraj (COPYEDITOR)" role="copyeditor" time="1555260817394" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/><pdf user="Varadaraj (COPYEDITOR)" role="copyeditor" time="1555260922409" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/><pdf user="Varadaraj (COPYEDITOR)" role="copyeditor" time="1555262511758" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/><pdf user="Varadaraj (COPYEDITOR)" role="copyeditor" time="1555263643829" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/></proof></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Varadaraj B</username><useremail>bvaradaraj1976@gmail.com</useremail><start-date>2019-04-14</start-date><start-time>16:30:56</start-time><end-date>2019-04-14</end-date><end-time>16:58:09</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Varadaraj</username><useremail>bvaradaraj1976@gmail.com</useremail><start-date>2019-04-14</start-date><start-time>16:58:47</start-time><end-date>2019-04-14</end-date><end-time>17:35:37</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Varadaraj</username><useremail>bvaradaraj1976@gmail.com</useremail><start-date>2019-04-14</start-date><start-time>17:36:41</start-time><end-date>2019-04-14</end-date><end-time>17:37:13</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Varadaraj</username><useremail>bvaradaraj1976@gmail.com</useremail><start-date>2019-04-14</start-date><start-time>17:38:29</start-time><end-date>2019-04-14</end-date><end-time>17:40:41</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>5302</start-word-count><start-word-count-without-ref>3572</start-word-count-without-ref><name>Typesetter Check</name><customer-stage-name>Typeset</customer-stage-name><start-date>2019-04-14 17:42:00</start-date><duration>2</duration><end-word-count>5302</end-word-count><end-word-count-without-ref>3572</end-word-count-without-ref><end-date>2019-04-15 05:14:56</end-date><sla-start-date>2019-04-14 17:42:00</sla-start-date><sla-end-date>2019-04-15 23:42:00</sla-end-date><planned-start-date>2019-04-14 17:42:00</planned-start-date><planned-end-date>2019-04-15 23:42:00</planned-end-date><status>completed</status><comments/><assigned><to>Asha Narayanan, ashan@exeterpm.com</to><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Asha (TYPESETTER)" role="typesetter" time="1555305261878" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server" reason="base-alignment" job-id="769601d9-ec4a-4355-9b30-93ce703effed"/></proof></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Asha Narayanan</username><useremail>ashan@exeterpm.com</useremail><start-date>2019-04-15</start-date><start-time>05:11:07</start-time><end-date>2019-04-15</end-date><end-time>05:13:15</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>5302</start-word-count><start-word-count-without-ref>3572</start-word-count-without-ref><name>Author Review</name><customer-stage-name>Author proof</customer-stage-name><start-date>2019-04-15 05:14:56</start-date><duration>18</duration><end-word-count>5308</end-word-count><end-word-count-without-ref>3578</end-word-count-without-ref><end-date>2019-04-15 13:06:27</end-date><sla-start-date>2019-04-15 05:14:56</sla-start-date><sla-end-date>2019-04-17 05:14:56</sla-end-date><planned-start-date>2019-04-15 05:14:56</planned-start-date><planned-end-date>2019-04-17 05:14:56</planned-end-date><status>completed</status><comments/><assigned><to>Tina T Wong, tina.wong.t.l@snec.com.sg</to><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><article-key><key live="true" email="tina.wong.t.l@snec.com.sg">https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b90fb76005cdc2cbaf9230c863a3531692f004df18d7fa981c74947d122aef2d348d4e6ea78af97667289c50737cbf4fdebe968d1951482cef69b8b6b0896dde402704c18d0ef9ef4b1811c3795323e03447f4a680af1df154dbd3f11ae32df99f0206ac02cf4aabcdeee9edf2cebcb8e</key></article-key><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Tina T Wong</username><useremail>tina.wong.t.l@snec.com.sg</useremail><start-date>2019-04-15</start-date><start-time>12:47:12</start-time><end-date>2019-04-15</end-date><end-time>12:53:26</end-time><status type="user">logged-off</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Tina T Wong</username><useremail>tina.wong.t.l@snec.com.sg</useremail><start-date>2019-04-15</start-date><start-time>12:53:43</start-time><end-date>2019-04-15</end-date><end-time>13:05:50</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>5308</start-word-count><start-word-count-without-ref>3578</start-word-count-without-ref><name>Publisher Review</name><customer-stage-name>Production QC</customer-stage-name><start-date>2019-04-15 13:06:27</start-date><duration>3</duration><end-word-count>5308</end-word-count><end-word-count-without-ref>3578</end-word-count-without-ref><end-date>2019-04-24 13:51:43</end-date><sla-start-date>2019-04-15 13:06:27</sla-start-date><sla-end-date>2019-04-16 13:06:27</sla-end-date><planned-start-date>2019-04-15 13:06:27</planned-start-date><planned-end-date>2019-04-16 13:06:27</planned-end-date><status>completed</status><comments/><assigned><to>Production Manager, prodmanager@bmj.com</to><by>System, Exeter</by><on>2019-04-24 13:47:06</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Production Manager</username><useremail>prodmanager@bmj.com</useremail><start-date>2019-04-24</start-date><start-time>13:47:06</start-time><end-date>2019-04-24</end-date><end-time>13:50:58</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>5308</start-word-count><start-word-count-without-ref>3578</start-word-count-without-ref><name>Typesetter Review</name><customer-stage-name>Corrections</customer-stage-name><start-date>2019-04-24 13:51:43</start-date><duration>7</duration><end-word-count>5306</end-word-count><end-word-count-without-ref>3576</end-word-count-without-ref><end-date>2019-04-25 07:27:48</end-date><sla-start-date>2019-04-24 13:51:43</sla-start-date><sla-end-date>2019-04-25 13:51:43</sla-end-date><planned-start-date>2019-04-24 13:51:43</planned-start-date><planned-end-date>2019-04-25 13:51:43</planned-end-date><status>completed</status><comments/><assigned><to>Thilip Kumar, thilipkumar@exeterpm.com</to><by>System, Exeter</by><on>2019-04-25 07:16:36</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Thilip (TYPESETTER)" role="typesetter" time="1556176874275" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server" reason="none" job-id="485d77ff-df8d-4818-a798-8d42d6c09abd"/><pdf user="Thilip (TYPESETTER)" role="typesetter" time="1556177069326" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server" reason="none" job-id="1b25784a-c9e5-4ae3-bed9-a75b113c0cc0"/><pdf user="Thilip (TYPESETTER)" role="typesetter" time="1556177181092" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server" reason="base-alignment" job-id="d4e3bf19-1c61-4990-9c13-39f84904d588"/></proof></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip Kumar</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:16:36</start-time><end-date>2019-04-25</end-date><end-time>07:19:35</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:19:53</start-time><end-date>2019-04-25</end-date><end-time>07:19:53</end-time><status type="system">open</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:19:55</start-time><end-date>2019-04-25</end-date><end-time>07:21:33</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:22:32</start-time><end-date>2019-04-25</end-date><end-time>07:22:32</end-time><status type="system">open</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:22:33</start-time><end-date>2019-04-25</end-date><end-time>07:23:34</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:23:39</start-time><end-date>2019-04-25</end-date><end-time>07:24:43</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:25:06</start-time><end-date>2019-04-25</end-date><end-time>07:27:13</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Thilip</username><useremail>thilipkumar@exeterpm.com</useremail><start-date>2019-04-25</start-date><start-time>07:27:20</start-time><end-date>2019-04-25</end-date><end-time>07:27:40</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>2</iteration><start-word-count>5306</start-word-count><start-word-count-without-ref>3576</start-word-count-without-ref><name>Publisher Review</name><customer-stage-name>Revises</customer-stage-name><start-date>2019-04-25 07:27:48</start-date><duration>0</duration><end-word-count>5306</end-word-count><end-word-count-without-ref>3576</end-word-count-without-ref><end-date>2019-04-29 01:15:08</end-date><sla-start-date>2019-04-25 07:27:48</sla-start-date><sla-end-date>2019-04-26 07:27:48</sla-end-date><planned-start-date>2019-04-25 07:27:48</planned-start-date><planned-end-date>2019-04-26 07:27:48</planned-end-date><status>completed</status><comments/><assigned><to>Malcolm Smith, msmith@bmj.com</to><by>System, Exeter</by><on>2019-04-29 01:11:08</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Malcolm (BMJ)" role="publisher" time="1556500386926" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462_print/proofing/bjophthalmol-2018-313462_print.pdf?method=server"/><pdf user="Malcolm (BMJ)" role="publisher" time="1556500438423" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server"/></proof></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Malcolm Smith</username><useremail>msmith@bmj.com</useremail><start-date>2019-04-29</start-date><start-time>01:11:08</start-time><end-date>2019-04-29</end-date><end-time>01:11:08</end-time><status type="user">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>5306</start-word-count><start-word-count-without-ref>3576</start-word-count-without-ref><name>Final Deliverables</name><customer-stage-name>Upload for Online First</customer-stage-name><start-date>2019-04-29 01:15:08</start-date><duration>3</duration><end-word-count>5306</end-word-count><end-word-count-without-ref>3576</end-word-count-without-ref><end-date>2019-04-30 03:44:39</end-date><sla-start-date>2019-04-29 01:15:08</sla-start-date><sla-end-date>2019-04-30 01:15:08</sla-end-date><planned-start-date>2019-04-29 01:15:08</planned-start-date><planned-end-date>2019-04-30 01:15:08</planned-end-date><status>completed</status><comments/><assigned><to>Usha Venkatesh, usha.venkatesh@exeterpremedia.com</to><by>Usha Venkatesh, usha.venkatesh@exeterpremedia.com</by><on>2019-04-30 03:37:03</on><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user><proof><pdf user="Usha (TYPESETTER)" role="typesetter" time="1556595548304" path="http://kriya2.kriyadocs.com/resources/bmj/bjo/bjophthalmol-2018-313462/proofing/bjophthalmol-2018-313462.pdf?method=server" reason="others" description="rfo" job-id="6de0a40e-5ed7-4c54-9774-310263fb5b5b"/></proof></object><job-logs><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Usha Venkatesh</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-04-30</start-date><start-time>03:37:05</start-time><end-date>2019-04-30</end-date><end-time>03:40:13</end-time><status type="system">in-active</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-04-30</start-date><start-time>03:43:54</start-time><end-date>2019-04-30</end-date><end-time>03:43:54</end-time><status type="system">open</status></log><log data-doi="bjophthalmol-2018-313462" data-project="bjo" data-customer="bmj"><username>Usha</username><useremail>usha.venkatesh@exeterpremedia.com</useremail><start-date>2019-04-30</start-date><start-time>03:43:54</start-time><end-date>2019-04-30</end-date><end-time>03:43:54</end-time><status type="system">signed-off</status></log></job-logs></stage><stage><iteration>1</iteration><start-word-count>5306</start-word-count><start-word-count-without-ref>3576</start-word-count-without-ref><name>Upload for Online First</name><customer-stage-name>Upload for Online First</customer-stage-name><start-date>2019-04-30 03:44:39</start-date><duration>0</duration><end-word-count>5306</end-word-count><end-word-count-without-ref>3576</end-word-count-without-ref><end-date>2019-04-30 18:00:28</end-date><sla-start-date>2019-04-30 03:44:39</sla-start-date><sla-end-date>2019-05-01 03:44:39</sla-end-date><planned-start-date>2019-04-30 03:44:39</planned-start-date><planned-end-date>2019-05-01 03:44:39</planned-end-date><status>completed</status><held-stage/><hold-state/><comments/><assigned><to/><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object><job-logs/></stage><stage><iteration>1</iteration><start-word-count>5306</start-word-count><start-word-count-without-ref>3576</start-word-count-without-ref><name>Archive</name><customer-stage-name>Article Bank</customer-stage-name><start-date>2019-04-30 18:00:28</start-date><end-date>2019-04-30 18:00:28</end-date><sla-start-date>2019-04-30 18:00:28</sla-start-date><sla-end-date>2019-04-30 18:00:28</sla-end-date><planned-start-date>2019-04-30 18:00:28</planned-start-date><planned-end-date>2019-04-30 18:00:28</planned-end-date><status>completed</status><comments/><assigned><to/><by/><on/><reason/></assigned><time-log><log><start/><end/><duration/><status type="system"/></log></time-log><error/><object><figure/><table/><box/><user><name/><id/><inserted/><deleted/></user></object></stage></workflow><production-notes><note type="workflow"><id>04e1615f-d8ec-41af-bf47-4193e225704b</id><fullname>Workflow</fullname><created>2019-04-08 09:00:36</created><content>Job created on 2019-04-08 09:00:36</content></note><note id="0c05461c-97b0-4f57-9f46-829cf9480903" type="workflow"><id>0c05461c-97b0-4f57-9f46-829cf9480903</id><fullname>Workflow</fullname><created>2019-04-08 09:00:45</created><content>Article signed-off from addJob to File download</content></note><note id="95e39a11-602b-4fac-8373-a569c79de5ce" type="workflow"><id>95e39a11-602b-4fac-8373-a569c79de5ce</id><fullname>Workflow</fullname><created>2019-04-08 09:01:03</created><content>Article signed-off from File download to Convert Files</content></note><note id="ad3e53bf-3465-4c07-a82a-0c95e8e18e28" type="workflow"><id>ad3e53bf-3465-4c07-a82a-0c95e8e18e28</id><fullname>Workflow</fullname><created>2019-04-08 09:01:13</created><content>Payment and license info has been updated {"license":"nonOA","copyrightStatement":"nonOA","paymentMethod":"No APC","paymentStatus":"no","currentStage":"Convert Files","holdType":"NoHold","holdStatus":"true","matchStage":"Convert Files"}</content></note><note id="da26102f-f9c4-4db6-a47c-b265b4e05379" type="workflow"><id>da26102f-f9c4-4db6-a47c-b265b4e05379</id><fullname>Workflow</fullname><created>2019-04-08 09:01:15</created><content>Article signed-off from Convert Files to Pre-editing</content></note><note id="9bfe4672-5479-4472-be4c-d46f0eca9f62" type="email"><id>9bfe4672-5479-4472-be4c-d46f0eca9f62</id><fullname>Workflow</fullname><created>2019-04-08 09:01:15</created><content><email-content><mail-id>f77a0d7d-b4de-4a0c-5d9b-cc24e307de13@exeterpremedia.com</mail-id><mail-subject>Job Notification: Article 10.1136/bjophthalmol-2018-313462 loaded </mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p>Dear typesetter</p><p>The article '<span class="article-id">10.1136/bjophthalmol-2018-313462</span>' is now ready for editing.</p><p>Thank you,</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="6b188f58-e33c-4b8c-a871-e4e64221b2b6" type="workflow"><id>6b188f58-e33c-4b8c-a871-e4e64221b2b6</id><fullname>Asha Narayanan</fullname><created>2019-04-09 11:11:29</created><content>Article signed-off from Pre-editing to Waiting for CE</content></note><note id="039c86f4-f29a-440e-b6b8-9ce9ac473f0d" type="email"><id>039c86f4-f29a-440e-b6b8-9ce9ac473f0d</id><fullname>Asha Narayanan</fullname><created>2019-04-09 11:11:32</created><content><email-content><mail-id>242da4fd-70eb-c9cc-2b82-a4cb3ef60b24@exeterpremedia.com</mail-id><mail-subject>Ready for Copyediting - 10.1136/bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>production.bjo@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p>This article is ready for copyediting. Please assign the copy editor in paw.</p><p>Thank you</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="e4916d45-974e-4dd7-94dd-5cdc0402fe03" type="paw"><id>e4916d45-974e-4dd7-94dd-5cdc0402fe03</id><fullname>Asha Narayanan</fullname><created>2019-04-09 11:11:34</created><content><div class="jsonresp"><div class="note-head">PAW Failed: Article moved from Clean up to Copy edit</div></div></content></note><note id="ab8dc35b-b4b8-42af-b45e-f840d003ed2c" type="workflow"><id>ab8dc35b-b4b8-42af-b45e-f840d003ed2c</id><fullname>kriyÄ (automation)</fullname><created>2019-04-10 14:15:05</created><content>Article signed-off from Waiting for CE to Copyediting</content></note><note id="e774a306-3cc4-4758-bd52-941c0dcccc08" type="email"><id>e774a306-3cc4-4758-bd52-941c0dcccc08</id><fullname>kriyÄ (automation)</fullname><created>2019-04-10 14:15:10</created><content><email-content><mail-id>94d4ec74-b867-af89-7bab-4ba1feda2f1e@exeterpremedia.com</mail-id><mail-subject>Copyediting for 10.1136/bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p>Dear Exeter</p><p>This article is ready for copyediting.</p><p>Kindly note, the online editing system is currently not supported on Internet Explorer. Please use <a href="https://www.google.com/chrome/">Google Chrome</a> to access the article.</p><p>Thank you</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="699060ba-f9da-47b4-960c-59cfb649cf46" type="paw"><id>699060ba-f9da-47b4-960c-59cfb649cf46</id><fullname>kriyÄ (automation)</fullname><created>2019-04-10 14:15:13</created><content><div class="jsonresp"><div class="note-head">PAW skipped: Article skipped to move from Copy edit to Copy edit</div></div></content></note><note id="1085fc52-4ef8-47b0-ada0-164ddbbe4f44"><id>a230fb43-58d8-4e4e-9f20-bd6ce6ffc318</id><fullname>Automation</fullname><created>2019-04-10 14:15:11</created><content>Article assigned to: <b>EXETER</b> for copyediting</content></note><note id="83d1b3bf-c05d-4aa7-b257-f5af7041801d" type="workflow"><id>83d1b3bf-c05d-4aa7-b257-f5af7041801d</id><fullname>Satish Raju, satishraju@exeterpm.com</fullname><created>2019-04-13 04:32:50</created><content>Assigned to : Varadaraj B, bvaradaraj1976@gmail.com</content></note><note id="c28de98c-e652-43aa-a381-ccb4a319ed8d" type="workflow"><id>c28de98c-e652-43aa-a381-ccb4a319ed8d</id><fullname>Satish Raju</fullname><created>2019-04-13 04:32:50</created><content>Success:Purchase Order created</content></note><note id="ae244b5c-e35e-407a-bb88-f33bbabbe45d" type="email"><id>ae244b5c-e35e-407a-bb88-f33bbabbe45d</id><fullname>Satish Raju</fullname><created>2019-04-13 04:32:52</created><content><email-content><mail-id>be59c1d7-2ce9-20a4-4dbf-7e4d4617887e@exeterpremedia.com</mail-id><mail-subject>bjophthalmol-2018-313462 - Article has been Assigned to Copyeditor</mail-subject><from>bmj@exeterpremedia.com</from><to>bvaradaraj1976@gmail.com</to><mail-body><p><b>bjophthalmol-2018-313462</b> has been Assigned</p></mail-body></email-content></content></note><note id="7a523c04-9d91-4723-9b86-74e860defcd3" type="workflow"><id>7a523c04-9d91-4723-9b86-74e860defcd3</id><fullname>Varadaraj B</fullname><created>2019-04-14 17:42:00</created><content>Article assigned to Asha Narayanan, ashan@exeterpm.com</content></note><note id="f0f20d3d-8a9f-4456-b25a-34c4044e9c1a" type="workflow"><id>f0f20d3d-8a9f-4456-b25a-34c4044e9c1a</id><fullname>Varadaraj B</fullname><created>2019-04-14 17:42:00</created><content>Article signed-off from Copyediting to Typesetter Check</content></note><note id="49f8d6a4-8b9d-434d-92d4-90763ce3e3be" type="email"><id>49f8d6a4-8b9d-434d-92d4-90763ce3e3be</id><fullname>Varadaraj B</fullname><created>2019-04-14 17:42:03</created><content><email-content><mail-id>278c0b48-8045-9dde-9239-6ffee4a26309@exeterpremedia.com</mail-id><mail-subject>Edited files to be typeset 10.1136/bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p><span class="article-id">10.1136/bjophthalmol-2018-313462</span></p><p>Dear Typesetter</p><p>The above article has been sent to you for typesetting.</p><p>Best wishes</p><p>Production Office</p></mail-body></email-content></content></note><note id="0584f1ed-1594-46b9-ac29-834cae527d4a" type="paw"><id>0584f1ed-1594-46b9-ac29-834cae527d4a</id><fullname>Varadaraj B</fullname><created>2019-04-14 17:42:03</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Copy edit to Typeset</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Copy edit"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Copy edit"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Typeset"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Typeset"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-14T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-17T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="56a7f267-ac26-477e-8a97-8c63d6cd2ddb" type="workflow"><id>56a7f267-ac26-477e-8a97-8c63d6cd2ddb</id><fullname>Asha Narayanan</fullname><created>2019-04-15 05:14:56</created><content>Article signed-off from Typesetter Check to Author Review</content></note><note id="94de45d6-24f5-4d4a-a459-1ad0b29a037c" type="paw"><id>94de45d6-24f5-4d4a-a459-1ad0b29a037c</id><fullname>Asha Narayanan</fullname><created>2019-04-15 05:15:00</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Typeset to Author proof</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Typeset"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"bjo"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Typeset"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Author proof"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Author proof"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-15T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-17T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="0e88c1bf-8ef5-44d2-aef6-6547c5b7b8b8" type="email"><id>0e88c1bf-8ef5-44d2-aef6-6547c5b7b8b8</id><fullname>Asha Narayanan</fullname><created>2019-04-15 05:15:00</created><content><email-content><mail-id>632d0bf7-c372-187f-939f-b5164a5dd10c@exeterpremedia.com</mail-id><mail-subject>Proof of your article for British Journal of Ophthalmology - 10.1136/bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>tina.wong.t.l@snec.com.sg</to><cc>bmj@exeterpremedia.com,production.bjo@bmj.com</cc><mail-body><p>Dear <span class="name">Tina T Wong</span>,</p><p>Iâm pleased to provide the proof of your article, which is available on our author proofing system here:</p><p><a style="background: #FF5722;padding: 3px 6px;border-radius: 3px;color: #fff !important;" href="https://kriya2.kriyadocs.com/review_content/?key=8e846e694f500fa895a31373e40f091fc2a17eb93b90fb76005cdc2cbaf9230c863a3531692f004df18d7fa981c74947d122aef2d348d4e6ea78af97667289c50737cbf4fdebe968d1951482cef69b8b6b0896dde402704c18d0ef9ef4b1811c3795323e03447f4a680af1df154dbd3f11ae32df99f0206ac02cf4aabcdeee9edf2cebcb8e">LINK</a></p><p>Please submit any corrections then ensure you click âApproveâ to complete the author proofing process. Signing off the paper will send the article back to the Production team so they can make any changes.</p><p>Please note, the online author proofing system cannot be used in the browser Internet Explorer. Please review your proofs in <a href="https://www.google.com/chrome/">Google Chrome</a>.</p><p>A PDF version of the proof is available to download and review, but all corrections must be submitted using the online system. Please contact us at production.bjo@bmj.com if you need any help using this.</p><p>This is the only opportunity you will have to correct your article before publication, so please review it carefully. Please ensure you respond to queries listed in the article. Minor errors cannot be corrected after publication and any serious scientific errors will result in a formal correction.</p><p>Reprints: If you wish to purchase reprints of your article, please fill in the <a href="http://authors.bmj.com/wp-content/uploads/2018/10/Standard_reprint_form_2018.pdf">reprint form</a>.</p><p>Thanks in advance.</p><p><span class="journal-title">British Journal of Ophthalmology</span> Production Team</p></mail-body></email-content></content></note><note id="92405f0b-530a-4daf-89e4-a30742ca9f20" type="workflow"><id>92405f0b-530a-4daf-89e4-a30742ca9f20</id><fullname>Tina T Wong</fullname><created>2019-04-15 13:06:27</created><content>Article signed-off from Author Review to Publisher Review</content></note><note id="277f0077-38b5-4e20-b667-ad45054dc2c9" type="email"><id>277f0077-38b5-4e20-b667-ad45054dc2c9</id><fullname>Tina T Wong</fullname><created>2019-04-15 13:06:33</created><content><email-content><mail-id>be4fd939-57e8-5a26-d241-29579387834a@exeterpremedia.com</mail-id><mail-subject>Author corrections completed for bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>production.bjo@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p>The corresponding author has finished reviewing the proof, the Production Editor should now sign in to Kriya 2 and review the corrections.</p><p>Thank you,</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="99b65a3d-c4f0-4986-9b26-b1a4d73b67fc" type="paw"><id>99b65a3d-c4f0-4986-9b26-b1a4d73b67fc</id><fullname>Tina T Wong</fullname><created>2019-04-15 13:06:34</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Author proof to Production QC</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Author proof"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"bjo"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Author proof"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Production QC"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Production QC"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-15T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-17T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="f5e73323-2d3d-4796-9751-55c0387a7ddb" type="workflow"><id>f5e73323-2d3d-4796-9751-55c0387a7ddb</id><fullname>Production Manager</fullname><created>2019-04-24 13:51:43</created><content>Article assigned to Asha Narayanan, ashan@exeterpm.com</content></note><note id="98bcd611-0c67-4ed4-b036-6be3ff047aa5" type="workflow"><id>98bcd611-0c67-4ed4-b036-6be3ff047aa5</id><fullname>Production Manager</fullname><created>2019-04-24 13:51:43</created><content>Article signed-off from Publisher Review to Typesetter Review</content></note><note id="d103795a-2a22-44f1-a4f8-1bf78e14fd44" type="email"><id>d103795a-2a22-44f1-a4f8-1bf78e14fd44</id><fullname>Production Manager</fullname><created>2019-04-24 13:51:46</created><content><email-content><mail-id>5c8bdc59-e849-a479-4a53-592d9c4aafbe@exeterpremedia.com</mail-id><mail-subject>10.1136/bjophthalmol-2018-313462 Corrections</mail-subject><from>bmj@exeterpremedia.com</from><to>bmj@exeterpremedia.com</to><mail-body><p>Dear Typesetter</p><p>The above proof has been sent to you for correction.</p><p>Best wishes</p><p>Production Office</p></mail-body></email-content></content></note><note id="bf0acbc7-1258-4567-87a7-ec7683f9af8e" type="paw"><id>bf0acbc7-1258-4567-87a7-ec7683f9af8e</id><fullname>Production Manager</fullname><created>2019-04-24 13:51:47</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Production QC to Corrections</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Production QC"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"bjo"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Production QC"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Corrections"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Corrections"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-24T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-26T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="c7deddee-ae78-4c9e-85f4-36000661825c" type="workflow"><id>c7deddee-ae78-4c9e-85f4-36000661825c</id><fullname>Thilip Kumar</fullname><created>2019-04-25 07:27:48</created><content>Article signed-off from Typesetter Review to Publisher Review</content></note><note id="49b1fcc6-9698-4247-8472-944f134d7307" type="paw"><id>49b1fcc6-9698-4247-8472-944f134d7307</id><fullname>Thilip Kumar</fullname><created>2019-04-25 07:27:53</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Corrections to Revises</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Corrections"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"bjo"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Corrections"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Revises"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Revises"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-25T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-26T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="18d9a232-defc-430b-8f3e-191277029b98" type="email"><id>18d9a232-defc-430b-8f3e-191277029b98</id><fullname>Thilip Kumar</fullname><created>2019-04-25 07:27:53</created><content><email-content><mail-id>8e16a926-ac81-24cc-e846-6bcb77e41221@exeterpremedia.com</mail-id><mail-subject>Corrections have been completed for 10.1136/bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>production.bjo@bmj.com</to><mail-body><p>Dear publisher</p><p>We have incorporated all requested corrections, resolved errors and ensured that the PDF and XML are in good shape.</p><p>Thank you,</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="79ccb087-b728-44de-8c02-6421f8c7ee40" type="workflow"><id>79ccb087-b728-44de-8c02-6421f8c7ee40</id><fullname>Malcolm Smith</fullname><created>2019-04-29 01:15:08</created><content>Article signed-off from Publisher Review to Final Deliverables</content></note><note id="599fd30e-286b-4f89-9aae-2d28d2df6db3" type="paw"><id>599fd30e-286b-4f89-9aae-2d28d2df6db3</id><fullname>Malcolm Smith</fullname><created>2019-04-29 01:15:10</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Revises to Upload for Online First</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"PAW stage and current stage is matching :Revises"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"bjo"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Revises"</span>, <br/><span class="key">"NextArticleStage":</span> <span class="string">"Upload for Online First"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticlestageto"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Upload for Online First"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-29T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="string">"2019-04-30T00:00:00"</span>, <br/><span class="key">"Ended":</span> <span class="null">null</span> } ] }</pre></div></div></content></note><note id="0b9d72a1-2e57-43ff-8e0b-390ac493107e" type="email"><id>0b9d72a1-2e57-43ff-8e0b-390ac493107e</id><fullname>Malcolm Smith</fullname><created>2019-04-29 01:15:11</created><content><email-content><mail-id>f4a028d9-c180-1fc7-1f8b-f726d01c6b3b@exeterpremedia.com</mail-id><mail-subject>Upload for Online First approved for 10.1136/bjophthalmol-2018-313462</mail-subject><from>bmj@exeterpremedia.com</from><to>production.bjo@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p><span class="article-id">10.1136/bjophthalmol-2018-313462</span> has been approved for Upload for Online First.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="9b688189-33de-40eb-92d7-b01c477f95ed"><id>16edc71a-390b-4970-9365-10c98b322397</id><fullname>Automation</fullname><created>2019-04-29 01:45:01</created><content>Approved email received for this article</content></note><note id="7df90efb-caf3-4748-bed4-77ca60111b8d" type="workflow"><id>7df90efb-caf3-4748-bed4-77ca60111b8d</id><fullname>Usha Venkatesh, usha.venkatesh@exeterpremedia.com</fullname><created>2019-04-30 03:37:04</created><content>Assigned to : Usha Venkatesh, usha.venkatesh@exeterpremedia.com</content></note><note id="092b98a8-8fc3-4c1e-b8d0-1c1f2f2e9135" type="workflow"><id>092b98a8-8fc3-4c1e-b8d0-1c1f2f2e9135</id><fullname>Usha Venkatesh</fullname><created>2019-04-30 03:44:39</created><content>Article signed-off from Final Deliverables to Upload for Online First</content></note><note id="85870fd3-fb26-46ef-beee-003e423c1c47" type="email"><id>85870fd3-fb26-46ef-beee-003e423c1c47</id><fullname>Usha Venkatesh</fullname><created>2019-04-30 03:44:42</created><content><email-content><mail-id>d6d2efdf-7e10-74a6-4846-4c4ec0469c28@exeterpremedia.com</mail-id><mail-subject>10.1136/bjophthalmol-2018-313462: Article has been uploaded to HighWire Express site</mail-subject><from>bmj@exeterpremedia.com</from><to>production.bjo@bmj.com</to><cc>bmj@exeterpremedia.com</cc><mail-body><p>Dear Publisher</p><p>We have uploaded the article on the HighWire Express site.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="c7845b78-c21d-475a-95e8-f6abc56943be"><id>1ee3b87e-9bc9-49a7-820d-1e32df1e7afe</id><fullname>Automation</fullname><created>2019-04-30 18:00:11</created><content>Published</content></note><note id="4eab3d23-18cc-4e94-b50b-9036395c9006" type="workflow"><id>4eab3d23-18cc-4e94-b50b-9036395c9006</id><fullname>Workflow</fullname><created>2019-04-30 18:00:28</created><content>Article signed-off from Upload for Online First to Archive</content></note><note id="fca2404b-f374-4475-93df-c53ce931689f" type="email"><id>fca2404b-f374-4475-93df-c53ce931689f</id><fullname>Workflow</fullname><created>2019-04-30 18:00:40</created><content><email-content><mail-id>4626fd38-89fa-0b88-2ec9-ca14339ebcc1@exeterpremedia.com</mail-id><mail-subject>10.1136/bjophthalmol-2018-313462: Article has been moved to Archive</mail-subject><from>bmj@exeterpremedia.com</from><to>production.bjo@bmj.com</to><mail-body><p>Dear Publisher</p><p>The uploaded article has been moved to Archive.</p><p>Best wishes</p><p style="font-size:10.0pt;">kriyÄ@BMJ</p></mail-body></email-content></content></note><note id="4c6e4e39-8a34-45f6-aec2-c31cd0d7a31b" type="paw"><id>4c6e4e39-8a34-45f6-aec2-c31cd0d7a31b</id><fullname>Workflow</fullname><created>2019-04-30 18:00:41</created><content><div class="jsonresp"><div class="note-head">PAW SUCCESS: Article moved from Upload for Online First to Article Bank</div><div class="jsondata"><pre>{ <br/><span class="key">"pawstage":</span> <span class="string">"Not processed: PAW stage and current stage"</span>, <br/><span class="key">"pawpost":</span> { <br/><span class="key">"Typesetter":</span> <span class="string">"5F52C243-5D08-44F3-AAC3-92517D348713"</span>, <br/><span class="key">"JournalAcronym":</span> <span class="string">"bjo"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ArticleStageTypeName":</span> <span class="string">"Upload for Online First"</span> }, <br/><span class="key">"pawurl":</span> <span class="string">"http://typesetter.publishingatwork.com/api/typesetter/completearticle"</span>, <br/><span class="key">"pawresponse":</span> [ { <br/><span class="key">"JournalAcronym":</span> <span class="string">"BJO"</span>, <br/><span class="key">"ManuscriptNum":</span> <span class="string">"bjophthalmol-2018-313462"</span>, <br/><span class="key">"ManuscriptPages":</span> <span class="number">4.9</span>, <br/><span class="key">"AuthorName":</span> <span class="string">"Prof. Tina T Wong"</span>, <br/><span class="key">"ArticleStage":</span> <span class="string">"Upload for Online First"</span>, <br/><span class="key">"Started":</span> <span class="string">"2019-04-29T00:00:00"</span>, <br/><span class="key">"Due":</span> <span class="null">null</span>, <br/><span class="key">"Ended":</span> <span class="string">"2019-04-30T18:01:00"</span> } ] }</pre></div></div></content></note></production-notes></article>